<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="907"><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 12-week study to compare the 24 h action to restore lung function with the combination of fluticasone furoate (FF) / vilanterol (VI), produced in the form of powder for inhalation and used by patients with chronic obstructive pulmonary disease (COPD), qd, and the combination of salmeterol / fluticasone propionate (FP), in the form of powder for inhalation, applied bid</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="165373"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>fluticasone propionate; salmeterol</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>fluticasone furoate; vilanterol</Interventions><Reference>2010-021059-25; HZC113107</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus</ProtocolTitle><Sponsor>Orion Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="104633"></Trial><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Charcoal; Seretide Diskus; Seretide Diskus; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Interventions><Reference>3106007; EudraCT 2012-00378-41; NCT01766843</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte</ProtocolTitle><Sponsor>ISTA Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10077"></Trial><Drug id="53134">tobramycin + prednisolone acetate (ophthalmic), ISTA</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>132</Patients><Biomarkers></Biomarkers><Condition>Ocular infection</Condition><Controls>prednisolone acetate</Controls><EnrollmentCount>132</EnrollmentCount><Interventions>tobramycin + prednisolone acetate (ophthalmic), ISTA</Interventions><Reference>ISTA-TP-CPK01; NCT00198523</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PED</ProtocolAcronym><ProtocolTitle>A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes</ProtocolTitle><Sponsor>Norwegian University of Science and Technology (NTNU)</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="101391"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>9</Patients><Biomarkers></Biomarkers><Condition>Retinopathy</Condition><Controls></Controls><EnrollmentCount>9</EnrollmentCount><Interventions>aflibercept; aflibercept; triamcinolone acetonide; verteporfin</Interventions><Reference>2012/1743; NCT01746875; PED</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II proof-of-concept trial of Sorafin-AD ointment versus topical mometasone in adults with atopic dermatitis</ProtocolTitle><Sponsor>Viralytics Ltd</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="69513"></Trial><Drug id="57631">auranofin + mometasone furoate (Sorafin dermatological formulation), Viralytics</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Atopic dermatitis</Condition><Controls>mometasone</Controls><EnrollmentCount>56</EnrollmentCount><Interventions>Sorafin-AD</Interventions><Reference>PSX-AD-001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>STAR</ProtocolAcronym><ProtocolTitle>A randomized, open-label, parallel-group study to compare the safety and efficacy of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma</ProtocolTitle><Sponsor>Takeda GmbH</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="76911"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>528</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>658</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; fluticasone</Interventions><Reference>BY9010/M1-134; STAR</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III, parallel group, comparative trial of NS-126C and fluticasone propionate in patients with perennial allergic rhinitis</ProtocolTitle><Sponsor>Hisamitsu Pharmaceutical Co Inc, Nippon Shinyaku Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="104452"></Trial><Drug id="12806">dexamethasone cipecilate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount></EnrollmentCount><Interventions>dexamethasone cipecilate</Interventions><Reference>JapicCTI-050155</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Investigational Study of Hydrocortisone</ProtocolTitle><Sponsor>Diurnal Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157428"></Trial><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>14</Patients><Biomarkers>Glucose; Insulin; Serum albumin (ALB); Serum corticosteroid-binding globulin (CBG); Serum cortisol</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>hydrocortisone</Controls><EnrollmentCount>14</EnrollmentCount><Interventions>dexamethasone; hydrocortisone (oral granules, adrenal insufficiency), Diurnal</Interventions><Reference>INFACORT 002; NCT01960530</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients</ProtocolTitle><Sponsor>Alcon Research Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="73801"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>722</Patients><Biomarkers></Biomarkers><Condition>Xerophthalmia</Condition><Controls></Controls><EnrollmentCount>722</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>C-10-078; NCT01276223</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 microg qd With Fluticasone Propionate (FP) 250 microg bid and FP 100 microg bid in Well-Controlled Asthmatic Japanese Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="178963"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>430</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>430</EnrollmentCount><Interventions>Relovair; fluticasone; fluticasone furoate</Interventions><Reference>201135; JapicCTI-142503; NCT02094937</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multicenter, randomized, double-blind, placebo-controlled, incomplete block, three-way crossover study to determine the effect of repeat inhaled doses of GW685698X compared to fluticasone propionate, on airway responsiveness to adenosine 5'-monophosphate (AMP) in patients with mild asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87425"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>FEV1; serum cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>GW685698X</Interventions><Reference>FFA10022</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparator Study Evaluating Patient Experience And Preference Of FFNS versus FPNS</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11559"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>360</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount>360</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>FFU105927; NCT00519636</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Exploratory, Open-Label, Intra-Individual, Active-Controlled Study Comparing the Efficacy and Safety of Betesil Versus Daivobet for the Treatment of Chronic Plaque Psoriasis</ProtocolTitle><Sponsor>Laboratoires Genevrier SA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="118017"></Trial><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls>calcipotriol + betamethasone dipropionate, LEO</Controls><EnrollmentCount>20</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Interventions><Reference>08F/BET01; EudraCT 2008-005518-29</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study of the Safety and Efficacy Of Intralesional Steroid, Tacrolimus (0.1%) Ointment and Minoxidil (5%) in the Treatment of Alopecia Areata</ProtocolTitle><Sponsor>Father Muller Med Coll</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="154386"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Alopecia areata</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>minoxidil; tacrolimus; triamcinolone acetonide</Interventions><Reference>CTRI/2013/08/003880</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical study about ophthalmic local administrations of triamcinolone acetonide for macular edema and/or retinal periphlebitis</ProtocolTitle><Sponsor>Yamagata University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="121608"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers>Retinal thickness</Biomarkers><Condition>Eale disease</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>JPRN-UMIN000005778</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of orBec as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)</ProtocolTitle><Sponsor>Soligenix Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="151308"></Trial><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>2</Patients><Biomarkers></Biomarkers><Condition>Gastrointestinal disease</Condition><Controls></Controls><EnrollmentCount>2</EnrollmentCount><Interventions>orBec</Interventions><Reference>BDP-GVHD-08; NCT01925950</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of topical CRx-191 in normal healthy volunteers</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23649"></Trial><Drug id="56234">mometasone + nortriptyline (topical cream, psoriasis), CombinatoRx</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Skin atrophy</Condition><Controls>Karison® Creme; mometasone furoate; nortriptyline HCl</Controls><EnrollmentCount>20</EnrollmentCount><Interventions>CRx-191</Interventions><Reference>CRx-191-002; EudraCT Number: 2006-005903-33; NCT00544687</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Ideal Management of Crohn's Disease: Top-Down Versus Step-Up Strategies - A Prospective, Controlled Trial in the Benelux</ProtocolTitle><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="120593"></Trial><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>130</Patients><Biomarkers></Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>130</EnrollmentCount><Interventions>Budenofalk; Entocort; Flagyl; Medrol; azathioprine; folic acid; infliximab; methotrexate; prednisolone</Interventions><Reference>ISRCTN61510219; NTR379</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label, Dose-Escalation Study of the Safety and Tolerability of 20089 (Triamcinolone Acetonide Intravitreal Injection) in the Treatment of Patients with Cystoid Macular Edema Associated with Retinal Vein Occlusion or Cataract Surgery</ProtocolTitle><Sponsor>Icon Bioscience Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="120774"></Trial><Drug id="60951">triamcinolone acetonide (controlled release/intravitreal injection/Verisome, diabetic macular edema), EyePoint</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>intraocular pressure</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>IBI-20089</Interventions><Reference>ACTRN12608000603314</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Injection of Triamcinolone Acetonide in Retinitis</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="122471"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>87</Patients><Biomarkers></Biomarkers><Condition>Retinitis pigmentosa</Condition><Controls></Controls><EnrollmentCount>87</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>IRCT201104266293N1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis</ProtocolTitle><Sponsor>University of Maryland</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="193417"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>2</Patients><Biomarkers>Adrenocorticotropic Hormone; Hydrocortisone</Biomarkers><Condition>Ulcerative colitis</Condition><Controls></Controls><EnrollmentCount>2</EnrollmentCount><Interventions>Entocort; hydrocortisone</Interventions><Reference>H-30365; NCT00805285</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-Pituitary-Adrenocortical Axis of Children Aged 5 to 11 Years With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="233443"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>111</Patients><Biomarkers>6 beta-Hydroxycortisol; Hydrocortisone</Biomarkers><Condition>Asthma</Condition><Controls>albuterol; montelukast</Controls><EnrollmentCount>111</EnrollmentCount><Interventions>Ellipta; albuterol; montelukast</Interventions><Reference>107118; NCT02483975</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23398"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Blood pressure; Cortisol; Heart rate; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>GW-642444M; GW-685698X; fluticasone furoate + vilanterol</Interventions><Reference>HZA105871; NCT00538057</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>ACCEPT</ProtocolAcronym><ProtocolTitle>Asthma Care With Alvesco (Ciclesonide) in Primary Care in Adults</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22240"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1121</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>1121</EnrollmentCount><Interventions>Alvesco</Interventions><Reference>ACCEPT; BY9010/CA-102; NCT00404547</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multicenter, randomized, blinded study of 14 weeks duration comparing the effect of CRx-139 plus DMARD therapy to that of steroid plus DMARD therapy using ACR-20 in subjects with active rheumatoid arthritis partially responsive to the DMARD</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="133649"></Trial><Drug id="45643">prednisolone + paroxetine (rheumatoid arthritis, inflammation), CombinatoRx</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>220</Patients><Biomarkers>CRP; cytokines</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>220</EnrollmentCount><Interventions>prednisolone + paroxetine (rheumatoid arthritis, inflammation), CombinatoRx</Interventions><Reference>CRx-139-002; CRx-139-RA; CZ::Protocol CRx-139-002; EudraCT 2004-004995-35; Protocol CRx-139-002</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Repeat Emergency Department Visits Among Patients With Asthma and COPD</ProtocolTitle><Sponsor>State University of New York</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="235195"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>prednisone; salbutamol, GlaxoSmithKline</Controls><EnrollmentCount>6</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; prednisone; salbutamol, GlaxoSmithKline</Interventions><Reference>754754; NCT02499887</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of ciclesonide and beclomethasone on lens opacification in adult subjects with moderate to severe persistent asthma</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22103"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1568</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><EnrollmentCount>1568</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>NCT00254956; SFY6160; XRP1526B/3027</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Novel budesonide suppository versus budesonide foam in acute ulcerative proctitis</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="291869"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>252</Patients><Biomarkers></Biomarkers><Condition>Ulcerative proctitis</Condition><Controls></Controls><EnrollmentCount>252</EnrollmentCount><Interventions>Rectabul; budesonide rectal suppository</Interventions><Reference>2016-001921-15; BUS-4/UCA</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Examine the Effect of Repeat Inhaled Doses of GW-870086X on Lung Function in Mild Asthmatic Male Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22317"></Trial><Drug id="54598">870086 (inhaled, asthma), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>870086 (inhaled, asthma), GlaxoSmithKline</Interventions><Reference>NCT00483899; SIG102335</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Role Of Intra-Operative Peri-Articular Steroid Injection In Reducing Post-Operative Pain And Improving Knee Function After Total Knee Arthroplasty: a Prospective, Randomized, Controlled Trial</ProtocolTitle><Sponsor>Rhone-Poulenc Rorer Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="134330"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>ACTRN12609000345280; ANZCTR83890</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13384"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>288</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>288</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>FFR30002; NCT00103454</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Reduced Fluence Versus Standard Photodynamic Therapy (In Combination With Intravitreal Triamcinolone Acetonide): A Prospective, Randomized, Comparative Study</ProtocolTitle><Sponsor>Medical University of Vienna</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="139550"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Choroidal neovascularization</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>photodynamic therapy; triamcinolone acetonide; verteporfin</Interventions><Reference>EudraCT 2005-000776-41</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 12-Month, Open-Label, Randomized, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW-685698/vilanterol (VI, GW-642444) Inhalation Powder Delivered Once Daily via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="139569"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>4820</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>4820</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>CCRN 997; UKCRN:13263</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect Of Pulsed Radiofrequency Treatment Of The Dorsal Root Ganglion In Spinal Stenosis With Intermittent Neurogenic Claudication</ProtocolTitle><Sponsor>Asan Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="143635"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Spinal stenosis</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>lidocaine; triamcinolone acetonide</Interventions><Reference>KCT0000743</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Intravitreal Triamcinolone Acetonide before Pan Retinal Photocoagulation for Improvement of Visual Acuity and Macular Edema in Diabetic Retinopathy</ProtocolTitle><Sponsor>Farabi Eye Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="143664"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>23</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic retinopathy</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>ACTRN12607000225415; HREC 356</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Use of Intravitreal Injection of Triamcinolone Acetonide in Diabetic Patients to Reduce Diabetic Macular Edema</ProtocolTitle><Sponsor>Suez Canal University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="138776"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>19</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>ACTRN12613000249752</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the efficacy and safety of a new steroid-antibiotic ophthalmic gel as anti-inflammatory and antimicrobial topical treatment following microincisional vitreo-retinal surgery</ProtocolTitle><Sponsor>SIFI Societa Industria Farmaceutica Italiana SpA</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="138949"></Trial><Drug id="56575">dexamethasone + netilmicin (ophthalmic), SIFI</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>103</Patients><Biomarkers>intraocular pressure</Biomarkers><Condition>Ocular inflammation</Condition><Controls>Tobradex</Controls><EnrollmentCount>103</EnrollmentCount><Interventions>Netildex</Interventions><Reference>2008-005082-64</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>SUPPORTS</ProtocolAcronym><ProtocolTitle>Study of orBec With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)</ProtocolTitle><Sponsor>Soligenix Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="58209"></Trial><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Graft versus host disease</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>beclomethasone dipropionate; prednisone</Interventions><Reference>2010-022247-37; ACTRN12610000593033; BDP-GVHD-03; NCT00926575; SUPPORTS</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluocinolone implant to treat macular degeneration</ProtocolTitle><Sponsor>National Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="4710"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Choroid disease</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Reference>01-EI-0058; 010058; NCT00008515</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>TELOS</ProtocolAcronym><ProtocolTitle>Study to Assess Efficacy and Safety of PT-009 Compared to PT-005, PT-008 and Symbicort Turbuhaler on Lung Function Over 24 Weeks in Subjects With Moderate to Very Severe COPD</ProtocolTitle><Sponsor>AstraZeneca AB, Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="260435"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2389</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort; budesonide; formoterol</Controls><EnrollmentCount>3316</EnrollmentCount><Interventions>PT-009</Interventions><Reference>2016-000154-34; D7820C00001; NCT02766608; PT009002; TELOS</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III study of AJG-511 in patients with active ulcerative colitis</ProtocolTitle><Sponsor>EA Pharma Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="215968"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Ulcerative colitis</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Rectabul</Interventions><Reference>AJG511/CT1; JapicCTI-142704</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants &gt;/= 12 Years Old With Persistent Asthma</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="167002"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1113</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>1113</EnrollmentCount><Interventions>Qvar</Interventions><Reference>2013-003397-27; BDB-AS-301; DRKS00005827; NCT02031640</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of GW-685698X in Healthy Japanese Male Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60174"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Serum cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>112018; HZA112018; NCT00972673</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87599"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers>Anterior chamber</Biomarkers><Condition>Cataract</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>EGP-437</Interventions><Reference>EGP-437-005; NCT01602068</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>VISION DMD</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Sponsor>ReveraGen BioPharma Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329964"></Trial><Drug id="70712">vamorolone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>120</Patients><Biomarkers>Afamin; Afamin; Angiopoietin-2; Angiopoietin-2; Angiotensinogen; Angiotensinogen; Ankle motion; Blood pressure; Body Mass Index; Body height; Body temperature; C-C motif chemokine 22; C-C motif chemokine 22; Collagen type I trimeric cross-linked peptide; Dystrophin; Elbow motion; Fibrinogen gamma chain; Fibrinogen gamma chain; Glucose; Growth hormone receptor; Growth hormone receptor; Heart rate; Hydrocortisone; Insulin; Insulin; Insulin-like growth factor binding protein 2; Insulin-like growth factor binding protein 2; Insulin-like growth factor-binding protein 5; Insulin-like growth factor-binding protein 5; Integrin alpha-1; Integrin alpha-1; Integrin alpha1beta1; Integrin alpha1beta1; Interleukin-22 receptor subunit alpha-2; Interleukin-22 receptor subunit alpha-2; Intraocular pressure; Knee motion; Leptin; Leptin; Low affinity immunoglobulin epsilon Fc receptor; Low affinity immunoglobulin epsilon Fc receptor; Lymphocytes; Lymphotoxin-alpha; Lymphotoxin-alpha; Lymphotoxin-beta; Lymphotoxin-beta; Macrophage metalloelastase; Macrophage metalloelastase; Osteocalcin; Procollagen Type I N-terminal peptide; Respiratory frequency; Saposin-D; Saposin-D; Six-minute walk distance; Stromelysin-1; Stromelysin-1; T-lymphocyte surface antigen Ly-9; T-lymphocyte surface antigen Ly-9; Total body mass</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls>prednisone; vamorolone; vamorolone</Controls><EnrollmentCount>120</EnrollmentCount><Interventions>vamorolone</Interventions><Reference>118942; 2017-002704-27; FDA IND 118942; NCT03439670; VBP15-004; VBP15-004-A1; VBP15-004-A2; VBP15-004-A3; VISION DMD</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multiple-dose, Pharmacokinetics Study of 'SYN-006 HFA MDI' Administered Orally to Healthy Volunteers</ProtocolTitle><Sponsor>Benefit Biotechnology Co, Ltd, Intech Biopharm Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="203681"></Trial><Drug id="91606">budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Interventions><Reference>MCPK10002J1; NCT02165033</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study investigating intravenously administrated Oncocort in patients with metastatic prostate cancer</ProtocolTitle><Sponsor>Enceladus Pharmaceuticals</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="291118"></Trial><Drug id="77410">dexamethasone (liposome formulation, castration resistant prostate carcinoma/multiple myeloma), Enceladus</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Alkaline phosphatase; Blood pressure; Body temperature; Estradiol; Follicle-stimulating hormone; Glucose; Heart rate; Hydrocortisone; Luteinizing Hormone; Lymphocytes; PR interval; Prostate-specific antigen; QRS complex; QT interval; Sex hormone-binding globulin; Testosterone</Biomarkers><Condition>Bone metastases</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>Oncocort</Interventions><Reference>2016-003121-42; CHDR1635</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="107743"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>547</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>547</EnrollmentCount><Interventions>Qnaze</Interventions><Reference>BDP-AR-306; NCT01783548</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy And Safety Study Of ME-609 And Acyclovir For Treatment Of Herpes Simplex Labialis</ProtocolTitle><Sponsor>Medivir AB</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11577"></Trial><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2437</Patients><Biomarkers></Biomarkers><Condition>Herpesvirus infection</Condition><Controls>acyclovir</Controls><EnrollmentCount>1443</EnrollmentCount><Interventions>ME-609</Interventions><Reference>609-04; NCT00361881</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Sophos</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of PT-009 Compared to PT-005 on COPD Exacerbations Over a 52 Weeks Period in Subjects With Moderate to Very Severe COPD</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="257369"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1941</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>formoterol</Controls><EnrollmentCount>1941</EnrollmentCount><Interventions>PT-009</Interventions><Reference>2016-000155-28; D7820C00002; NCT02727660; PT009003; Sophos</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase IIa, FF/VI Study to Measure FeNO in Asthmatic Patients</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="256043"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>27</Patients><Biomarkers>Forced expiratory volume; Fractional concentration of exhaled nitric oxide; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>Relvar</Interventions><Reference>201499; NCT02712047</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IV Fluticasone Furoate Nasal Spray (Veramyst) Long-Term Pediatric Growth Study</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="14133"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>450</Patients><Biomarkers>Cortisol</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>474</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>EudraCT: 2007-005148-26; FFR101782; NCT00570492</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery</ProtocolTitle><Sponsor>Icon Bioscience Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="240288"></Trial><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>194</Patients><Biomarkers>Corneal endothelium; Fundus of eye; Intraocular pressure; Visual acuity</Biomarkers><Condition>Ocular inflammation</Condition><Controls>prednisolone</Controls><EnrollmentCount>194</EnrollmentCount><Interventions>IBI-10090</Interventions><Reference>C15-01; NCT02547623</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation of the safety and efficacy of Budesonide (Zentacort capsules) in patients with Crohn's disease</ProtocolTitle><Sponsor>Zeria Pharmaceutical Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="357577"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Zentacort</Interventions><Reference>JapicCTI-184152</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>HULK</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="277937"></Trial><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Fovea centralis; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>CLS-1003; triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical; triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Interventions><Reference>CLS1004-101; HULK; NCT02944240; NCT02949024</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TDMX Study</ProtocolAcronym><ProtocolTitle>Open-Label, Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Edema</ProtocolTitle><Sponsor>University of Sydney</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="177951"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>64</Patients><Biomarkers>Macula retinae; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>64</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>ACTRN12605000244606; NCT00148330; NHMRC project 402573; TDMX Study</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis</ProtocolTitle><Sponsor>Mantecorp Industria Quimica e Farmaceutica Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="180987"></Trial><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>170</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>170</EnrollmentCount><Interventions>Prednisolone acetate cream; betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Interventions><Reference>NCT01011621; PRE/P/08-1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis</ProtocolTitle><Sponsor>Mantecorp Industria Quimica e Farmaceutica Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="180987"></Trial><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>170</Patients><Biomarkers></Biomarkers><Condition>Seborrheic dermatitis</Condition><Controls></Controls><EnrollmentCount>170</EnrollmentCount><Interventions>Prednisolone acetate cream; betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Interventions><Reference>NCT01011621; PRE/P/08-1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation Of Durezol9415 For Macular Edema And Neovascular Disease</ProtocolTitle><Sponsor>Yamagata University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="234454"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>20</Patients><Biomarkers>Fovea centralis</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Interventions><Reference>JPRN-UMIN000001432; UMIN000001432</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Asthma Exacerbation Study</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="64836"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2019</Patients><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>2020</EnrollmentCount><Interventions>Relovair; fluticasone furoate</Interventions><Reference>106837; 2009-011461-84; HZA106837; JapicCTI-101072; NCT01086384</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 years)</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22129"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>101</Patients><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>BY9010/AR-101; NCT00305461</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77484"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>399</Patients><Biomarkers></Biomarkers><Condition>Gout</Condition><Controls>triamcinolone acetonide</Controls><EnrollmentCount>397</EnrollmentCount><Interventions>canakinumab; canakinumab-LYO; canakinumab-PFS</Interventions><Reference>2010-024173-39; CACZ885H2361; NCT01356602</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Ciclesonide Versus Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22083"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>700</Patients><Biomarkers>FEV</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>708</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>EFC6164; NCT00174720; XRP1526B/3031</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 12-Week Study To Compare Lung Function Within 24 H With The Combination Of Fluticasone Furoate (FF)/Vilanterol (VI) Of 100/25 microg, qd, And A Combination Of Fluticasone Propionate/Salmeterol Of 250/50 microg, bid, In Patients With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="165358"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>110</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><EnrollmentCount>110</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>2010-023418-29; HZC113109</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="80899"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>242</Patients><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>248</EnrollmentCount><Interventions>albuterol/salbutamol; fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>115283; FFA115283; NCT01436071</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="197089"></Trial><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>338</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77776"></Trial><Drug id="59618">fosdagrocorat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>C-terminal telopeptide of collagen type I; Collagen type I trimeric cross-linked peptide; Plasma cortisol; Plasma insulin; Serum adiponectin; Serum glucose; Serum osteocalcin; Urine N terminal telopeptide of type I collagen (uNTX)</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>PF-04171327</Interventions><Reference>A9391012; NCT01362673</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>DC 06/02</ProtocolAcronym><ProtocolTitle>Once-Daily Oral Modified-Release Hydrocortisone in Patients With Adrenal Insufficiency</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="57668"></Trial><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>64</Patients><Biomarkers>Glycated hemoglobin; Hydrocortisone</Biomarkers><Condition>Addisons disease</Condition><Controls>hydrocortisone</Controls><EnrollmentCount>64</EnrollmentCount><Interventions>dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Interventions><Reference>104-07; DC 06/02; EudraCT: 2006-0007084-89; NCT00915343</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Effect of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157075"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>283</Patients><Biomarkers>Bone Mineral Density (BMD); Lumbar spine bone mineral density</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><EnrollmentCount>283</EnrollmentCount><Interventions>Relovair</Interventions><Reference>102972; 2012-004801-28; HZC102972; NCT01957150</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy study to evaluate fluticasone furoate/vilanterol inhalation powder delivered once daily via the Dry Powder Inhaler Ellipta compared with usual ICS/LABA maintenance therapy delivered by dry powder Inhaler in subjects with persistent asthma</ProtocolTitle><Sponsor>GlaxoSmithKline Research &amp; Development Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="309224"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>422</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>Symbicort Turbohaler; Viani</Controls><EnrollmentCount>422</EnrollmentCount><Interventions>Relvar Ellipta</Interventions><Reference>2014-000551-81; HZA116492</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus</ProtocolTitle><Sponsor>CHU de Quebec-Universite Laval</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="198682"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>56</Patients><Biomarkers>Blood cell count; Thyroid-stimulating hormone</Biomarkers><Condition>Vulvar intraepithelial neoplasia</Condition><Controls></Controls><EnrollmentCount>56</EnrollmentCount><Interventions>clobetasol; tacrolimus</Interventions><Reference>NCT00757874; STJUSTINEH</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF-5993 in Healthy Volunteers</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258618"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Blood pressure; Diastolic blood pressure; Glucose; Heart rate; QT interval; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>CHF-5993; HFA-pressurised Metered Dose Inhaler; NEXThaler Dry Powder Inhaler; Valved Holding Chamber</Interventions><Reference>2015-005198-19; CCD-05993BA1-01; NCT02743013</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Adrenal Insufficiency in Children</ProtocolTitle><Sponsor>Diurnal Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="256755"></Trial><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>Infacort</Interventions><Reference>2014-002265-30; INFACORT-003; NCT02720952</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="32426"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>17</Patients><Biomarkers></Biomarkers><Condition>Atrophy</Condition><Controls></Controls><EnrollmentCount>17</EnrollmentCount><Interventions>Medidur FA</Interventions><Reference>C-01-08-004; NCT00695318</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Effects of Fluticasone Furoate and GW-642444-M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="73503"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Blood pressure; Heart rate; Heart rate; Serum cortisol; Serum potassium</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>Relovair</Interventions><Reference>111789; NCT01266941</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW-642444 Are Processed by the Body in Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75477"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>GW-642444; fluticasone furoate; fluticasone furoate/GW-642444</Interventions><Reference>102934; NCT01299558</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>GRAVITAS-301</ProtocolAcronym><ProtocolTitle>A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease</ProtocolTitle><Sponsor>Incyte Corp, MEDPACE SINGAPORE PTE LTD</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="297219"></Trial><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>439</Patients><Biomarkers>Blood platelets; Neutrophils</Biomarkers><Condition>Graft versus host disease</Condition><Controls>Medrol; Rayos</Controls><EnrollmentCount>439</EnrollmentCount><Interventions>Medrol; Rayos; itacitinib</Interventions><Reference>2017-000538-78; GRAVITAS-301; INCB 39110-301; INCB39110-301; NCT03139604</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>LIPMAT</ProtocolAcronym><ProtocolTitle>Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="234690"></Trial><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Blood flow; Cephalic vein; Radial artery</Biomarkers><Condition>Fistula</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Nanocort</Interventions><Reference>2015-002488-40; LIPMAT; LIPMAT; NCT02495662</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ILA115938</ProtocolAcronym><ProtocolTitle>Evaluate the Safety, Efficacy and Dose Response of GSK-573719 in Combination With Fluticasone Furoate in Subjects With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86335"></Trial><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>421</Patients><Biomarkers>FEV1; Peak Expiratory Flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Controls><EnrollmentCount>421</EnrollmentCount><Interventions>fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Reference>115938; ILA115938; ILA115938; NCT01573624</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Assess the Efficacy and Safety of PT-010 Compared to PT-009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="290987"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>Forced expiratory volume; Inspiratory capacity</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>PT-009; PT-010</Interventions><Reference>NCT03081247; PT010017</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study to Compare Fluticasone Furoate (FF) Single-strip Inhaler With FF Two-strip Inhaler and With FF/Vilanterol Combination</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="82997"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>115440; NCT01485445</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-up</ProtocolTitle><Sponsor>Anika Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="324751"></Trial><Drug id="103224">CINGAL</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>526</Patients><Biomarkers></Biomarkers><Condition>Arthralgia</Condition><Controls>Monovisc; triamcinolone hexacetonide</Controls><EnrollmentCount>526</EnrollmentCount><Interventions>CINGAL</Interventions><Reference>2017-003205-18; CINGAL 17-02; NCT03390036</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Dose-Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer</ProtocolTitle><Sponsor>Soligenix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="64387"></Trial><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Enteritis</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>SGX-201</Interventions><Reference>1R43CA141968-01; BDP-ENT-01; NCT01073384</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Safety and Tolerability of PT-010, PT-009 and PT-003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>AstraZeneca plc, Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="239329"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers>Bone mineral density; Lumbar spine bone mineral density</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>500</EnrollmentCount><Interventions>PT-003; PT-009; PT-010; symbicort</Interventions><Reference>NCT02536508; NCT03313570; PT010008</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration</ProtocolTitle><Sponsor>Diurnal Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="300900"></Trial><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>Infacort</Interventions><Reference>2016-001388-36; INFACORT 006; NCT03178214</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>480 Biomedical Sinus Drug Depot</ProtocolTitle><Sponsor>Lyra Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280158"></Trial><Drug id="103922">mometasone furoate (sustained release transmucosal formulation, chronic sinusitis), Lyra Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Chronic sinusitis</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>mometasone</Interventions><Reference>480MFSDD2016-001; NCT02942186; NCT02967731</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long Term Safety Of GW-685698X Via Nasal Biopsy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12096"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls>mometasone (nasal/ dermatological)</Controls><EnrollmentCount>125</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>FFR104503; NCT00224523</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study In Adults And Adolescents With Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12097"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>285</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>288</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>FFR103184; NCT00225823</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of FX-006 in Patients With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="83055"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Cortisol</Biomarkers><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>FX-006</Interventions><Reference>FX006-2011-002; NCT01487200</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis</ProtocolTitle><Sponsor>LEO Pharma A/S</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="353433"></Trial><Drug id="112485">SEGRA (topical, plaque psoriasis), Leo Pharma</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>13</Patients><Biomarkers>Alanine transaminase; Albumin; Aspartate aminotransferase; Bicarbonates; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Erythrocytes; Glucose; Heart; Heart rate; Hematocrit; Hemoglobin; Ketones; Lactate dehydrogenase; Leukocyte count; Lung; Mean corpuscular hemoglobin; Nitrite; Phosphate; Potassium; Skin; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea nitrogen; Uric acid; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Psoriasis</Condition><Controls>betamethasone valerate</Controls><EnrollmentCount>13</EnrollmentCount><Interventions>LEO-134310</Interventions><Reference>2018-000140-26; LP0155-1375; NCT03669757</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>CAPRA-2</ProtocolAcronym><ProtocolTitle>Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra) Therapy in Patients With Active Rheumatoid Arthritis</ProtocolTitle><Sponsor>Horizon Pharma plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9663"></Trial><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>350</Patients><Biomarkers>ACR20; ACR50; ACR70; Joint swelling; Joint tenderness</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>350</EnrollmentCount><Interventions>prednisone (oral, delayed release), Horizon/Mundipharma</Interventions><Reference>CAPRA-2; EudraCT-Number: 2007-003508-36; NCT00650078; NP01-007</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open Psoriasis Plaque Test to Evaluate Efficacy of Different Comparator to Mapracorat</ProtocolTitle><Sponsor>Bayer AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="325659"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Skin</Biomarkers><Condition>Psoriasis</Condition><Controls>calcipotriene + betamethasone dipropionate; calcipotriol; clobetasol; prednicarbate</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>mapracorat</Interventions><Reference>1404003; 16599; 2012-004171-39; NCT03399526</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Study of OTO-104 in Subjects With Unilateral Meniere's Disease</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="352993"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>160</Patients><Biomarkers></Biomarkers><Condition>Meniere disease</Condition><Controls></Controls><EnrollmentCount>160</EnrollmentCount><Interventions>OTO-104</Interventions><Reference>104-201811; NCT03664674</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67836"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>140</Patients><Biomarkers>serum cortisol</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>loratadine; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Reference>2014-004646-98; NCT01154153; TRICA_L_04286</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CASSIE</ProtocolAcronym><ProtocolTitle>Randomized, Control Trial on Combined Iluvien and Lucentis for Diabetic Macular Oedema</ProtocolTitle><Sponsor>Imperial College London</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="364319"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls>Lucentis</Controls><EnrollmentCount></EnrollmentCount><Interventions>Iluvien; Lucentis</Interventions><Reference>CASSIE; NCT03784443; P78912</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparator Study Evaluating Patient Preference Of FFNS versus FPNS</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11295"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>377</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount>377</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>FFU105924; NCT00539006</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails</ProtocolTitle><Sponsor>Mahidol University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="94221"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls>clobetasol propionate foam, Connetics</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>triamcinolone</Interventions><Reference>NCT01703325; Si599/2010</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PRF in Management of Chronic Multiple Oral Ulcers</ProtocolTitle><Sponsor>Beni-Suef University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373754"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Pemphigoid</Condition><Controls>Dermovate; orabase</Controls><EnrollmentCount>20</EnrollmentCount><Interventions>orabase; platelet rich fibrin gel</Interventions><Reference>00UAD; NCT03878771</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PRF in Management of Chronic Multiple Oral Ulcers</ProtocolTitle><Sponsor>Beni-Suef University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373754"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Mouth ulcer</Condition><Controls>Dermovate; orabase</Controls><EnrollmentCount>20</EnrollmentCount><Interventions>orabase; platelet rich fibrin gel</Interventions><Reference>00UAD; NCT03878771</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Deflazacort (Emflaza) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)</ProtocolTitle><Sponsor>PTC Therapeutics Inc</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="364440"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Forced Vital Capacity; Fukutin-related protein; Maximal expiratory pressure; Maximal inspiratory mouth pressure</Biomarkers><Condition>Limb girdle muscular dystrophy</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>deflazacort</Interventions><Reference>NCT03783923; PTCEMF-GD-004-LGMD</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>ATTeST</ProtocolAcronym><ProtocolTitle>EDS in Ataxia Telangiectasia Patients</ProtocolTitle><Sponsor>EryDel SPA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="260767"></Trial><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>180</Patients><Biomarkers></Biomarkers><Condition>Ataxia telangiectasia</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>EryDex</Interventions><Reference>115929; 2015-005241-31; ATTeST; CTRI/2017/02/007912; IEDAT-02-2015; NCT02770807</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single-Dose Pharmacokinetics of Deflazacort</ProtocolTitle><Sponsor>PTC Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="215408"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>58</Patients><Biomarkers>6 beta-Hydroxycortisol; Hydrocortisone</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>58</EnrollmentCount><Interventions>clarithromycin; deflazacort; deflazacort; rifampin</Interventions><Reference>MP-104-CL-025; NCT02286635</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="303059"></Trial><Drug id="61788">glucocorticoid receptor agonists (immune disorders, inflammatory diseases), Bristol-Myers Squibb</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>BMS-791826; prednisolone</Interventions><Reference>IM125-001; NCT03198013</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Clinical Study of GK-664S in Plaque Psoriasis Patients</ProtocolTitle><Sponsor>Maruho Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="226223"></Trial><Drug id="96680">clobetasol propionate shampoo (psoriasis), Galderma/Maruho</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>GK-664-S</Interventions><Reference>JapicCTI-152858</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Positive Controlled, Parallel, Phase II Trial To Evaluate The Efficacy And Safety Of Betamethasone Injection In The Local Blockage Treatment Of Oral Erosion Lichen Planus</ProtocolTitle><Sponsor>Sichuan University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="91441"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Lichen</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>betamethasone; triamcinolone acetonide</Interventions><Reference>ChiCTR-TRC-11001225</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Short-Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11760"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>91</Patients><Biomarkers>Ear pressure</Biomarkers><Condition>Middle ear disease</Condition><Controls></Controls><EnrollmentCount>91</EnrollmentCount><Interventions>Azmacort</Interventions><Reference>103-04; IST4008; NCT00279916; XRG5029C/4008</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW-685698X Inhalation Powder 200, 400, 600 and 800 microg Administered qd in the Morning and Fluticasone Propionate 500 microg bid via Diskus Inhalation Powder Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (= 12 years old) with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="117748"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>510</Patients><Biomarkers>Forced expiratory volume in 1 s; Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls>Flixotide</Controls><EnrollmentCount>510</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>EudraCT 2005-001122-87; FFA20003</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PED</ProtocolAcronym><ProtocolTitle>A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes</ProtocolTitle><Sponsor>Norwegian University of Science and Technology (NTNU)</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="101391"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>9</Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>9</EnrollmentCount><Interventions>aflibercept; aflibercept; triamcinolone acetonide; verteporfin</Interventions><Reference>2012/1743; NCT01746875; PED</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combined PDT and Intravitreal Bevacizumab versus Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="33340"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls>bevacizumab; triamcinolone acetonide; verteporfin</Controls><EnrollmentCount></EnrollmentCount><Interventions>bevacizumab; verteporfin</Interventions><Reference>8542; NCT00370539</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Controlled Trial of Intravitreal Bevacizumab Monotherapy Versus Triple Therapy With Half Fluence Verteporfin Photodynamic Therapy and Intravitreal Bevacizumab and Triamcinolone Acetonide for the Treatment of Neovascular Age-Related Macular Degeneration</ProtocolTitle><Sponsor>Hong Kong Eye Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="94644"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Pigment epithelium-derived factor; Retinal thickness; Vascular endothelial growth factor; Vascular endothelial growth factors</Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>bevacizumab; bevacizumab; triamcinolone acetonide; verteporfin</Interventions><Reference>CUHK_CCT00272; ChiCTR-TRC-10001137</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, double-dummy, parallel-group study to investigate the efficacy and safety of ciclesonide compared with budesonide in adolescents with severe asthma</ProtocolTitle><Sponsor>Takeda GmbH</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="76905"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>403</Patients><Biomarkers>FEV1; cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>431</EnrollmentCount><Interventions>budesonide; ciclesonide</Interventions><Reference>EudraCT No: 2004-001233-41</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo</ProtocolTitle><Sponsor>University of British Columbia</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="104547"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Vitiligo</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>H12-02140; NCT01766609</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid</ProtocolTitle><Sponsor>Sanofi SA, Takeda Pharmaceuticals International GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22084"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>456</Patients><Biomarkers>FEV1; FVC</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>456</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>EFC6163; NCT00174733; XRP1526B/3030</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Intralesional Bleomycin in Comparision to Combination of Intralesional 5-Fluorouracil and Triamcinolone Acetonide in Patients of Keloid and Hypertrophic Scars: A Randomized, Open-Labelled, Comparative Study</ProtocolTitle><Sponsor>Government Medical College, Bhavnagar</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162474"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Hypertrophic skin disease</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>5-fluorouracil; bleomycin; triamcinolone acetonide</Interventions><Reference>CTRI/2013/11/004155</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multiple-Dose Escalation Trial Of PF-04308515 In Healthy Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="65603"></Trial><Drug id="64584">PF-4308515</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>58</EnrollmentCount><Interventions>PF-04308515</Interventions><Reference>B0861002; NCT01101932</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot, Randomized Study to Compare Antibiotic Therapy (Ciprofloxacin, Trimethoprim and Metronidazole) with Standard Therapy (Budesonide) in the Treatment of Active Crohns Disease</ProtocolTitle><Sponsor>Royal Liverpool and Broadgreen University Hospitals NHS Trust</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="116894"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Crohns disease</Condition><Controls>Entocort</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>ciprofloxacin; metronidazole; trimethoprim</Interventions><Reference>UKCRN 13163</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>SCOS</ProtocolAcronym><ProtocolTitle>A 28-week, randomized, triple-blinded, placebo-controlled, parallel-group study to assess the effectiveness of long-acting beta-2-agonist, salmeterol monotherapy versus continued therapy with inhaled corticosteroids (ICS) in patients with persistent asthma</ProtocolTitle><Sponsor>University of California</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76806"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>164</Patients><Biomarkers>FEV1; PEF</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>164</EnrollmentCount><Interventions>salmeterol; triamcinolone acetonide</Interventions><Reference>SCOS</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, open-label study to assess the safety and efficacy of Nasacort in patients with seasonal and perennial allergic rhinitis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="89194"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>651</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>651</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>XRG5029C/4005</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, multicenter, randomized, single-blind, active-controlled, parallel group study to assess the safety and efficacy of Nasacort compared to Rhinocort Aqua in patients with seasonal allergic rhinitis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="91058"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>476</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls>budesonide (inhaled formulations), AstraZeneca</Controls><EnrollmentCount>476</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>XRG5029C/4007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Study on the Effectiveness, Safety and Acceptability Of Clobetasol Propionate Foam-cooled (OLUX) in Comparison With Cream Aceponato Methylprednisolone in the Treatment of Allergic Contact Dermatitis</ProtocolTitle><Sponsor>Mipharm SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="117327"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>82</Patients><Biomarkers></Biomarkers><Condition>Skin allergy</Condition><Controls>methylprednisolone aceponate</Controls><EnrollmentCount>82</EnrollmentCount><Interventions>clobetasol propionate foam, Connetics</Interventions><Reference>EudraCT 2008-004331-38; olux 01/08</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate Opthalmic Emulsion in the Treatment of Postoperative Inflammation</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21570"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00407225; SJE2079/2-01-PC</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study of Intranasal Fluticasone Once Daily Compared with Once-Daily Cetirizine in the Treatment of Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="153743"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>237</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>237</EnrollmentCount><Interventions>cetirizine; fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>FNM40072</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Two Doses of Qvar by Breath Operated and Metered Dose Inhalers in Asthmatic Children</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22290"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>440</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>440</EnrollmentCount><Interventions>Qvar</Interventions><Reference>IXR-302-25-197; NCT00094016</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TAC-202</ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis</ProtocolTitle><Sponsor>ZARS Pharma Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88586"></Trial><Drug id="64063">triamcinolone acetonide (DuraPeel cream, dermatitis/psoriasis), Nuvo Research</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition>Dermatitis</Condition><Controls></Controls><EnrollmentCount>56</EnrollmentCount><Interventions>triamcinolone acetonide (DuraPeel cream, dermatitis), Nuvo Research</Interventions><Reference>NCT00890968; TAC-202; TAC-202</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TPDT</ProtocolAcronym><ProtocolTitle>The Safety and Efficacy of Posterior Juxta-scleral (40 mg) or Intra-vitreal (4 mg) Triamcinolone Acetonide, in Addition to Verteporfin Photodynamic Therapy for Choroidal Neovascularization (CNV), in Age-related Macular Degeneration (AMD): A Randomized, Controlled Trial</ProtocolTitle><Sponsor>Newcastle Upon Tyne Hospitals NHS Trust</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="122573"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Choroidal neovascularization</Condition><Controls>verteporfin</Controls><EnrollmentCount>400</EnrollmentCount><Interventions>triamcinolone acetonide; verteporfin</Interventions><Reference>ISRCTN81615611; NRR Pub ID N0503172670 (03428); TPDT</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label Randomized Pilot Trial to Evaluate Tolerability, Safety and Applicability of AKITA Inhaled Budesonide Suspension in Children aged 3 to 11 years with Mild to Moderate Asthma</ProtocolTitle><Sponsor>Activaero GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="118612"></Trial><Drug id="83838">budesonide (controlled release/inhaled/AKITA, adult asthma), Vectura</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>FEV1; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>budesonide (controlled release/inhaled/AKITA, adult asthma),  Activaero</Interventions><Reference>Acti-SCIPE-001; EudraCT 2010-023981-27</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus</ProtocolTitle><Sponsor>Orion Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="132070"></Trial><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Interventions><Reference>3106008; EUDRACT 2012-003782-18; NCT01856621</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration</ProtocolTitle><Sponsor>Asociacion Para Evitar la Ceguera en Mexico</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="122141"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>transpupillary thermal rherapy; triamcinolone acetonide</Interventions><Reference>ISRCTN74123635</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study to Examine the Safety and Efficacy of Posterior Juxtascleral Triamcinolone Acetonide Administration, in Addition to Visudyne Photoynamic Therapy for Predominantly Classic Choroidal Neovascularization Secondary to Age Related Macular Degeneration: An Open-Label, Randomized, Active-Controlled Trial</ProtocolTitle><Sponsor>Kings College Hospital NHS Trust</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="142831"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>triamcinolone acetonide; verteporfin</Interventions><Reference>EudraCT 2005-002466-11; version125/05/05</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination therapy for DME</ProtocolTitle><Sponsor>Mie University School of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="256819"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls>ranibizumab</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>ranibizumab; triamcinolone acetonide</Interventions><Reference>UMIN000021630</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>KRONOS</ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multicenter Study to Assess the Efficacy and Safety of PT-010, PT-003, and PT-009 Compared With Symbicort Turbuhaler</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="234795"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1900</Patients><Biomarkers>Eosinophils; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort Turbuhaler</Controls><EnrollmentCount>1800</EnrollmentCount><Interventions>PT-003; PT-009; PT-010</Interventions><Reference>JapicCTI-184079; KRONOS; NCT02497001; PT010006</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability Study of SYN-006, Pulmicort pMDI and Meptin Air in Healthy Adult</ProtocolTitle><Sponsor>Intech Biopharm Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="197305"></Trial><Drug id="91606">budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>budesonide (inhaled formulations), AstraZeneca; procaterol hydrochloride (Meptin Air)</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Interventions><Reference>MCPK09003J1; NCT02165046</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II study of Efficacy and Safety of SJE-2079 in the Treatment for Diabetic Macular Edema</ProtocolTitle><Sponsor>Senju Usa Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124785"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Interventions><Reference>JPRN-UMIN000005648</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose GW-685698X Magnesium Stearate Study In Asthmatic Patients</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22276"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Forced expiratory volume; Hydrocortisone; PR interval; Peak expiratory flow rate; QRS complex; QT interval</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>HZA108799; NCT00444509</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Determine the Efficacy of Subacromial Bursa Corticosteroid Injection in Stroke Patients With Periarticular Shoulder Disorder</ProtocolTitle><Sponsor>Ajou University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="127285"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>AJIRB-MED-CT4-09-124; KCT0000104</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Single-Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics</ProtocolTitle><Sponsor>PTC Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="215407"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>End stage renal disease</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>deflazacort</Interventions><Reference>MP-104-CL-024; NCT02286622</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Safety of Repeat Administration of FX-006 Administered to Patients With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="287683"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>208</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>208</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2016-011; NCT03046446</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Evaluation of The Assistant Efficacy of Periodontal Treatment for The Oral Erosion Lichen Planus and The Post-Treatment</ProtocolTitle><Sponsor>Sichuan University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="168620"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Lichen</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>ChiCTR-TRC-13004128</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients</ProtocolTitle><Sponsor>Medivir AB</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23402"></Trial><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>201</Patients><Biomarkers></Biomarkers><Condition>Herpesvirus infection</Condition><Controls>acyclovir</Controls><EnrollmentCount>201</EnrollmentCount><Interventions>ME-609</Interventions><Reference>609-06; NCT00735761</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Periappendiceal Injection of Steroids in Ulcerative Colitis</ProtocolTitle><Sponsor>Postgraduate Institute of Medical Education and Research</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="128187"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers>Cytokine</Biomarkers><Condition>Ulcerative colitis</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>CTRI/2012/04/002605; Project number: P-130</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness Intra-articular Corticosteroid</ProtocolTitle><Sponsor>Universidade Federal de Sao Paulo - UNIFESP</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="129636"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>IIA- 3131- AR; NCT01851278</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus</ProtocolTitle><Sponsor>Orion Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="196211"></Trial><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>129</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Carbomix granules; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><EnrollmentCount>129</EnrollmentCount><Interventions>Carbomix granules; fluticasone propionate + salmeterol xinafoate; fluticasone propionate + salmeterol xinafoate</Interventions><Reference>3106009; NCT02162485</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22961"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>102</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>102</EnrollmentCount><Interventions>GW-685698</Interventions><Reference>2015-004888-37; FFR111158; NCT00730756</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide for Induction of Remission in Incomplete Microscopical Colitis</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="188822"></Trial><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>106</Patients><Biomarkers>Collagen; Lymphocytes</Biomarkers><Condition>Colitis</Condition><Controls></Controls><EnrollmentCount>106</EnrollmentCount><Interventions>budesonide</Interventions><Reference>2013-001912-31; BUG-3/MIC; NCT02142634</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23384"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Blood pressure; Heart rate; Hydrocortisone; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Avamys; Relovair</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>vilanterol</Interventions><Reference>HZA102940; NCT00625196</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multicenter, Randomized, Three Parallel-Groups to Estimate the Safety and Efficacy of Triamcinolone Acetonide Associated Laser, the Laser Associated Bevacizumab Versus Laser Alone for the Treatment of Diffuse Diabetic Macular Edema</ProtocolTitle><Sponsor>Roche Holding AG, Sanofi SA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="130318"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>105</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>105</EnrollmentCount><Interventions>bevacizumab; triamcinolone acetonide</Interventions><Reference>ALBA2009; EudraCT 2009-014654-15</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW-642444) in Adult and Adolescent Asthmatics</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="68324"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>609</Patients><Biomarkers>Forced expiratory volume in 1 s (FEV1); Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>612</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>106827; 2010-019590-15; HZA106827; NCT01165138; P/119/2011</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intra-oral Treatment of OLP With Rivelin-CLO Patches</ProtocolTitle><Sponsor>AFYX Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="346927"></Trial><Drug id="111733">clobetasol propionate  patch (intraoral, bio-adhesive, oral lichen planus), Dermtreat Aps</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>240</Patients><Biomarkers></Biomarkers><Condition>Lichen</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>Rivelin-CLO</Interventions><Reference>2017-002193-40; DT-001-R-004; NCT03592342</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ACT DMD</ProtocolAcronym><ProtocolTitle>Phase III Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy</ProtocolTitle><Sponsor>PTC Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="119769"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>230</Patients><Biomarkers>Dystrophin; Muscle; Six-minute walk distance</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls>deflazacort; prednisone</Controls><EnrollmentCount>230</EnrollmentCount><Interventions>ataluren</Interventions><Reference>2012-004527-20; 2017-001223-49; 431; 68; ACT DMD; IND Number Number: 68,431; NCT01826487; PTC124-GD-020-DMD</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Controlled Trial of Intravitreal Triamcinolone in Patients with Diabetic Macular edema Refractory to Laser Treatment</ProtocolTitle><Sponsor>Department of Health</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="135441"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers>Intra-ocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>ISRCTN90614292; N0192133909</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13577"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>288</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>288</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>FFR104861; NCT00197262</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Safety and Efficacy of Combined Subtenon Triamcinolone and Grid Laser Photocoagulation as Primary Treatment for Diabetic Macular Edema - A Pilot Study</ProtocolTitle><Sponsor>Chinese University of Hong Kong</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="135786"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>grid laser photocoagulation treatment; triamcinolone acetonide</Interventions><Reference>CUHK_CCT00130; ChiCTR-TRC-09000743</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine</ProtocolTitle><Sponsor>GlaxoSmithKline Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13581"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1000</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>1000</EnrollmentCount><Interventions>fexofenadine; fluticasone furoate</Interventions><Reference>2015-004885-27; FFU109045; NCT00435461</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis</ProtocolTitle><Sponsor>Ligand Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="58894"></Trial><Drug id="62431">budesonide + azelastine (intranasal Captisol-enabled, allergic rhinitis), Sedor Pharmaceuticals</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>108</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>108</EnrollmentCount><Interventions>Astelin; CDX-313; Rhinocort Aqua</Interventions><Reference>CDX313CT001; NCT00940953; P2DS07001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to compare the blood concentration of budesonide and the bronchodilatory effect after administration of the following study drugs: Budesonide-Salmeterol DPI capsule 75-25 microg, Budesonide-Salmeterol DPI capsule 75-12.5 microg, Budesonide-Salmeterol DPI capsule 75-6.25 microg delivered by the Axahaler versus Serevent Diskus 50 microg + Pulmicort Turbuhaler 100 microg co-administration in asthmatic children</ProtocolTitle><Sponsor>Laboratoires SMB SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="337272"></Trial><Drug id="78537">budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Glucose; Heart rate; Peak expiratory flow rate; Potassium; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>Pulmicort Turbuhaler; Serevent Diskus</Controls><EnrollmentCount>48</EnrollmentCount><Interventions>Busal</Interventions><Reference>2017-003330-91; BUSAL-II-17-1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, non-randomized, pharmacokinetic and safety study of repeat-doses of fluticasone furoate and GW-42444M combination in healthy subjects and in subjects with mild, moderate or severe hepatic impairment</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="257760"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Heart rate; Hydrocortisone; Potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>GW-642444-M; fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>2010-020157-13; HZA111789</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, non-randomized, pharmacokinetic and safety study of repeat-doses of fluticasone furoate and GW-42444M combination in healthy subjects and in subjects with mild, moderate or severe hepatic impairment</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="257760"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Heart rate; Hydrocortisone; Potassium</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>GW-642444-M; fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>2010-020157-13; HZA111789</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Of Perennial Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13878"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>65</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>65</EnrollmentCount><Interventions>GW-685698</Interventions><Reference>FFR100688; JapicCTI-050024; NCT00358475</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine</ProtocolTitle><Sponsor>GlaxoSmithKline Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13883"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>680</Patients><Biomarkers>Peak nasal inspiratory flow; Peak nasal inspiratory flow</Biomarkers><Condition>Allergic rhinitis</Condition><Controls>fexofenadine</Controls><EnrollmentCount>680</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>2015-004873-34; FFU109047; NCT00502775</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Qvar Versus Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients</ProtocolTitle><Sponsor>IVAX Research Inc, Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="22588"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Forced expiratory volume in 1 s</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount>49</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Reference>IXR-402-4-196; NCT00071552</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="61703"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1626</Patients><Biomarkers>Eosinophils; FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><EnrollmentCount>1626</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate</Interventions><Reference>102871; HZC102871; NCT01009463</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="187642"></Trial><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1363</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>625</EnrollmentCount><Interventions>Airexar Spiromax; fluticasone</Interventions><Reference>2014-001149-25; FSS-AS-301; NCT02139644</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma</ProtocolTitle><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="308779"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>870</Patients><Biomarkers>Forced expiratory volume; Glucose; PR interval; Peak expiratory flow rate; QRS complex; QT interval</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate</Controls><EnrollmentCount>870</EnrollmentCount><Interventions>ELLIPTA dry powder inhaler; Ellipta</Interventions><Reference>107116; 2016-004086-87; CTR20181312; HZA107116; JapicCTI-183937; NCT03248128</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis</ProtocolTitle><Sponsor>InSite Vision Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="28944"></Trial><Drug id="55854">azithromycin + dexamethasone (sustained release, DuraSite), InSite</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Blepharoconjunctivitis</Condition><Controls>AzaSite; dexamethasone</Controls><EnrollmentCount></EnrollmentCount><Interventions>AzaSite Plus</Interventions><Reference>C-07-502-003; NCT00754949</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ADO pMDI</ProtocolAcronym><ProtocolTitle>Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="113665"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>FEV1; Heart rate; Plasma glucose; Plasma potassium</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>AeroChamber Plus; Foster; Qvar; formoterol fumarate (Atimos)</Interventions><Reference>2011-005108-14; ADO pMDI; CCD-1104-PR-0062; NCT01803087</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Compare the Clinical Effects of Beclomethasone Dipropionate MDI With Spacer and Budesonide MDI With Spacer in the Treatment of Children With Mild Persistent Asthma Aged 7 to 15 Years</ProtocolTitle><Sponsor>Department of Pharmacology, PGIMER</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="156545"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>85</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>85</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; budesonide</Interventions><Reference>CTRI/2013/03/003495</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluocinolone implant to treat macular degeneration</ProtocolTitle><Sponsor>National Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="4710"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Reference>01-EI-0058; 010058; NCT00008515</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vitrectomy combined with IVTA for DME</ProtocolTitle><Sponsor>Tohoku University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="228441"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>60</Patients><Biomarkers>Retina</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide; vitrectomy</Interventions><Reference>UMIN000017250</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics</ProtocolTitle><Sponsor>University of Virginia</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="283200"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>95</Patients><Biomarkers>Carbon monoxide diffusing capacity</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>95</EnrollmentCount><Interventions>Anoro Ellipta; Arnuity Ellipta; hyper polarized xenon-129 MRI</Interventions><Reference>19352; NCT03002389</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>CTS</ProtocolAcronym><ProtocolTitle>Chalazia Treatment Study</ProtocolTitle><Sponsor>University of Washington</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="165479"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Chalazion</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>5-fluorouracil; 5-fluorouracil; incision and curettage; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Reference>42336; 42336-D; CTS; NCT02025023; STUDY00003748</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Fluticasone Furoate(FF)/GW-642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="63564"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1224</Patients><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>1226</EnrollmentCount><Interventions>GW-642444; Relovair; fluticasone furoate</Interventions><Reference>112207; 2009-013067-19; HZC112207; JapicCTI-101097; NCT01054885</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 6-Month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate(FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="63573"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1030</Patients><Biomarkers>Cortisol; FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>1031</EnrollmentCount><Interventions>GW-642444; Relovair; fluticasone furoate</Interventions><Reference>112206; HZC112206; JapicCTI-101096; NCT01053988</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Safety and Efficacy of BOL-303242X Ophthalmic Suspension in Dry Eye Syndrome</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="68287"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>350</Patients><Biomarkers></Biomarkers><Condition>Xerophthalmia</Condition><Controls></Controls><EnrollmentCount>350</EnrollmentCount><Interventions>BOL-303242X</Interventions><Reference>637; EudraCT: 2010-018441-61; NCT01163643</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety Study of PT-010 in Healthy Subjects</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="204168"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>72</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>59</EnrollmentCount><Interventions>PT-009; PT-010; Symbicort Turbohaler</Interventions><Reference>NCT02189304; PT010002-00</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Dermatitis</ProtocolTitle><Sponsor>Stiefel</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="55280"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Dermatitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>clobetasol propionate</Interventions><Reference>NCT00828464; U0280-401</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>TRIGGER</ProtocolAcronym><ProtocolTitle>Triple in Asthma High Strength Versus ICS/LABA HS and Tiotropium</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="252801"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1433</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>Foster; Foster; Tiotropium Respimat</Controls><EnrollmentCount>1433</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>2015-000717-40; CCD-05993AB2-02; NCT02676089; TRIGGER</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 24-week study to evaluate the effect of fluticasone furoate/vilanterol 100/25 microg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="220553"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>408</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><EnrollmentCount>408</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>2010-023091-10; HZC113108</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Second, Phase III Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Sponsor>Ocular Therapeutix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="178013"></Trial><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>241</Patients><Biomarkers>Anterior chamber; Intraocular pressure</Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>NCT02089113; OTX-14-003</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar Ellipta DPI on Ventilation Heterogeneity in Asthma</ProtocolTitle><Sponsor>Mundipharma International Corp Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="259438"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>105</Patients><Biomarkers>Airway resistance; Forced Vital Capacity; Forced expiratory flow ; Forced expiratory volume; Lung; Lung clearance index; Partial pressure of oxygen</Biomarkers><Condition>Asthma</Condition><Controls>Relvar Ellipta</Controls><EnrollmentCount>105</EnrollmentCount><Interventions>Abriff</Interventions><Reference>2015-000801-38; KFL3502; NCT02753712</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of PT-009, PT-008, and PT-005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="205952"></Trial><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>180</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>PT-009; budesonide; formoterol</Interventions><Reference>NCT02196077; PT009001</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of PT-009, PT-008, and PT-005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="205952"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>180</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>PT-009; budesonide; formoterol</Interventions><Reference>NCT02196077; PT009001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Compare the Effects of Fluticasone Furoate Nasal Spray versus Placebo in Patients With Nasal Polypoid Disease</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="61959"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Nasal polyps</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>NA_00029405; NCT01013701</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye</ProtocolTitle><Sponsor>Ocular Therapeutix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="231838"></Trial><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>43</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Xerophthalmia</Condition><Controls></Controls><EnrollmentCount>43</EnrollmentCount><Interventions>OTX-DP</Interventions><Reference>NCT02468700; OTX-14-006</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dropless Versus Standard Drops Contralateral Eye Study</ProtocolTitle><Sponsor>Carolina Eyecare Physicians, LLC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="236566"></Trial><Drug id="95157">triamcinolone acetonide + moxifloxicin hydrochloride + vancomycin (ocular disease), Harrow Health</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>66</Patients><Biomarkers>Central cornea; Intraocular pressure; Macula retinae</Biomarkers><Condition>Ocular infection</Condition><Controls>Moxeza; nepafenac; prednisolone acetate</Controls><EnrollmentCount>59</EnrollmentCount><Interventions>TriMoxiVanc; TriMoxiVanc; nepafenac</Interventions><Reference>CEP 14-002; NCT02515045</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort</ProtocolTitle><Sponsor>PTC Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="216535"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Dystrophin</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>deflazacort</Interventions><Reference>MP-104-CL-022OLE; NCT02295748</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide Capsules Versus Mesalazine Granules Versus Placebo in Collagenous Colitis</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="19193"></Trial><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>92</Patients><Biomarkers></Biomarkers><Condition>Colitis</Condition><Controls></Controls><EnrollmentCount>92</EnrollmentCount><Interventions>budesonide; mesalazine</Interventions><Reference>2006-004159-39; BUC-60/COC; NCT00450086</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Asthma Exacerbation Study</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="64836"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2019</Patients><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>2020</EnrollmentCount><Interventions>Relovair; fluticasone furoate</Interventions><Reference>106837; 2009-011461-84; HZA106837; JapicCTI-101072; NCT01086384</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis</ProtocolTitle><Sponsor>Bausch Health Companies Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="236598"></Trial><Drug id="109395">halobetasol propionate (0.01% topical lotion, plaque psoriasis), Ortho Dermatologics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>213</Patients><Biomarkers>Body surface area</Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>213</EnrollmentCount><Interventions>Bryhali</Interventions><Reference>NCT02515097; V01-122A-302</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ATEMD</ProtocolAcronym><ProtocolTitle>Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema</ProtocolTitle><Sponsor>Universidade Federal de Sao Paulo - UNIFESP</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24389"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>65</Patients><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>142</EnrollmentCount><Interventions>bevacizumab; bevacizumab; triamcinolone acetonide; triamcinolone acetonide</Interventions><Reference>108/08; ATEMD; NCT00737971</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Beclomethasone dipropionate HFA in adult and adolescent subjects with persistent asthma</ProtocolTitle><Sponsor>Adamis Pharmaceuticals Corp</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="369472"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>480</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>Qvar</Controls><EnrollmentCount>480</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Reference>APC-1000-02; NCT03834012</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Triple study</ProtocolAcronym><ProtocolTitle>Pharmacokineticsof the active components of anextrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G)delivered via a hydrofluoroalkane 134-a pressurized-metered dose inhaler (HFA pMDI) in Chinese healthy adults</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA, West China Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="358796"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>CHF-5993; hydrofluoroalkane 134-a pressurized-metered dose inhaler (HFA pMDI)</Interventions><Reference>ChiCTR1800019095; Triple study</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Long-term Safety Study of Fluticasone Furoate (FF)/GW-642444 in Japanese Subjects With COPD</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="230954"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>187</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bicarbonates; Bilirubin; Blood platelets; Blood pressure; Carbon dioxide; Chlorides; Creatine kinase; Creatinine; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Hydrocortisone; Ketones; Lactate dehydrogenase; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; Potassium; Sodium; Total protein; Urea; Urea nitrogen; Uric acid; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>187</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>114156; JapicCTI-101342; NCT01192191</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="197089"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>338</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate versus Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery</ProtocolTitle><Sponsor>Cincinnati Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="72412"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>52</Patients><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Ocular inflammation</Condition><Controls>prednisolone acetate</Controls><EnrollmentCount>52</EnrollmentCount><Interventions>Durezol</Interventions><Reference>NCT01244334; SEMC 5/2009-011</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Sponsor>Ocular Therapeutix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90260"></Trial><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Ocular pain</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>OTX-DP</Interventions><Reference>NCT01666210; OTX-12-002</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sunovion Growth Study Pediatric Subjects With Mild Asthma and Allergic Rhinitis</ProtocolTitle><Sponsor>West Penn Allegheny Health System Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86234"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>Alvesco; Beconase; Omnaris; Qvar</Interventions><Reference>NCT01550471; RC#5401</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="257588"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>1055</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bicarbonates; Bilirubin; Blood platelets; Body temperature; Bone mineral density; Calcium; Carbon dioxide; Chlorine; Creatine kinase; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Forced expiratory volume; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; Phosphorus; Potassium; Sodium; Systolic blood pressure; Urea nitrogen; Uric acid; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Ellipta; umeclidinium bromide</Controls><EnrollmentCount>1058</EnrollmentCount><Interventions>Elebrato Ellipta</Interventions><Reference>200812; 2015-005212-14; JapicCTI-163329; NCT02729051</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy of Administration of Cyclosporine (Low-Dose and High-Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis</ProtocolTitle><Sponsor>Fovea Pharmaceuticals SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66292"></Trial><Drug id="56186">ciclosporin + prednisolone (allergic conjunctivitis), CombinatoRx/Fovea</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>716</Patients><Biomarkers></Biomarkers><Condition>Allergic conjunctivitis</Condition><Controls></Controls><EnrollmentCount>716</EnrollmentCount><Interventions>cyclosporine; cyclosporine + prednisolone (allergic conjunctivitis), CombinatoRx/Fovea; prednisolone</Interventions><Reference>10-003-03; FOV1101/CLIN202; NCT01120132</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy</ProtocolTitle><Sponsor>GlaxoSmithKline Research &amp; Development Ltd, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22441"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>627</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bicarbonates; Bilirubin; Blood platelets; Blood pressure; Calcium; Carbon dioxide; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; FEV1; Glucose; Heart rate; Hematocrit; Hemoglobin; Ketones; Lactate dehydrogenase; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; PEF; Phosphorus; Potassium; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Urea; Uric acid; Urinary protein; cortisol; gamma-Glutamyltransferase</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>627</EnrollmentCount><Interventions>fluticasone; fluticasone furoate</Interventions><Reference>2007-004458-98; FFA109684; NCT00603746</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide for Maintenance Treatment of Collagenous Colitis</ProtocolTitle><Sponsor>University of Dresden</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="64504"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition>Colitis</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>budesonide</Interventions><Reference>MIMIC; NCT00180076</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66890"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>470</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>474</EnrollmentCount><Interventions>Qnaze</Interventions><Reference>BDP-AR-302; NCT01134705</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability and PD Activity of Inhaled TPI-1020 Versus Inhaled Budesonide in COPD Patients</ProtocolTitle><Sponsor>Pharmaxis Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="3700"></Trial><Drug id="29656">TPI-1020</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>62</Patients><Biomarkers>Cytokines; Neutrophils</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>budesonide</Controls><EnrollmentCount>62</EnrollmentCount><Interventions>TPI-1020 </Interventions><Reference>NCT00483743; TPI 1020-203</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>CareOnTIME</ProtocolAcronym><ProtocolTitle>Innovative Treatment in Congenital Adrenal Hyperplasia</ProtocolTitle><Sponsor>Universita degli Studi di Napoli Federico II</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="362194"></Trial><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Antral follicles; Blood pressure; Body Mass Index; Bone mineral density; Hemoglobin A, glycosylated; High-density lipoprotein cholesterol; Testosterone/Androstenedione ratio; Total cholesterol; Triglycerides</Biomarkers><Condition>Congenital adrenal hyperplasia</Condition><Controls>cortisone acetate; dexamethasone; hydrocortisone; prednisolone; prednisone</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Plenadren</Interventions><Reference>140/16; CareOnTIME; NCT03760835</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>ORBIT2</ProtocolAcronym><ProtocolTitle>An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="258090"></Trial><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers>Eosinophils</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>budesonide</Interventions><Reference>NCT02736409; ORBIT2; SHP621-302</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>FAVOR</ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="30143"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Reference>C-01-08-006; FAVOR; NCT00770770</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of glycerol, two topical steroids, and a topical immune modulator against skin irritation</ProtocolTitle><Sponsor>Odense University Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="31700"></Trial><Drug id="59469">triamcinolone acetonide (topical, dermatoses, AzoneTS), Echo</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Contact dermatitis</Condition><Controls>vehicle ointment (paraffin oil/soft white paraffin)</Controls><EnrollmentCount>36</EnrollmentCount><Interventions>Clarelux; Durhalieve; Protopic; glycerol</Interventions><Reference>2008-001678-34; NCT00779792; WA+TR_1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Open-Label, Phase III, Multicenter, Parallel Group Study to Evaluate Efficacy and Safety Study of GK-664-S in Subjects With Moderate-to-Severe Scalp Eczema Dermatitis Except for Seborrheic Dermatitis</ProtocolTitle><Sponsor>Maruho Co Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="366908"></Trial><Drug id="96680">clobetasol propionate shampoo (psoriasis), Galderma/Maruho</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Eczema</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>GK-664-S</Interventions><Reference>JapicCTI-184247</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relovair PD PK in Chinese Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="95532"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Blood pressure; Heart rate; Potassium; QT interval; Serum cortisol; Whole blood potassium</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>115199; NCT01711463</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="257690"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Ellipta inhaler; fluticasone furoate + umeclidinium + vilanterol (dry powder inhaled, COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; salbutamol, GlaxoSmithKline; umeclidinium bromide</Interventions><Reference>205165; NCT02731846</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Effect of GW-870086-X on Allergen Challenge in Mild Asthmatics</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="48265"></Trial><Drug id="54598">870086 (inhaled, asthma), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; FEV1; Glucose; Heart rate; Hematocrit; Hemoglobin; Interleukin-8; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Myeloperoxidase; Neutrophils; Potassium; Reticulocytes; Sodium; Systolic blood pressure; Total protein; gamma-Glutamyltransferase</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>870086 (inhaled, asthma), GlaxoSmithKline</Interventions><Reference>110762; 2007-005791-14; NCT00857857</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>PRO-145/III</ProtocolAcronym><ProtocolTitle>Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification</ProtocolTitle><Sponsor>Laboratorios Sophia</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="355334"></Trial><Drug id="112786">Difluprednate (ophthalmic solution, ocular inflammation/ocular pain), Laboratorios Sophia</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>178</Patients><Biomarkers>Anterior chamber; Intraocular pressure; Retina</Biomarkers><Condition>Pain</Condition><Controls>Prednefrin</Controls><EnrollmentCount>178</EnrollmentCount><Interventions>PRO-145</Interventions><Reference>NCT03693989; PRO-145/III; SOPH145-0716 / III</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug Use Investigation for Allermist</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="78401"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><Patients>2000</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>2000</EnrollmentCount><Interventions>Allermist</Interventions><Reference>113407; NCT01376206</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Different Concentrations of ZK-245186 in Atopic Dermatitis (AD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71668"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>263</Patients><Biomarkers></Biomarkers><Condition>Atopic dermatitis</Condition><Controls></Controls><EnrollmentCount>263</EnrollmentCount><Interventions>mapracorat</Interventions><Reference>1403380; 15267; NCT01228513</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Assess The Efficacy Of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 Microg Once-Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 Microg Twice-daily In Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="94705"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>828</Patients><Biomarkers>Forced expiratory volume in 1 s (FEV1)</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><EnrollmentCount>828</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>077855 and 050703; 116974; NCT01706328; RLV116974</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF/Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="97979"></Trial><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline; umeclidinium</Interventions><Reference>116524; NCT01725685</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF/Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="97979"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline; umeclidinium</Interventions><Reference>116524; NCT01725685</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 6-Month Extension Study of OTO-104 in Meniere's Disease</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="260634"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>141</Patients><Biomarkers></Biomarkers><Condition>Meniere disease</Condition><Controls></Controls><EnrollmentCount>141</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>104-201610; 2016-000766-29; NCT02768662</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>AVERTS-2</ProtocolAcronym><ProtocolTitle>Study of OTO-104 in Subjects With Unilateral Meniere's Disease</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="256498"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>174</Patients><Biomarkers></Biomarkers><Condition>Meniere disease</Condition><Controls></Controls><EnrollmentCount>176</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>104-201508; 2015-004496-71; AVERTS-2; NCT02717442</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>EEFFEK</ProtocolAcronym><ProtocolTitle>Early Effect of Cingal Compared to Monovisc in Patients With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Pharmascience Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="289267"></Trial><Drug id="103224">CINGAL</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>Monovisc</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>CINGAL</Interventions><Reference>CIN-401; EEFFEK; NCT03062787</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>Ethos</ProtocolAcronym><ProtocolTitle>Study to Assess the Efficacy and Safety of PT-010 Relative to PT-003 and PT-009 in Subjects With Moderate to Very Severe COPD</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="231627"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>8564</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>8564</EnrollmentCount><Interventions>PT-003; PT-009; PT-010</Interventions><Reference>118313; 2014-005671-92; Ethos; JapicCTI-184078; NCT02465567; PT010005</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomised, Double-blind, Placebo-controlled, 6-way Cross-over Design Study to Investigate the Effect of 250 microg Single Inhaled Doses of GW-685698X and Fluticasone Propionate on Airway Responsiveness to Adenosine 5’-monophosphate (AMP) Challenge in Mild Asthmatic Patients</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87519"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>FVC</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>GW-685698X; fluticasone propionate</Interventions><Reference>FFA10027</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>FLASH</ProtocolAcronym><ProtocolTitle>A Dose-Ranging Study of CHF-1531 in Asthmatic Subjects</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="291496"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>67</Patients><Biomarkers>Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Glucose; Heart rate; PR interval; Peak expiratory flow rate; Potassium; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>Perforomist</Controls><EnrollmentCount>67</EnrollmentCount><Interventions>CHF-1531</Interventions><Reference>CCD-05993AA3-03; FLASH; NCT03086460</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vasoconstriction Trial With LEO-90100 Aerosol Foam</ProtocolTitle><Sponsor>LEO Pharma A/S</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280409"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls>Dermovate; Diprosone; Elocon; Locoid</Controls><EnrollmentCount>36</EnrollmentCount><Interventions>Enstilar</Interventions><Reference>LP0053-1276; NCT02973776</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2 to 5 Years With Perennial Allergic Rhinitis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12107"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>474</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>460</EnrollmentCount><Interventions>Nasacort AQ</Interventions><Reference>NCT00132925; XRG5029C_3502</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis</ProtocolTitle><Sponsor>LEO Pharma A/S</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="353433"></Trial><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>13</Patients><Biomarkers>Alanine transaminase; Albumin; Aspartate aminotransferase; Bicarbonates; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Erythrocytes; Glucose; Heart; Heart rate; Hematocrit; Hemoglobin; Ketones; Lactate dehydrogenase; Leukocyte count; Lung; Mean corpuscular hemoglobin; Nitrite; Phosphate; Potassium; Skin; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea nitrogen; Uric acid; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Psoriasis</Condition><Controls>betamethasone valerate</Controls><EnrollmentCount>13</EnrollmentCount><Interventions>LEO-134310</Interventions><Reference>2018-000140-26; LP0155-1375; NCT03669757</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide</ProtocolTitle><Sponsor>Anika Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="301892"></Trial><Drug id="103224">CINGAL</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>576</Patients><Biomarkers></Biomarkers><Condition>Arthralgia</Condition><Controls>Monovisc; triamcinolone hexacetonide</Controls><EnrollmentCount>576</EnrollmentCount><Interventions>CINGAL</Interventions><Reference>2017-000355-46; CINGAL 16-02; NCT03191903</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="236849"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>251</Patients><Biomarkers>Anterior chamber</Biomarkers><Condition>Uveitis</Condition><Controls>prednisolone acetate ophthalmic</Controls><EnrollmentCount>251</EnrollmentCount><Interventions>EGP-437; EyeGate II Drug Delivery System (EGDS); ocular iontophoresis</Interventions><Reference>EGP-437-006; NCT02517619</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of FX-006 on Synovial Inflammation in Patients With osteoarthritis (OA) of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="340019"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Estimated glomerular filtration rate; Synovial membrane</Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>FX-006</Interventions><Reference>FX006-2017-014; NCT03529942</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis</ProtocolTitle><Sponsor>Bausch Health Americas, Inc.</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="384836"></Trial><Drug id="109395">halobetasol propionate (0.01% topical lotion, plaque psoriasis), Ortho Dermatologics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>45</Patients><Biomarkers>Body surface area; Hydrocortisone</Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>IDP-122</Interventions><Reference>NCT03987763; V01-122A-401</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA</ProtocolTitle><Sponsor>University of Kansas Medical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="375286"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>NCT03895840; STUDY00142926</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized trial for the evaluation of Triamcinolone Acetonide and Fibrin Glue in the prevention of seroma formation after axillary dissection</ProtocolTitle><Sponsor>Tan Tock Seng Hospital</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="161209"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Fibrin Glue; triamcinolone acetonide</Interventions><Reference>2011/02145</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>LOGAN</ProtocolAcronym><ProtocolTitle>A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT-007 and PT-008 Administered Separately</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="363124"></Trial><Drug id="109733">budesonide + salbutamol (asthma), Pearl/ Avillion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>91</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>PT-007; PT-008</Controls><EnrollmentCount>91</EnrollmentCount><Interventions>PT-027</Interventions><Reference>D6930C00003; LOGAN; NCT03772223</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI-54903 XX Via Respimat Soft MistTM Inhaler B in Healthy Male Subjects</ProtocolTitle><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="208595"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>ciclesonide (metered dose inhaler), Nycomed</Controls><EnrollmentCount>56</EnrollmentCount><Interventions>BI-54903; butylated hydroxytoluene</Interventions><Reference>1256.1; NCT02221375</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21685"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>438</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>219</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00430092; ST-601A-002b</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="61354"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>80</Patients><Biomarkers>CYP3A4; Hydrocortisone</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>113477; NCT01000597</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Does Extra-Fine Hydrofluoroalkane-Beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)?</ProtocolTitle><Sponsor>University of Dundee</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="58085"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Blood cells; C-reactive protein; Cortisol/Creatinine ratio; Glucose; Hydrocortisone; Interleukin-6; Nitric oxide; Tumor necrosis factor</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>prednisolone</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>Qvar</Interventions><Reference>2008-005909-19; NCT00921921; PAW002</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of Three Doses of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="64307"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>54</Patients><Biomarkers>Blood pressure; Cortisol; Diastolic blood pressure; FEV1; Fasting glucose; Potassium; Pulse rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>54</EnrollmentCount><Interventions>Relovair</Interventions><Reference>110946; NCT01072149</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="225253"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; mometasone (nasal)</Interventions><Reference>201474; NCT02397915</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte</ProtocolTitle><Sponsor>ISTA Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10077"></Trial><Drug id="53134">tobramycin + prednisolone acetate (ophthalmic), ISTA</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>132</Patients><Biomarkers></Biomarkers><Condition>Bacterial infection</Condition><Controls>prednisolone acetate</Controls><EnrollmentCount>132</EnrollmentCount><Interventions>tobramycin + prednisolone acetate (ophthalmic), ISTA</Interventions><Reference>ISTA-TP-CPK01; NCT00198523</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="187399"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>343</Patients><Biomarkers></Biomarkers><Condition>Ulcerative colitis</Condition><Controls>mesalazine</Controls><EnrollmentCount>343</EnrollmentCount><Interventions>Uceris</Interventions><Reference>2006-005377-22; BUC-57/UCA; NCT00747110</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intracameral different dosage triamcinolone acetonide preventing anterior uveitis after pediatric cataract surgery</ProtocolTitle><Sponsor>Beijing Shijitan Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="151509"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers>Intraocular Pressure</Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>ChiCTR-TRC-13003465</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects Of Single Doses Of GW-784568-X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="14031"></Trial><Drug id="56749">784568</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>69</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount>45</EnrollmentCount><Interventions>GW-784568-X</Interventions><Reference>BGS105049; NCT00404586</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Placebo-Controlled Clinical Trial of Intravitreal Triamcinolone for Refractory Diabetic Macular Edema</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="166045"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>76</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>76</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>8126; NCT00369863</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Single Dose-Escalation Study of PF-04308515 in Healthy Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60956"></Trial><Drug id="64584">PF-4308515</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Unidentified indication</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>PF-04308515</Interventions><Reference>B0861001; NCT00990015</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="70171"></Trial><Drug id="64584">PF-4308515</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>C-peptide; Plasma glucose; Plasma insulin</Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>PF-04308515; prednisone</Interventions><Reference>B0861004; NCT01199029</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Multicenter, One-Year Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of CRx-102 in Subjects with Active Rheumatoid Arthritis</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="125078"></Trial><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>616</Patients><Biomarkers>ACTH; CRP; HgbA1c; IOP; lipid; platelet</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>616</EnrollmentCount><Interventions>CRx-102</Interventions><Reference>CRx-102-007E; EudraCT 2007-004399-38</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Topical Steroid/antibiotic Association Treatments Following Phacoemulsification Cataract Extraction</ProtocolTitle><Sponsor>SIFI Societa Industria Farmaceutica Italiana SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="118314"></Trial><Drug id="56575">dexamethasone + netilmicin (ophthalmic), SIFI</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>240</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls>BETABIOPTAL</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>dexamethasone + netilmicin (ophthalmic), SIFI</Interventions><Reference>033/SI; EudraCT 2006-003305-13</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, parallel and Controlled study to Evaluate Inhibition effect of different doses of triamcinolone acetonide in inhibiting anterior uveitis after combined phacoemulsification and trabeculectomy</ProtocolTitle><Sponsor>Beijing Shijitan Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="98799"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>90</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>Phacoemulsification; Trabeculectomy; triamcinolone acetonide</Interventions><Reference>ChiCTR-TRC-12002314</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>EXCITED</ProtocolAcronym><ProtocolTitle>Comparison of the Efficacy of a Fixed Combination of Ciclesonide and Formoterol versus a Fixed Combination of Fluticasone and Salmeterol</ProtocolTitle><Sponsor>Mainz University Hospital, Takeda GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="116883"></Trial><Drug id="48419">ciclesonide + formoterol (inhaled, asthma), Altana/sanofi-aventis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>160</Patients><Biomarkers>Cortisol; Creatinine; FEV1</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone + salmeterol</Controls><EnrollmentCount>160</EnrollmentCount><Interventions>ciclesonide + formoterol (inhaled, asthma), Altana/sanofi-aventis</Interventions><Reference>BY9010/M1-502; EXCITED; EudraCT 2004-002983-80</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot, Randomized Study to Compare Antibiotic Therapy (Ciprofloxacin, Trimethoprim and Metronidazole) with Standard Therapy (Budesonide) in the Treatment of Active Crohns Disease</ProtocolTitle><Sponsor>Royal Liverpool and Broadgreen University Hospitals NHS Trust</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="116894"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Escherichia coli infection</Condition><Controls>Entocort</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>ciprofloxacin; metronidazole; trimethoprim</Interventions><Reference>UKCRN 13163</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Sustained Triamcinolone Release for Inhibition of Diabetic macular Edema. A phase I, safety and tolerability study of tramiconolone acetonide (intravitreal implant) for the potential treatment of diabteic macular edema.</ProtocolTitle><Sponsor>SurModics Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="5034"></Trial><Drug id="55108">triamcinolone acetonide (intravitreal implant, I-vation, diabetic macular edema), SurModics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Triamcinolone acetonide</Interventions><Reference>STRIDE</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Study on the Effectiveness, Safety and Acceptability Of Clobetasol Propionate Foam-cooled (OLUX) in Comparison With Cream Aceponato Methylprednisolone in the Treatment of Allergic Contact Dermatitis</ProtocolTitle><Sponsor>Mipharm SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="117327"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>82</Patients><Biomarkers></Biomarkers><Condition>Contact dermatitis</Condition><Controls>methylprednisolone aceponate</Controls><EnrollmentCount>82</EnrollmentCount><Interventions>clobetasol propionate foam, Connetics</Interventions><Reference>EudraCT 2008-004331-38; olux 01/08</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 microg qd With Fluticasone Propionate (FP) 250 microg bid and FP 100 microg bid in Well-Controlled Asthmatic Japanese Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="178963"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>430</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>430</EnrollmentCount><Interventions>Relovair; fluticasone; fluticasone furoate</Interventions><Reference>201135; JapicCTI-142503; NCT02094937</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease</ProtocolTitle><Sponsor>Santen Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="72186"></Trial><Drug id="66735">DE-110</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Xerophthalmia</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>DE-110</Interventions><Reference>30-002; NCT01239069</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW-685698X Inhalation Powder 25, 50, 100, and 200 microg Administered Once Daily in the Morning and Fluticasone Propionate 100 microg bid via Diskus Inhalation Powder compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (&gt;/= 12 years old) with Persistent Asthma Symptomatic on Non-ICS Therapy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="118070"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>700</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><EnrollmentCount>700</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>2005-001123-11; FFA100240</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III, Randomized, Parallel-roup, Open Study to Compare the Therapeutic Efficacy and Safety of SMB Budesonide-Salmeterol DPI Capsule 150/25 microg bid Delivered by the Axahaler Versus Symbicort Turbuhaler 200/12 microg bid Over 12 Weeks in Moderate to Severe Persistent Asthmatic Patients</ProtocolTitle><Sponsor>Laboratoires SMB SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="118139"></Trial><Drug id="78537">budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>216</Patients><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls>budesonide + formoterol fumarate, AstraZeneca</Controls><EnrollmentCount>216</EnrollmentCount><Interventions>budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Interventions><Reference>BUSAL-III-08-1; EudraCT 2008-004833-70</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hydrodilatation with corticosteroid versus corticosteroid injection alone in adhesive capsulitis of shoulder</ProtocolTitle><Sponsor>Ajou University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268407"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>64</Patients><Biomarkers></Biomarkers><Condition>Adhesive capsulitis</Condition><Controls>lidocaine; triamcinolone acetonide</Controls><EnrollmentCount>64</EnrollmentCount><Interventions>hydrodilatation; lidocaine; triamcinolone acetonide</Interventions><Reference>AJIRB-MED-CT4-10-104; KCT0002006</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TRIMADE</ProtocolAcronym><ProtocolTitle>Triple Therapy for Diabetic Macular Edema: Intravitreal Bevacizumab, Triamcinolone Acetonide and Macular Photocoagulation</ProtocolTitle><Sponsor>Sorocaba Eye Bank</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="92537"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>bevacizumab; laser photocoagulation; triamcinolone acetonide</Interventions><Reference>ChiCTR-TNC-09000606; TRIMADE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Injection of Triamicinolone Acetonide Into the Sub-Tenon Capsule for Treatment of Macular Edema</ProtocolTitle><Sponsor>University Of Tokyo, Graduate School Of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="122358"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>40</Patients><Biomarkers>Blood glucose level; Blood pressure; Hemoglobin A1c (HbA1c); Intraocular pressure</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>JPRN-UMIN000000907</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, comparative, dose-confirmation study of BTR-15 to target pediatric asthma patients</ProtocolTitle><Sponsor>Teijin Pharma Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="122480"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>beclomethasone dipropionate</Controls><EnrollmentCount></EnrollmentCount><Interventions>BTR-15</Interventions><Reference>JapicCTI-090805</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product</ProtocolTitle><Sponsor>Taro Pharmaceuticals USA Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="275506"></Trial><Drug id="103843">DSXS-1538b</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>DSXS-1538b</Interventions><Reference>DSXS 1538B; NCT02933502</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prospective Study into the Effect of an Intraocular Injection of a Steroid in the Prevention of Glaucoma Drainage Surgery Failure After Cataract Surgery</ProtocolTitle><Sponsor>Royal Victorian Eye and Ear Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="123904"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>110</Patients><Biomarkers>intraoccular pressure</Biomarkers><Condition>Glaucoma</Condition><Controls></Controls><EnrollmentCount>110</EnrollmentCount><Interventions>5-fluorouracil; triamcinolone acetonide</Interventions><Reference>ACTRN12611000336987; U1111-1120-4139</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis</ProtocolTitle><Sponsor>Bausch Health Companies Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="262106"></Trial><Drug id="109395">halobetasol propionate (0.01% topical lotion, plaque psoriasis), Ortho Dermatologics</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls>Ultravate</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Jemdel</Interventions><Reference>NCT02785185; V01-122A-203</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TRIBUTE</ProtocolAcronym><ProtocolTitle>A Two-arm, Parallel-Group Study of Fixed Combination of CHF-5993 Versus Ultibro in COPD Patients</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="243510"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>1532</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Ultibro Breezhaler</Controls><EnrollmentCount>1532</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>2014-001704-22; CCD-05993AA1-08; NCT02579850; TRIBUTE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase I, Dose-Varying Study</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="63816"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Scleritis</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>1R01FD003910; EGP-IST-001; NCT01059955</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23384"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Blood pressure; Heart rate; Hydrocortisone; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Asthma</Condition><Controls>Avamys; Relovair</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>vilanterol</Interventions><Reference>HZA102940; NCT00625196</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21749"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00407056; SJE2079/3-02-PC</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 years)</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22072"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>249</Patients><Biomarkers>FEV1; Forced Vital Capacity; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>budesonide</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>BY9010/M1-136; NCT00163384</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="31793"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>105</Patients><Biomarkers></Biomarkers><Condition>Xerophthalmia</Condition><Controls></Controls><EnrollmentCount>89</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>EGP-437-002; NCT00765804</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Controlled Trial of Transforaminal Injections for Sciatica</ProtocolTitle><Sponsor>Newcastle Bone and Joint institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="135001"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>240</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>bupivacaine, AstraZeneca</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Reference>06/12/13/3/01; ACTRN12608000401358; ANZCTR82969</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF-5993 pMDI Combination in Healthy Volunteers</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="221592"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Blood pressure; Heart rate; QT interval</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi; charcoal block; pressurized metered dose inhaler</Interventions><Reference>CCD-05993AB2-01; NCT02359292</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Repeat Emergency Department Visits Among Patients With Asthma and COPD</ProtocolTitle><Sponsor>State University of New York</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="235195"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>prednisone; salbutamol, GlaxoSmithKline</Controls><EnrollmentCount>6</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; prednisone; salbutamol, GlaxoSmithKline</Interventions><Reference>754754; NCT02499887</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy</ProtocolTitle><Sponsor>University of Sao Paulo</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="165786"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Proliferative diabetic retinopathy</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>panretinal photocoagulation; triamcinolone acetonide</Interventions><Reference>310/05; NCT00443521</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="165530"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Macular focal laser photocoagulation; Vitrectomy; triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto</Interventions><Reference>2006-05-029; NCT00371410</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Trial in Patients With Steroid Responsive Inflammatory Ocular Conditions. Clinical Trial Is to Study Efficacy, Safety and Tolerability of Moxifloxacin HCL + Difluprednate Ophthalmic Solution Versus Moxifloxacin HCL + Dexamethasone Phosphate Eye Drops</ProtocolTitle><Sponsor>Ajanta Pharma Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="132784"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>200</Patients><Biomarkers>Intra occular pressure (IOP)</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon; moxifloxacin (ophthalmic), Alcon</Interventions><Reference>AJ/SC/12/2009; CTRI/2010/091/001121</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>HPA Axis Study in Adults</ProtocolTitle><Sponsor>Bayer AG, Intendis GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79784"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers></Biomarkers><Condition>Atopic dermatitis</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>mapracorat</Interventions><Reference>1403161; 1403161; NCT01408511</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to assess the effect of fluticasone furoate on growth rate in children aged 5 to 11</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="253752"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>2015-000841-22; HZA107112</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Extension Study for Patients Entered Into Study Infacort 003</ProtocolTitle><Sponsor>Diurnal Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="257842"></Trial><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>24</Patients><Biomarkers>17-alpha-hydroxyprogesterone; Androgens; Androstenedione; Testosterone</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>Infacort</Interventions><Reference>2015-000458-40; INFACORT 004; NCT02733367</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematological Cancer</ProtocolTitle><Sponsor>Fred Hutchinson Cancer Research Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="58495"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Graft versus host disease</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; methotrexate; tacrolimus</Interventions><Reference>2079.00; NCI-2009-01544; NCT00489203</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="14192"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>301</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>301</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>FFR106080; NCT00289198</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Intravitreal Triamcinolone Acetonide before Pan Retinal Photocoagulation for Improvement of Visual Acuity and Macular Edema in Diabetic Retinopathy</ProtocolTitle><Sponsor>Farabi Eye Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="143664"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>23</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>ACTRN12607000225415; HREC 356</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="14092"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>64</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls>fluticasone furoate</Controls><EnrollmentCount>64</EnrollmentCount><Interventions>fluticasone furoate; oxymetazoline; oxymetazoline</Interventions><Reference>15059B; NCT00584987</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 12-Week Study to Evaluate the 24-h Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 microg Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 microg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="142783"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>800</Patients><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><EnrollmentCount>800</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>EudraCT: 2012-003106-27; RLV116974</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>SGX-203 for The Treatment of Pediatric Crohn's Disease</ProtocolTitle><Sponsor>Soligenix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="125927"></Trial><Drug id="116385">beclomethasone dipropionate (oral dual release tablet, Crohn’s disease), Soligenix</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>beclomethasone dipropionate (oral dual release), Soligenix/Sigma-Tau</Interventions><Reference>BDP-PCD-01</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Pharmacokinetics of Infacort Versus Immediate-release Hydrocortisone</ProtocolTitle><Sponsor>Diurnal Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="261362"></Trial><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Addisons disease</Condition><Controls>hydrocortisone</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>Infacort</Interventions><Reference>2013-000260-28; INFACORT 001; NCT02777268</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Daily versus as-needed use of fluticasone furoate nasal spray in patients with allergic rhinitis: A randomized, controlled trial</ProtocolTitle><Sponsor>Mahidol University, Siriraj Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="290776"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>110</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>110</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>TCTR20170310002</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87111"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>369</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>369</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Reference>790; NCT01591161</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87111"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>369</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>369</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Reference>790; NCT01591161</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life</ProtocolTitle><Sponsor>University of Kansas</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="48539"></Trial><Drug id="12806">dexamethasone cipecilate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Multiple myeloma</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>dexamethasone cipecilate; doxorubicin (liposomal, STEALTH), Alza; thalidomide</Interventions><Reference>Doxil; NCT00222105</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Fluticasone Furoate(FF)/GW-642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="63564"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1224</Patients><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>1226</EnrollmentCount><Interventions>GW-642444; Relovair; fluticasone furoate</Interventions><Reference>112207; 2009-013067-19; HZC112207; JapicCTI-101097; NCT01054885</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of ciclesonide versus fluticasone propionate in patients with mild to moderate asthma (12 to 75 years)</ProtocolTitle><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22040"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>480</Patients><Biomarkers>FEV1; Forced Vital Capacity</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><EnrollmentCount>480</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>2004-001072-39; BY9010/M1-142; NCT00163423</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of FX-006 versus Normal Saline in Patients With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="182577"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>310</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>310</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2014-006; NCT02116972</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evidence Synthesis and Mixed Treatment Comparison of Efficacy of Treatments for the Maintenance of COPD</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="158632"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>1</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>1</EnrollmentCount><Interventions>budesonide + formoterol fumarate, AstraZeneca; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Interventions><Reference>200342</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>TRINITY</ProtocolAcronym><ProtocolTitle>Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="148190"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2691</Patients><Biomarkers>Forced expiratory volume in 1 s</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Fostair; Spiriva; Spiriva; beclometasone dipropionate + formoterol fumarate + tiotropium bromide</Controls><EnrollmentCount>3686</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>2013-000063-91; CCD-1208-PR-0090; NCT01911364; TRINITY</Reference></Row><Row><ArmCount>9</ArmCount><ProtocolAcronym>AOT</ProtocolAcronym><ProtocolTitle>Triamcinolone acetonide to prevent PVR in eyes undergoing vitreoretinal surgery for open globe trauma</ProtocolTitle><Sponsor>Moorfields Eye Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="133460"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Retinopathy</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Kenalog; flurbiprofen (Froben); guttae prednisolone (Pred Forte); triamcinolone acetonide</Interventions><Reference>2007-005138-35; AOT; CHAD1024</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>RIFLE</ProtocolAcronym><ProtocolTitle>A Crossover Study to Compare Rayos to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE</ProtocolTitle><Sponsor>Ampel BioSolutions, LLC</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="294933"></Trial><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>62</Patients><Biomarkers></Biomarkers><Condition>Fatigue</Condition><Controls>prednisone</Controls><EnrollmentCount>62</EnrollmentCount><Interventions>Rayos</Interventions><Reference>AMP-002; NCT03098823; RIFLE</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long Term Safety Trial of Z-102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="88095"></Trial><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>prednisone</Controls><EnrollmentCount>18</EnrollmentCount><Interventions>prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Interventions><Reference>NCT01612377; Z102-009</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Sponsor>Ocular Therapeutix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258056"></Trial><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>438</Patients><Biomarkers>Anterior chamber; Intraocular pressure; Leukocyte count</Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>438</EnrollmentCount><Interventions>OTX-DP</Interventions><Reference>NCT02736175; OTX-15-003</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>AVERTS-1</ProtocolAcronym><ProtocolTitle>Study of OTO-104 in Subjects With Unilateral Meniere's Disease</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="246584"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>165</Patients><Biomarkers></Biomarkers><Condition>Meniere disease</Condition><Controls></Controls><EnrollmentCount>165</EnrollmentCount><Interventions>OTO-104</Interventions><Reference>104-201506; AVERTS-1; NCT02612337</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of FX-006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="221476"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>484</Patients><Biomarkers>Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide injectable suspension</Controls><EnrollmentCount>484</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>2014-005329-11; FX006-2014-008; NCT02357459</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Characterize the PK and Local Extent and Duration of Exposure From FX-006 in Patients With OA of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="249253"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>81</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide (Kenalog)</Controls><EnrollmentCount>81</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2015-009; NCT02637323</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate Safety, Tolerability and Efficacy of Oral B-FAHF-2 in Mild-to-Moderate Crohns Disease</ProtocolTitle><Sponsor>Mount Sinai School of Medicine</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="385284"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Calprotectin; Cytokines</Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>B-FAHF-2; Entocort EC</Interventions><Reference>0266-3308; GCO 19-0125; NCT03992469</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>DELIVER</ProtocolAcronym><ProtocolTitle>A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort</ProtocolTitle><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="89428"></Trial><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>TNF-alpha</Biomarkers><Condition>Peripheral vascular disease</Condition><Controls>methylprednisolone (Pfizer)</Controls><EnrollmentCount>21</EnrollmentCount><Interventions>prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos</Interventions><Reference>DELIVER; NCT01647685; NL39717.018.12</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-label, Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6 to 11 Years Old</ProtocolTitle><Sponsor>Meda Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86381"></Trial><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>54</Patients><Biomarkers></Biomarkers><Condition>Herpes simplex virus infection</Condition><Controls></Controls><EnrollmentCount>54</EnrollmentCount><Interventions>aciclovir + hydrocortisone (dermatological), Medivir</Interventions><Reference>MP 800; NCT01574612</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Tristar</ProtocolAcronym><ProtocolTitle>Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="231716"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1479</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Relovair; Spiriva</Controls><EnrollmentCount>1479</EnrollmentCount><Interventions>CHF-5993</Interventions><Reference>2014-001487-35; CCD-05993AA1-07; NCT02467452; Tristar</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis</ProtocolTitle><Sponsor>Alcon Research Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="70332"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>110</Patients><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>111</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon; prednisolone acetate</Interventions><Reference>C-10-034; NCT01201798</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis</ProtocolTitle><Sponsor>University of California San Diego</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="57129"></Trial><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>33</Patients><Biomarkers></Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls></Controls><EnrollmentCount>33</EnrollmentCount><Interventions>Prevacid; budesonide (oral, eosinophilic esophagitis), Meritage</Interventions><Reference>NCT00638456; VPI-106-01</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study In Pediatric Subjects With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="93137"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>99</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Cortisol; Hemoglobin; Mean corpuscular volume; Urea nitrogen; gamma-Glutamyltransferase</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>99</EnrollmentCount><Interventions>Qnaze</Interventions><Reference>BDP-AR-307; NCT01697956</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>OTO-104 for Meniere's Disease</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="64740"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Meniere disease</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>OTO-104</Interventions><Reference>104-200901; NCT01084525</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction Study of CHF-5993 With Cimetidine</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="215420"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>26</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992; beclomethasone dipropionate + formoterol fumarate + CHF-5992; cimetidine</Interventions><Reference>2013-005491-18; CCD-05993AA1-12; NCT02287272</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Study Will Evaluate the Efficacy of AZD-5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71513"></Trial><Drug id="64294">AZD-5423</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Eosinophils; FEV1; Neutrophils</Biomarkers><Condition>Asthma</Condition><Controls>budesonide (inhaled formulations), AstraZeneca</Controls><EnrollmentCount>27</EnrollmentCount><Interventions>AZD-5423</Interventions><Reference>D2340C00005; NCT01225549</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="250160"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Vitreous humor disease</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>EyeGate II drug delivery system; dexamethasone</Interventions><Reference>EGP-437-010; NCT02644694</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>VIDA</ProtocolAcronym><ProtocolTitle>Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma</ProtocolTitle><Sponsor>Milton S. Hershey Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="188785"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>408</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Vitamin D deficiency</Condition><Controls></Controls><EnrollmentCount>408</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; vitamin D3</Interventions><Reference>1U10HL098115; ASTHMANET 001; NCT01248065; VIDA</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157921"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Reference>200284; NCT01962467</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157921"></Trial><Drug id="89013">fluticasone furoate + levocabastine (intranasal spray, perennial and seasonal allergic rhinitis), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Reference>200284; NCT01962467</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157921"></Trial><Drug id="89013">fluticasone furoate + levocabastine (intranasal spray, perennial and seasonal allergic rhinitis), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Reference>200284; NCT01962467</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, randomized, single-blind, positive controlled trials that assess the effect, safety and cost in patients with mild to moderate psoriasis vulgaris and compare fufangbingsuanlvbeitasuo (Jinniuer) ointment to gaibosanchunbeitamisong (Defubao) ointment</ProtocolTitle><Sponsor>Curegen (Jiangsu) Pharmaceuticals Inc, The First Hospital Of China Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="256863"></Trial><Drug id="96651">clobetasol propionate + tretinoin (topical/ointment, psoriasis vulgaris), Jiangsu Zeyuan Pharmaceutical</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>240</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls>calcipotriol betamethasone (Defubao)</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>Jinniuer</Interventions><Reference>ChiCTR-IPR-16008126</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Sponsor>Bausch Health Companies Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62013"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>265</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition>Ulcerative proctitis</Condition><Controls></Controls><EnrollmentCount>265</EnrollmentCount><Interventions>Rectabul</Interventions><Reference>BUCF3001; NCT01008410</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of the Effects of Inhaled Fluticasone Furoate/GW-642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="64852"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>73</Patients><Biomarkers>Cortisol</Biomarkers><Condition>Asthma</Condition><Controls>prednisolone</Controls><EnrollmentCount>185</EnrollmentCount><Interventions>Relovair</Interventions><Reference>106851; HZA106851; NCT01086410</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>CareOnTIME</ProtocolAcronym><ProtocolTitle>Innovative Treatment in Congenital Adrenal Hyperplasia</ProtocolTitle><Sponsor>Universita degli Studi di Napoli Federico II</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="362194"></Trial><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Antral follicles; Blood pressure; Body Mass Index; Bone mineral density; Hemoglobin A, glycosylated; High-density lipoprotein cholesterol; Testosterone/Androstenedione ratio; Total cholesterol; Triglycerides</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>cortisone acetate; dexamethasone; hydrocortisone; prednisolone; prednisone</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Plenadren</Interventions><Reference>140/16; CareOnTIME; NCT03760835</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relovair Lung Deflation Study</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="92645"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>45</Patients><Biomarkers>Arterial stiffness; Ejection fraction; Left atrial ejection fraction; Left atrium; Left ventricle; Pulmonary artery; Pulse Wave Transit Time; Pulse wave velocity; Right ventricle; Right ventricular ejection fraction; Stroke volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>Relovair</Interventions><Reference>116601; 2012-000927-42; HZC116601; NCT01691885</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>MARS-1</ProtocolAcronym><ProtocolTitle>Multicenter Study to Evaluate CRx-102 versus Each of Its Components to Treat Active Rheumatoid Arthritis</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="5373"></Trial><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>51</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>51</EnrollmentCount><Interventions>CRx-102</Interventions><Reference>CRx-102-007; MARS-1; NCT00551707</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62468"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>340</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>340</EnrollmentCount><Interventions>Qnaze</Interventions><Reference>BDP-AR-301; NCT01024608</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>DOUBle</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis</ProtocolTitle><Sponsor>InSite Vision Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79770"></Trial><Drug id="55854">azithromycin + dexamethasone (sustained release, DuraSite), InSite</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>907</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Blepharitis</Condition><Controls>azithromycin (ophthalmic sustained release, DuraSite), InSite; dexamethasone (sustained release, DuraSite), InSite</Controls><EnrollmentCount>917</EnrollmentCount><Interventions>azithromycin + dexamethasone (sustained release, DuraSite), InSite</Interventions><Reference>C-10-502-004; DOUBle; NCT01408082</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Investigation of the Pharmacokinetics of GSK-961081 and Fluticasone Propionate in Healthy Volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="81468"></Trial><Drug id="78547">batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Blood glucose; FEV1; Heart rate; Serum cortisol; Serum potassium; Urine cortisol</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>GSK-961081 + fluticasone propionate (COPD), GlaxoSmithKline; batefenterol succinate; batefenterol succinate; fluticasone; fluticasone</Interventions><Reference>113423; NCT01449799</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to see if it is safe to give a new asthma controller drug and a new asthma reliever drug together (called fluticasone furoate/vilanterol) to 5 to 11 year old children with asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="211035"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>26</Patients><Biomarkers>Diastolic blood pressure; Glucose; Heart rate; Hydrocortisone; Potassium; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Controls><EnrollmentCount>26</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>2012-000754-55; HZA112777</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19 mg) in Patients with Retinitis Pigmentosa</ProtocolTitle><Sponsor>Moorfields Eye Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="328923"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Choroid; Oxygen saturation; Retina; Transcriptional regulator ERG</Biomarkers><Condition>Retinitis pigmentosa</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Iluvien</Interventions><Reference>2016-002523-28; KHAK1001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relovair PD PK in Chinese Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="95532"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Blood pressure; Heart rate; Potassium; QT interval; Serum cortisol; Whole blood potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>115199; NCT01711463</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label Study of OTO-104 in Subjects With Meniere's Disease</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="258351"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition>Meniere disease</Condition><Controls></Controls><EnrollmentCount>34</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>104-201505; NCT02740387</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Evaluate The Efficacy And Safety Of Sunpharma-1505 Compared With Reference-1505 In Subjects With Active Rheumatoid Arthritis</ProtocolTitle><Sponsor>Sun Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="238910"></Trial><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>330</Patients><Biomarkers>Joint swelling; Joint tenderness</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>methylprednisolone</Controls><EnrollmentCount>330</EnrollmentCount><Interventions>Nanocort</Interventions><Reference>2015-002924-17; CLR_15_05; NCT02534896</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>PRO-145/III</ProtocolAcronym><ProtocolTitle>Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification</ProtocolTitle><Sponsor>Laboratorios Sophia</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="355334"></Trial><Drug id="112786">Difluprednate (ophthalmic solution, ocular inflammation/ocular pain), Laboratorios Sophia</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>178</Patients><Biomarkers>Anterior chamber; Intraocular pressure; Retina</Biomarkers><Condition>Ocular inflammation</Condition><Controls>Prednefrin</Controls><EnrollmentCount>178</EnrollmentCount><Interventions>PRO-145</Interventions><Reference>NCT03693989; PRO-145/III; SOPH145-0716 / III</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PALADIN</ProtocolAcronym><ProtocolTitle>Phase IV IOP Signals Associated With Iluvien</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="227463"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>153</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>153</EnrollmentCount><Interventions>Iluvien</Interventions><Reference>M-01-15-004; NCT02424019; PALADIN</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>VISION-DMD</ProtocolAcronym><ProtocolTitle>Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Sponsor>ReveraGen BioPharma Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="287053"></Trial><Drug id="70712">vamorolone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>17-alpha-hydroxyprogesterone; Adrenocorticotropic hormone; Blood pressure; Body Mass Index; Body temperature; C-terminal telopeptide of collagen type I; Corticosterone; Cortodoxone; Glucose; Heart rate; High-density lipoprotein cholesterol; Hydrocortisone; Insulin; Low-density lipoprotein cholesterol; Muscle strength; Osteocalcin; Procollagen Type I N-terminal peptide; Respiratory frequency; Six-minute walk distance; Testosterone; Total body mass; Total cholesterol; Triglycerides</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>vamorolone</Interventions><Reference>2017-003568-10; NCT03038399; VBP15-LTE; VISION-DMD</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PEER</ProtocolAcronym><ProtocolTitle>Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="42073"></Trial><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>71</Patients><Biomarkers>Blood pressure; Eosinophils</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls></Controls><EnrollmentCount>82</EnrollmentCount><Interventions>budesonide (oral, eosinophilic esophagitis), Meritage</Interventions><Reference>MPI-101-01; NCT00762073; PEER</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 6-Month Extension Study of OTO-104 in Meniere's Disease</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="255564"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>189</Patients><Biomarkers></Biomarkers><Condition>Meniere disease</Condition><Controls></Controls><EnrollmentCount>189</EnrollmentCount><Interventions>OTO-104</Interventions><Reference>104-201509; NCT02706730</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration</ProtocolTitle><Sponsor>National Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="95955"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Wet age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Azmacort; photodynamic therapy (PDT)</Interventions><Reference>05-EI-0064; 050064; NCT00100009</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="243854"></Trial><Drug id="78547">batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>63</Patients><Biomarkers>Heart rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>63</EnrollmentCount><Interventions>batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Interventions><Reference>201546; NCT02573870</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study to Compare Fluticasone Furoate (FF) Single-strip Inhaler With FF Two-strip Inhaler and With FF/Vilanterol Combination</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="82997"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>115440; NCT01485445</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280709"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>99mTc; beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Interventions><Reference>2016-001088-35; CCD-05993AA1-15; NCT02975843</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, double-blind, randomized, parallel-group, placebo-controlled study of deflazacort for the treatment of patients with Duchenne muscular dystrophy (DMD)</ProtocolTitle><Sponsor>Marathon Pharmaceuticals LLC</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="332308"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>29</Patients><Biomarkers></Biomarkers><Condition>Duchenne dystrophy</Condition><Controls></Controls><EnrollmentCount>29</EnrollmentCount><Interventions>Emflaza</Interventions><Reference>MP-104-NM-002</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>AZD-5423 Multiple Ascending Dose Study</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="63153"></Trial><Drug id="64294">AZD-5423</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>AZD-5423</Interventions><Reference>D2340C00002; EudraCT No: 2009-016611-38; NCT01037504</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="301426"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>101</Patients><Biomarkers>Anterior chamber</Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>EyeGate; dexamethasone</Interventions><Reference>EGP-437-009; NCT03180255</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus</ProtocolTitle><Sponsor>Orion Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="289048"></Trial><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>64</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>Seretide; Seretide; charcoal</Controls><EnrollmentCount>64</EnrollmentCount><Interventions>charcoal; fluticasone propionate + salmeterol xinafoate; fluticasone propionate + salmeterol xinafoate</Interventions><Reference>3106010; NCT03060044</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>STORM</ProtocolAcronym><ProtocolTitle>Lung Deposition of TRIMBOW pMDI in Healthy Volunteers, Asthmatic and COPD Patients</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="365704"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers>FEV / FVC ratio; Forced expiratory flow ; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>2017-005030-29; CLI-05993AA1-20; NCT03795350; STORM</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide</ProtocolTitle><Sponsor>Anika Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="301892"></Trial><Drug id="103224">CINGAL</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>576</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Monovisc; triamcinolone hexacetonide</Controls><EnrollmentCount>576</EnrollmentCount><Interventions>CINGAL</Interventions><Reference>2017-000355-46; CINGAL 16-02; NCT03191903</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>SAIMI</ProtocolAcronym><ProtocolTitle>Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus</ProtocolTitle><Sponsor>Orion Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="307440"></Trial><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>64</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>Seretide Diskus</Controls><EnrollmentCount>64</EnrollmentCount><Interventions>fluticasone propionate + salmeterol xinafoate</Interventions><Reference>3106012; NCT03238482; SAIMI</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PTCEMF</ProtocolAcronym><ProtocolTitle>A Phase III Study of Emflaza (Deflazacort) in Patients With Duchenne Muscular Dystrophy</ProtocolTitle><Sponsor>PTC Therapeutics Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="351212"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients></Patients><Biomarkers>Body height; Bone mineral density; Total body mass</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Emflaza</Interventions><Reference>NCT03642145; PTCEMF; PTCEMF-GD-003</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Vilanterol on Methacholine Challenge Results</ProtocolTitle><Sponsor>University of Saskatchewan</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="316341"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>17</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>17</EnrollmentCount><Interventions>Arnuity; Breo; Ellipta</Interventions><Reference>NCT03315000; VIL-2017</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Vilanterol on Methacholine Challenge Results</ProtocolTitle><Sponsor>University of Saskatchewan</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="316341"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>17</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>17</EnrollmentCount><Interventions>Arnuity; Breo; Ellipta</Interventions><Reference>NCT03315000; VIL-2017</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD-5423 When Administered in Different Ways</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75917"></Trial><Drug id="64294">AZD-5423</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>AZD-5423</Interventions><Reference>D2340C00008; NCT01310322</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77700"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>197</Patients><Biomarkers></Biomarkers><Condition>Atopic dermatitis</Condition><Controls></Controls><EnrollmentCount>197</EnrollmentCount><Interventions>mapracorat</Interventions><Reference>1403440; 15616; 2010-024279-14; NCT01359787</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide versus Mesalazine versus Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="238809"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>320</Patients><Biomarkers></Biomarkers><Condition>Ulcerative proctitis</Condition><Controls>mesalazine</Controls><EnrollmentCount>320</EnrollmentCount><Interventions>Rectabul; Rectabul; mesalazine</Interventions><Reference>2012-003362-41; BUS-2/UCA; NCT01966783</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Safety and Tolerability of NCX-4251 for the Treatment of Acute Exacerbations of Blepharitis</ProtocolTitle><Sponsor>NicOx SA, Nicox Ophthalmics Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="318225"></Trial><Drug id="91859">fluticasone (ocular inflammation, pain), Nicox Ophthalmics</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Blepharitis</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NCX-4251</Interventions><Reference>NCT03926026; NCX-4251-01</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>OVB in EA</ProtocolAcronym><ProtocolTitle>Oral Viscous Budesonide in Anastomotic Stricture After Esophageal Atresia Repair</ProtocolTitle><Sponsor>CHU de Quebec-Universite Laval</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="386068"></Trial><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Body height; Total body mass</Biomarkers><Condition>Esophageal disease</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>budesonide</Interventions><Reference>NCT03999008; OVB IN EA; OVB in EA</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A non-randomized, open-label, two period crossover study in healthy adult male subjects to determine the excretion balance and pharmacokinetics of [14C]-GW-685698, administered as single doses of oral and intravenous infusion</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="202329"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>5</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>5</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>FFR10008</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>LOGAN</ProtocolAcronym><ProtocolTitle>A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT-007 and PT-008 Administered Separately</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="363124"></Trial><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>91</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>PT-007; PT-008</Controls><EnrollmentCount>91</EnrollmentCount><Interventions>PT-027</Interventions><Reference>D6930C00003; LOGAN; NCT03772223</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers</ProtocolTitle><Sponsor>PTC Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="233499"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>deflazacort</Interventions><Reference>MP-104-CL-026; NCT02485431</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21683"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>438</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>219</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00429923; ST-601A-002a</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>PREMED</ProtocolAcronym><ProtocolTitle>Prevention of Macular Edema After Cataract Surgery</ProtocolTitle><Sponsor>Maastricht University Medical Center, University Eye Clinic Maastricht</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="105848"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1127</Patients><Biomarkers>Intraocular pressure; Macula retinae; Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>1127</EnrollmentCount><Interventions>Azmacort; bevacizumab; bromfenac; bromfenac; dexamethasone; dexamethasone</Interventions><Reference>2012-004873-14; NCT01774474; NL42463.068.12; NL_42463; PREMED</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Short-Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11760"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>91</Patients><Biomarkers>Ear pressure</Biomarkers><Condition>Rhinitis</Condition><Controls></Controls><EnrollmentCount>91</EnrollmentCount><Interventions>Azmacort</Interventions><Reference>103-04; IST4008; NCT00279916; XRG5029C/4008</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW-685698X Inhalation Powder 100, 200, 300 and 400 microg Administered qd in the Morning and Fluticasone Propionate 250 microg bid via Diskus Inhalation Powder Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (= 12 years old) with Persistent Asthma Symptomatic on Low-Dose ICS Therapy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="117759"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>700</Patients><Biomarkers>FEV1 (forced expiratory volume in 1 s); PEF (peak expiratory flow)</Biomarkers><Condition>Asthma</Condition><Controls>Flixotide</Controls><EnrollmentCount>700</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>2005-001124-36; FFA20002; FFA20003</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66663"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>198</Patients><Biomarkers></Biomarkers><Condition>Xerophthalmia</Condition><Controls></Controls><EnrollmentCount>198</EnrollmentCount><Interventions>EGP-437</Interventions><Reference>EGP-437-003; NCT01129856</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery</ProtocolTitle><Sponsor>Alcon Research Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66419"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls>prednisolone acetate</Controls><EnrollmentCount>80</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>C-10-004; NCT01124045</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Pediatric Subjects With Asthma Over a Year</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="271148"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>450</Patients><Biomarkers>Body height</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>450</EnrollmentCount><Interventions>fluticasone furoate; montelukast; salbutamol</Interventions><Reference>114971; 2016-002551-22; HZA114971; NCT02889809; P/276/2016</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-label Study to Compare Systemic Side Effects of High Dose Fluticasone/Salmeterol with that of High Dose Ciclesonide/Salmeterol in Symptomatic Asthmatics</ProtocolTitle><Sponsor>Hull and East Yorkshire Hospitals NHS Trust</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="116685"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Cortisol; Creatinine; Forced expiratory volume in 1 s (FEV1)</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; fluticasone propionate; salmeterol</Interventions><Reference>AcadMed CTU03/05; EudraCT 2006-002450-30</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>FAME</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="4360"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>37</Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Reference>C-01-06-002; FAME; NCT00490815</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intranasal Steroids and the Nasal Ocular Response</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11749"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>15061B; NCT00473915</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Randomized, Partially-blinded, Crossover Study to Evaluate the Systemic Effect of Two Doses of the SMB Budesonide-salmeterol DPI Fixed-dose Combination Capsule (300/25 microg bid and 150/25 microg bid) Delivered by the Axahaler Versus Pulmicort Turbohaler 400 microg bid and Serevent Diskus 50 microg bid Versus Placebo in Mild Persistent Asthmatic Patients</ProtocolTitle><Sponsor>Laboratoires SMB SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="118182"></Trial><Drug id="78537">budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>budesonide (inhaled formulations), AstraZeneca; budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB; salmeterol</Interventions><Reference>BUSAL-II-10-2; EudraCT 2010-020794-16</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus</ProtocolTitle><Sponsor>Orion Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="132070"></Trial><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Interventions><Reference>3106008; EUDRACT 2012-003782-18; NCT01856621</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study to Examine the Safety and Efficacy of Posterior Juxtascleral Triamcinolone Acetonide Administration, in Addition to Visudyne Photoynamic Therapy for Predominantly Classic Choroidal Neovascularization Secondary to Age Related Macular Degeneration: An Open-Label, Randomized, Active-Controlled Trial</ProtocolTitle><Sponsor>Kings College Hospital NHS Trust</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="142831"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Choroidal neovascularization</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>triamcinolone acetonide; verteporfin</Interventions><Reference>EudraCT 2005-002466-11; version125/05/05</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A RCT of Local Steroid Injection for Prevention of Post-ESD Esophageal Stenosis</ProtocolTitle><Sponsor>Keiyukai Sapporo Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="122329"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>JPRN-UMIN000006327</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prospective Study into the Effect of an Intraocular Injection of a Steroid in the Prevention of Glaucoma Drainage Surgery Failure After Cataract Surgery</ProtocolTitle><Sponsor>Royal Victorian Eye and Ear Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="123904"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>110</Patients><Biomarkers>intraoccular pressure</Biomarkers><Condition>Cataract</Condition><Controls></Controls><EnrollmentCount>110</EnrollmentCount><Interventions>5-fluorouracil; triamcinolone acetonide</Interventions><Reference>ACTRN12611000336987; U1111-1120-4139</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dropless Versus Less Drops Pharmaceutical Regimens After Cataract Surgery</ProtocolTitle><Sponsor>Eye Center of North Florida</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="264759"></Trial><Drug id="95157">triamcinolone acetonide + moxifloxicin hydrochloride + vancomycin (ocular disease), Harrow Health</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>25</Patients><Biomarkers>Central cornea; Intraocular pressure; Macula retinae</Biomarkers><Condition>Ocular disease</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>Imprimis Less Drops; PredKeterolac; triamcinolone acetonide + moxifloxicin hydrochloride + vancomycin (ocular disease), Imprimis</Interventions><Reference>BF-2015-011; NCT02819908</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>UVEXATE</ProtocolAcronym><ProtocolTitle>Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="169537"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>7</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>7</EnrollmentCount><Interventions>methotrexate; methylprednisolone; prednisone; prednisone; triamcinolone acetonide</Interventions><Reference>NCT00918554; P070140; UVEXATE</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Effectiveness of Corticosteroid Preparation in Sympathetic Ganglion Block on Lymphedema</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="127593"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>66</Patients><Biomarkers>Arm circumference</Biomarkers><Condition>Lymphedema</Condition><Controls></Controls><EnrollmentCount>66</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; triamcinolone acetonide</Interventions><Reference>2010-0206; KCT0000300</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study FFR116364, a Placebo-Controlled Study of GW-685698X in Pediatric Subjects With Perennial Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88789"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>261</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>261</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>116364; FFR116364; JapicCTI-121888; NCT01630135</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Repeat Dose GW-685698X With Magnesium Stearate, Excipient Bridging Study, In Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23655"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Diastolic blood pressure; Heart rate; Peak expiratory flow rate; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>HZA102928; NCT00522678</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23384"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Blood pressure; Heart rate; Hydrocortisone; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Avamys; Relovair</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>vilanterol</Interventions><Reference>HZA102940; NCT00625196</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Controlled Trial on Therapeutic Effects of Sub-Tenons Capsule Injection of Triamcinolone Acetonide in Prevention of Occurrence and Inhibition of Progression of Diabetic Macular Edema Caused by Panretinal Photocoagulation</ProtocolTitle><Sponsor>Kyoto University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="136114"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Panretinal photocoagulation; triamcinolone acetonide</Interventions><Reference>JPRN-C000000455</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of ciclesonide and beclomethasone on lens opacification in adult subjects with moderate to severe persistent asthma</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22103"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1568</Patients><Biomarkers></Biomarkers><Condition>Respiratory disorder</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><EnrollmentCount>1568</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>NCT00254956; SFY6160; XRP1526B/3027</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21568"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00406341; SJE2079/3-03</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of IBI-10090 in Ocular Surgery Patients</ProtocolTitle><Sponsor>Icon Bioscience Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87882"></Trial><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>172</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>172</EnrollmentCount><Interventions>IBI-10090</Interventions><Reference>C11-01; NCT01606735</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the safety and efficacy of fluticasone propionate aqueous spray and triamcinolone acetonide  aqueous nasal spray in patients with seasonal allergic rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87544"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>451</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls>triamcinolone acetonide</Controls><EnrollmentCount>481</EnrollmentCount><Interventions>fluticasone</Interventions><Reference>FLTA4007</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Two Doses of Qvar versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22589"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>415</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>415</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Reference>IXR-301-4-197; NCT00109668</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two doses of nebulised budesonide delivered by the VR475 Inhalation System, with an open-label comparison to conventionally nebulized budesonide, in patients with uncontrolled asthma despite treatment with high dose inhaled corticosteroid and at least a second controller (GINA Step 4) and those receiving oral corticosteroid (GINA Step 5)</ProtocolTitle><Sponsor>Syneos Health Inc, Vectura Group plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="253447"></Trial><Drug id="83838">budesonide (controlled release/inhaled/AKITA, adult asthma), Vectura</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>702</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory flow ; Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>PARI BOY inhalation system; budesonide</Controls><EnrollmentCount>702</EnrollmentCount><Interventions>VR-475 inhalation system; budesonide</Interventions><Reference>2015-000353-20; 2015-CT0310; PHRR160330-001192; VR475/3/001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of steroid injection and wrist splint in carpal tunnel syndrome</ProtocolTitle><Sponsor>Yasouj University of Medical Sciences and Health Services</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="139713"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Carpal tunnel syndrome</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>triamcinolone acetonide; wrist splint</Interventions><Reference>6/10/12/90/پ; IRCT2012110210799N3</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, randomized controlled Clinical Trial of Early Vitrectomy for Diffuse Diabetic Macular Edema</ProtocolTitle><Sponsor>Kagoshima University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="138006"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>162</Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>162</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>JPRN-UMIN000008957</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="201346"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><Patients></Patients><Biomarkers>Albumin; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Bone mineral density; Prothrombin time</Biomarkers><Condition>Autoimmune hepatitis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Entocort</Interventions><Reference>07-003586; BUDESONIDE; NCT00587119</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Controlled Trial of Triamcinolone Intravitreal Injection Versus Vitrectomy for Diabetic Macular Edema</ProtocolTitle><Sponsor>Kagoshima University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="142064"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>20</Patients><Biomarkers>Fovea centralis; Macula retinae; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>pars plana vitrectomy; triamcinolone acetonide</Interventions><Reference>JPRN-C000000432</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW-685698X Aqueous Nasal Spray Or Placebo Nasal Spray</ProtocolTitle><Sponsor>GlaxoSmithKline Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="14025"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>56</Patients><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>56</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>FFR101747; NCT00109486</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open, multicenter, phase IIIb, long-term follow-up study to assess the safety, tolerability and efficacy of once-daily oral modified-release hydrocortisone in patients with adrenal insufficiency</ProtocolTitle><Sponsor>DuoCort Pharma AB</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="142192"></Trial><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>80</Patients><Biomarkers>Glucose; High-density lipoprotein cholesterol</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls></Controls><EnrollmentCount>86</EnrollmentCount><Interventions>hydrocortisone</Interventions><Reference>2008-003990-42; DC08/01</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>LIPMAT</ProtocolAcronym><ProtocolTitle>Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="234690"></Trial><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Blood flow; Cephalic vein; Radial artery</Biomarkers><Condition>Kidney dialysis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Nanocort</Interventions><Reference>2015-002488-40; LIPMAT; LIPMAT; NCT02495662</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III, Clinical Trial Multicenter, Randomized for the Evaluation of the Safety and Efficacy of the Combined Treatment of Intravitreal Triamcinolone and Photodynamic Therapy Versus Intravitreal Bevacizumab and Photodynamic Therapy Versus Intravitreal Bevacizumab for the Treatment of Neo-Vascular Maculopathy Type Retinal Angiomatous Prolipheration (RAP)</ProtocolTitle><Sponsor>Ospedale Luigi Sacco Azienda Ospedaliera Polo Universitario, Polo Universitario</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="142760"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>108</Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>108</EnrollmentCount><Interventions>PPA-904; Photodynamic therapy; bevacizumab; bevacizumab; triamcinolone acetonide</Interventions><Reference>EudraCT 2008-001468-34; HLS01/2008</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Blind intra-articular injection with low- and high-dose corticosteroid in adhesive capsulitis: a randomized, double-blind, controlled trial</ProtocolTitle><Sponsor>Ajou University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="227263"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>94</Patients><Biomarkers></Biomarkers><Condition>Arthralgia</Condition><Controls></Controls><EnrollmentCount>94</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>AJIRB-MED-CT4-15-005; KCT0001451</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Growth Hormone Therapy in Pediatric Crohn's Disease</ProtocolTitle><Sponsor>Cincinnati Children's Hospital Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157135"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Calprotectin; Insulin-like Growth Factor 1</Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>Entocort; Nutropin AQ; prednisone</Interventions><Reference>CCHMC IRB #: 04-12-06; IND # 71,344; NCT00109473</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of CRx-191 to assess activity in plaque psoriasis</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="36819"></Trial><Drug id="56234">mometasone + nortriptyline (topical cream, psoriasis), CombinatoRx</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>CRx-191</Interventions><Reference>CRx-191-001; Eudra CT #: 2006-005848-87; NCT00557739</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>HPA Axis Study in Japanese Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79701"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Atopic dermatitis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>mapracorat</Interventions><Reference>1403460; 15519; NCT01407510</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-dose ICS Therapy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88126"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>207</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; FEV1; Glucose; Heart rate; Hematocrit; Hemoglobin; Lactate dehydrogenase; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; PEF; Phosphorus; Potassium; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Urea nitrogen; Uric acid; cortisol; gamma-Glutamyltransferase</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>622</EnrollmentCount><Interventions>fluticasone; fluticasone furoate</Interventions><Reference>2007-004459-13; FFA109685; NCT00603278</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatments for Non - Septic Olecranon Bursitis: Choosing among Observation, Aspiration and Aspiration with Steroid Injection</ProtocolTitle><Sponsor>Myongji Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="232350"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Bursitis</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>KCT0001525; MJH-14-086</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intracameral different dosage triamcinolone acetonide preventing anterior uveitis after uveitic cataract</ProtocolTitle><Sponsor>Beijing Shijitan Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="151518"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers>Intraocular Pressure; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>ChiCTR-TRC-13003466</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="58697"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>53</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>53</EnrollmentCount><Interventions>Qvar; darunavir; ritonavir</Interventions><Reference>09-CC-0186; 090186; NCT00936793</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Entocort for Children With Mild to Moderate Crohn's Disease</ProtocolTitle><Sponsor>Perrigo Co plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="81223"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>108</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>123</EnrollmentCount><Interventions>Entocort</Interventions><Reference>2011-003743-22; D9422C00001; NCT01444092</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluticasone Nasal Spray Patient Preference Study</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13880"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>127</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>127</EnrollmentCount><Interventions>fluticasone furoate; fluticasone propionate</Interventions><Reference>FFU108556; NCT00398476</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="61731"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Histamine; Tryptase</Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Veramyst; olopatadine</Interventions><Reference>09-287-B; NCT01007253</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71760"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>250</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>250</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Reference>663; NCT01230125</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>BALLOON</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 years)</ProtocolTitle><Sponsor>ALTANA AG, AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22042"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1000</Patients><Biomarkers>Forced expiratory flow ; Forced expiratory volume; Hydrocortisone; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>1000</EnrollmentCount><Interventions>Alvesco</Interventions><Reference>2005-001242-17; BALLOON; BY9010/M1-207; NCT00163449</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients</ProtocolTitle><Sponsor>Icon Bioscience Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="70911"></Trial><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>IBI-10090</Interventions><Reference>C10-01; NCT01214174</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery</ProtocolTitle><Sponsor>Icon Bioscience Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="163346"></Trial><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>394</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>394</EnrollmentCount><Interventions>Dexycu</Interventions><Reference>C13-04; NCT02006888</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety Study of PT-010 in Healthy Subjects</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="204168"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>72</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>59</EnrollmentCount><Interventions>PT-009; PT-010; Symbicort Turbohaler</Interventions><Reference>NCT02189304; PT010002-00</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FST-201 In The Treatment of Acute Fungal Otitis Externa</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="59122"></Trial><Drug id="64095">dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Ear disease</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>FST-201</Interventions><Reference>FST201-AFOE-02; NCT00945646</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Effects of FX-006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="260068"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>33</Patients><Biomarkers>Glucose</Biomarkers><Condition>Non-insulin dependent diabetes</Condition><Controls>triamcinolone acetonide injectable suspension (Kenalog)</Controls><EnrollmentCount>33</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2015-010; NCT02762370</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multicenter, prospective, double-blind, in parallel-groups, randomized, placebo-controlled clinical trial to evaluate the short-term efficacy and safety of betamethasone valerate 2.25 mg medicated plaster in patients with chronic lateral epicondylitis (tennis elbow)</ProtocolTitle><Sponsor>Institut Biochimique SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="269724"></Trial><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers>Blood pressure; Heart rate</Biomarkers><Condition>Lateral epicondylitis</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Interventions><Reference>14I-BMT09; 2014-004119-35</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12 to 17 With Plaque Psoriasis</ProtocolTitle><Sponsor>Mayne Pharma Group Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="385266"></Trial><Drug id="114745">halobetasol propionate (0.05% topical foam, plaque psoriasis), Mayne Pharma</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>halobetasol propionate</Interventions><Reference>122-0551-209; NCT03992261</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of FX-006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="221476"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>484</Patients><Biomarkers>Knee stiffness</Biomarkers><Condition>Pain</Condition><Controls>triamcinolone acetonide injectable suspension</Controls><EnrollmentCount>484</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>2014-005329-11; FX006-2014-008; NCT02357459</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dropless Versus Standard Drops Contralateral Eye Study</ProtocolTitle><Sponsor>Carolina Eyecare Physicians, LLC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="236566"></Trial><Drug id="95157">triamcinolone acetonide + moxifloxicin hydrochloride + vancomycin (ocular disease), Harrow Health</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>66</Patients><Biomarkers>Central cornea; Intraocular pressure; Macula retinae</Biomarkers><Condition>Ocular inflammation</Condition><Controls>Moxeza; nepafenac; prednisolone acetate</Controls><EnrollmentCount>59</EnrollmentCount><Interventions>TriMoxiVanc; TriMoxiVanc; nepafenac</Interventions><Reference>CEP 14-002; NCT02515045</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Canakinumab (ACZ-885) in Patients With Frequent Flares for Whom Non-steroidal Anti-Inflammatory Drug (NSAIDs) and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="77770"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>136</Patients><Biomarkers>hsCRP</Biomarkers><Condition>Gout</Condition><Controls>triamcinolone acetonide</Controls><EnrollmentCount>136</EnrollmentCount><Interventions>canakinumab</Interventions><Reference>2010-024172-26; CACZ885H2358; NCT01362608</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>ReDOS</ProtocolAcronym><ProtocolTitle>Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Academic and Community Cancer Research United</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="222641"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>123</Patients><Biomarkers>GTPase KRas</Biomarkers><Condition>Adenocarcinoma</Condition><Controls></Controls><EnrollmentCount>123</EnrollmentCount><Interventions>clobetasol; regorafenib</Interventions><Reference>NCI-2015-00011; NCT02368886; P30CA015083; RU021407I; ReDOS</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>RAINBOW</ProtocolAcronym><ProtocolTitle>A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6 to 11 years) With Asthma</ProtocolTitle><Sponsor>Takeda GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22308"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1050</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>1080</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>BY9010/M1-209; NCT00384189; RAINBOW; U1111-1172-2297</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)</ProtocolTitle><Sponsor>LEO Pharma A/S</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="223294"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Interleukin-13; Interleukin-17D; Protein S100-A1</Biomarkers><Condition>Atopic dermatitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>betamethasone; clobetasol propionate foam, Connetics; pimecrolimus</Interventions><Reference>EXP-1184; NCT02376049</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="83808"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>193</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>193</EnrollmentCount><Interventions>dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate; prednisolone (oral suspension, inflammation), Taro Pharmaceuticals</Interventions><Reference>EGP-437-004; NCT01505088</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>TOPAZ</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="303712"></Trial><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>460</Patients><Biomarkers>Fovea centralis; Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls>Lucentis</Controls><EnrollmentCount>460</EnrollmentCount><Interventions>Avastin; Lucentis; triamcinolone acetonide</Interventions><Reference>2017-002089-37; CLS1003-302; CTRI/2018/05/014044; NCT03203447; TOPAZ</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ELITRA</ProtocolAcronym><ProtocolTitle>Efficacy of LAMA Added to ICS in Treatment of Asthma</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="216299"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>98</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>98</EnrollmentCount><Interventions>Qvar; glycopyrronium bromide (inhaled, COPD), Chiesi</Interventions><Reference>2014-001442-16; CCD-05993AB1-02; CCD-5993AB1-02; ELITRA; NCT02296411</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Efficacy and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis</ProtocolTitle><Sponsor>Amgen Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71945"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>592</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>592</EnrollmentCount><Interventions>Enbrel; Enbrel; Enbrel + Primolux; Primolux</Interventions><Reference>20080470; NCT01235442</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>Salford Lung Study 2</ProtocolAcronym><ProtocolTitle>An Effectiveness Study Comparing Fluticasone Furoate (FF, GW-685698)/Vilanterol (VI, GW-642444) With Standard Treatment in Asthma</ProtocolTitle><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline Research &amp; Development Ltd, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="94845"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>4233</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>inhaled corticosteroids therapy; long acting beta 2-agonist therapy; long acting bronchodilator therapy</Controls><EnrollmentCount>4233</EnrollmentCount><Interventions>Relvar Ellipta</Interventions><Reference>115150; 2011-005553-31; HZA115150; NCT01706198; Salford Lung Study 2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation</ProtocolTitle><Sponsor>Dresden University of Technology</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77387"></Trial><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>94</Patients><Biomarkers></Biomarkers><Condition>Graft versus host disease</Condition><Controls></Controls><EnrollmentCount>242</EnrollmentCount><Interventions>Budenofalk</Interventions><Reference>NCT00180089; PROGAST</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66887"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>107</EnrollmentCount><Interventions>Qnaze</Interventions><Reference>BDP-AR-304; NCT01133626</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PVSD-ICS</ProtocolAcronym><ProtocolTitle>The predictive value of the acute effect of beclomethasone-dipropionate on a mannitol challenge test for the outcome of longterm treatment with beclomethasone-dipropionate in childhood asthma</ProtocolTitle><Sponsor>Medisch Spectrum Twente Enschede</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="267741"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>beclomethasone dipropionate, (CFC-free), Teva</Interventions><Reference>2016-002276-27; PVSD-ICS; PVSD-ICS</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157921"></Trial><Drug id="89013">fluticasone furoate + levocabastine (intranasal spray, perennial and seasonal allergic rhinitis), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Reference>200284; NCT01962467</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of GW-685698X 100 microg Administered Once-Daily Either in the Morning or the Evening and GW-685698X 250 microg Administered Once-Daily in the Evening Via Diskhaler for 28 Days in Subjects With Persistent Bronchial Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="83590"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>575</Patients><Biomarkers>Cortisol; FEV1; PEF</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>669</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>FFA20001; NCT01499446</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 years)</ProtocolTitle><Sponsor>AstraZeneca plc, Takeda Pharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22091"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>744</Patients><Biomarkers>FEV1; cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount>750</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>2004-000825-31; BY9010/M1-206; NCT00163462</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>AMETHYST</ProtocolAcronym><ProtocolTitle>An Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma</ProtocolTitle><Sponsor>Enceladus Pharmaceuticals</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="294570"></Trial><Drug id="77410">dexamethasone (liposome formulation, castration resistant prostate carcinoma/multiple myeloma), Enceladus</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Bilirubin; Blood platelets; Calcium; Creatine kinase; Creatinine; Gamma-glutamyltranspeptidase 1; Glucose; Leukocyte count; Phosphorus; Potassium; Sodium; Total cholesterol</Biomarkers><Condition>Multiple myeloma</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>14-097; 2014-005137-32; AMETHYST; NCT03033316</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Bronchodilator Effect of a Single-Dose of Fluticasone Furoate (FF)/Vilanterol (VI) 100/25 microg Combination When Administered in Adult Patients With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="123588"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>32</Patients><Biomarkers>Forced expiratory volume in 1 s (FEV1)</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>Ellipta dry powder inhaler; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>116592; NCT01837316</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Sponsor>Bausch Health Companies Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62013"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>265</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition>Rectosigmoiditis</Condition><Controls></Controls><EnrollmentCount>265</EnrollmentCount><Interventions>Rectabul</Interventions><Reference>BUCF3001; NCT01008410</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-Inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction</ProtocolTitle><Sponsor>SIFI Societa Industria Farmaceutica Italiana SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280555"></Trial><Drug id="56575">dexamethasone + netilmicin (ophthalmic), SIFI</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>180</Patients><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Ocular inflammation</Condition><Controls>Netildex eye drops solution; bromfenac</Controls><EnrollmentCount>180</EnrollmentCount><Interventions>Netildex; XanterGel; bromfenac</Interventions><Reference>044-SI; 2016-002138-63; NCT02973880</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of BOL-303242X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="55690"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>415</Patients><Biomarkers></Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>415</EnrollmentCount><Interventions>BOL-303242X</Interventions><Reference>2009-011913-26; 588; NCT00905450</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22504"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00616993; ST-601-004</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW-642444M) Combination and FF on an Allergen Induced Asthmatic Response</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66839"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>52</Patients><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + vilanterol</Interventions><Reference>113090; NCT01128569</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Responsiveness of Lower Airways in Adult Patients (18 to 60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate</ProtocolTitle><Sponsor>AstraZeneca plc, Byk Nederland BV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22406"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>37</Patients><Biomarkers>Adenosine Monophosphate; Forced expiratory volume; Slow vital capacity</Biomarkers><Condition>Asthma</Condition><Controls>Ventolin; fluticasone</Controls><EnrollmentCount>37</EnrollmentCount><Interventions>Ventolin; ciclesonide</Interventions><Reference>BY9010/NL-101; ISRCTN37115189; NCT00306163; NTR711</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Staphylococcus Aureus Colonization in Hand Eczema</ProtocolTitle><Sponsor>Mount Sinai School of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87172"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Staphylococcus aureus infection</Condition><Controls>clobetasol propionate foam, Connetics</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Altabax; clobetasol propionate foam, Connetics</Interventions><Reference>GCO 11-0038; NCT01591785</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of FX-006 in Patients With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="83071"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>229</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide (Kenalog-40)</Controls><EnrollmentCount>229</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2011-001; NCT01487161</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="47773"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>487</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>487</EnrollmentCount><Interventions>Qnaze</Interventions><Reference>BDP-AR-201; NCT00854360</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TRI-D</ProtocolAcronym><ProtocolTitle>Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="346870"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>366</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Fostair</Controls><EnrollmentCount>366</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>2017-004405-41; CLI-05993BA1-02; NCT03590379; TRI-D</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71284"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; vilanterol</Interventions><Reference>102932; NCT01213849</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>INCOGNITO</ProtocolAcronym><ProtocolTitle>Investigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol</ProtocolTitle><Sponsor>University of Dundee</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="299300"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>80</Patients><Biomarkers>C5a anaphylatoxin chemotactic receptor; Complement receptor type 1; Cytokines; Forced expiratory volume; Integrin alpha-IIb; Integrin alpha-M; Interleukin-1 beta; Interleukin-13; Interleukin-17A; Interleukin-8; Leukocyte elastase; Neutrophil extracellular trap; Neutrophils; Resistin</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Relvar Ellipta</Controls><EnrollmentCount>80</EnrollmentCount><Interventions>Spiolto Respimat</Interventions><Reference>2016-004473-41; 2016RC22; INCOGNITO; NCT03152149</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280709"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>99mTc; beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Interventions><Reference>2016-001088-35; CCD-05993AA1-15; NCT02975843</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GSK-961081 Alone and With Fluticasone Furoate (FF), Phase I (PhI), Single-Dose Regimen (SD), Repeat-Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="251911"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Globulins; Glucose; Hematocrit; Hemoglobin; Ketones; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Nitrite; PR interval; Phosphate; Potassium; QRS complex; QT interval; Respiratory frequency; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea; Uric acid; Urinary specific gravity; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>batefenterol succinate; batefenterol succinate + fluticasone furoate; fluticasone furoate; fluticasone furoate + vilanterol trifenatate; fluticasone furoate + vilanterol trifenatate</Interventions><Reference>201958; NCT02666287</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="284379"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>425</Patients><Biomarkers>Diastolic blood pressure; Forced expiratory flow ; Forced expiratory volume; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate; salbutamol</Controls><EnrollmentCount>425</EnrollmentCount><Interventions>ELLIPTA dry powder inhaler; fluticasone furoate; salbutamol; umeclidinium bromide</Interventions><Reference>2016-002843-40; 205832; NCT03012061</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Study of D-9421-C 9 mg in Patients With Active Crohn's Disease in Japan</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="84227"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>123</Patients><Biomarkers></Biomarkers><Condition>Crohns disease</Condition><Controls>mesalazine</Controls><EnrollmentCount>123</EnrollmentCount><Interventions>budesonide</Interventions><Reference>2014-004132-20; D9423C00001; JapicCTI-121765; NCT01514240</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 and 110 microg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="227683"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>358</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Potassium; Respiratory frequency; Sodium; Systolic blood pressure; Total protein; Urea nitrogen; Urinary specific gravity</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>358</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>201492; NCT02424539</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>NACHO</ProtocolAcronym><ProtocolTitle>Nasal Allergen Challenge-Reproducibility of Biomarkers and Effect of Topical Steroid Treatment</ProtocolTitle><Sponsor>Hamilton Health Sciences Corp</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329091"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Eosinophils; Peak nasal inspiratory flow</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Nasacort AQ</Interventions><Reference>DC002544/HIREB3820; NACHO; NCT03431961</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Double-blind (neither physician nor patient knows of the actual treatment which can be with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (one of the treatment groups receives medication without active substance), phase II/III study on the efficacy and tolerability of oral budesonide suspension in comparison with placebo in children and adolescents with eosinophilic esophagitis</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="374819"></Trial><Drug id="106967">budesonide (orodispersible tablet, eosinophilic esophagitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>Jorveza</Interventions><Reference>2017-003737-29; BUU-5/EEA; PEDEOS-1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>National Jewish Health</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="3697"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Qvar</Interventions><Reference>HS-1277; NCT00238082</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PRF in Management of Chronic Multiple Oral Ulcers</ProtocolTitle><Sponsor>Beni-Suef University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373754"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Pemphigus</Condition><Controls>Dermovate; orabase</Controls><EnrollmentCount>20</EnrollmentCount><Interventions>orabase; platelet rich fibrin gel</Interventions><Reference>00UAD; NCT03878771</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>DENALI</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT-027) Used Four Times Daily in Adults and Children 4 Years of Age or Older With Asthma</ProtocolTitle><Sponsor>Avillion LLP</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="370792"></Trial><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>600</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>PT-008; PT007</Controls><EnrollmentCount>600</EnrollmentCount><Interventions>PT-027</Interventions><Reference>2018-003674-27; AV004; DENALI; NCT03847896</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Safety and Efficacy of PT-010, PT-003, and PT-009 in Japanese Subjects With COPD Compared With Symbicort Turbohaler</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="310434"></Trial><Drug id="70143">budesonide + formoterol (inhalant aerosol, chronic obstructive pulmonary disease), Pearl Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>324</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort</Controls><EnrollmentCount>324</EnrollmentCount><Interventions>PT-003; PT-009; PT-010</Interventions><Reference>JapicCTI-184080; NCT03262012; PT010007</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)</ProtocolTitle><Sponsor>Aerie Pharmaceuticals Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="360004"></Trial><Drug id="101388">dexamethasone (ophthalmic implant, DME), Aerie Pharmaceuticals/ Envisia</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>AR-1105</Interventions><Reference>AR-1105-CS201; NCT03739593</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EryDex Pharmacokinetics in Healthy Volunteers</ProtocolTitle><Sponsor>EryDel SPA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="151307"></Trial><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel (group 1B); dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel (group 2B)</Interventions><Reference>IED-PK01-2013; NCT01925859</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP-15 in Healthy Adult Subjects</ProtocolTitle><Sponsor>ReveraGen BioPharma Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="226791"></Trial><Drug id="70712">vamorolone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>86</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>86</EnrollmentCount><Interventions>vamorolone</Interventions><Reference>NCT02415439; VBP15-001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="99986"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>61</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>61</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Reference>794; NCT01736462</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ELBRUS</ProtocolAcronym><ProtocolTitle>A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT-027 Compared With Pulmicort Flexhaler</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="379001"></Trial><Drug id="109733">budesonide + salbutamol (asthma), Pearl/ Avillion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>66</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Pulmicort Flexhaler</Controls><EnrollmentCount>66</EnrollmentCount><Interventions>PT-027</Interventions><Reference>D6930C00011; ELBRUS; NCT03934333</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Budesonide Rectal Aerosol Foam and Uceris Rectal Aerosol Foam</ProtocolTitle><Sponsor>Perrigo Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="263269"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Rectabul</Controls><EnrollmentCount></EnrollmentCount><Interventions>budesonide</Interventions><Reference>NCT02800824; PRG-NY-16-007</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157076"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>71</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>71</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine (intranasal spray, perennial and seasonal allergic rhinitis); levocabastine hydrochloride</Interventions><Reference>200286; NCT01957202</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="189017"></Trial><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1661</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>882</EnrollmentCount><Interventions>fluticasone propionate; salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Interventions><Reference>2014-000923-25; FSS-AS-30017; NCT02141854</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>OLiVIA</ProtocolAcronym><ProtocolTitle>Effects of QVAR in Smokers With Asthma</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="100542"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>43</Patients><Biomarkers>FEF25; FEF25-75; FEF50; FEF75; FEV1; FEV1/FVC; FVC/SVC; PEF</Biomarkers><Condition>Asthma</Condition><Controls>Clenil (Chiesi); Flixotide</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>QVAR</Interventions><Reference>2012-005350-39; 20122011; NCT01741285; OLiVIA</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PST/Laser versus Laser Alone for CSME</ProtocolTitle><Sponsor>Edward Hines Jr. VA Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="100166"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>NCT00229918; PST/CSME</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis</ProtocolTitle><Sponsor>InSite Vision Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10106"></Trial><Drug id="55854">azithromycin + dexamethasone (sustained release, DuraSite), InSite</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>417</Patients><Biomarkers></Biomarkers><Condition>Blepharoconjunctivitis</Condition><Controls>AzaSite; dexamethasone</Controls><EnrollmentCount>417</EnrollmentCount><Interventions>AzaSite Plus</Interventions><Reference>C-07-502-002; NCT00578955</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Bevacizumab versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="69043"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Retinal venous occlusion</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>bevacizumab; triamcinolone acetonide</Interventions><Reference>8886; NCT01178697</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ACE</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, two-arm, parallel-group study to compare the efficacy and safety of ciclesonide 320 mg versus ciclesonide 160 mg in patients with severe persistent asthma</ProtocolTitle><Sponsor>Takeda GmbH</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="76906"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>680</Patients><Biomarkers>cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>896</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>ACE; BY9010/M1-140</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="129552"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>17</Patients><Biomarkers></Biomarkers><Condition>Proctitis</Condition><Controls></Controls><EnrollmentCount>17</EnrollmentCount><Interventions>Rectabul</Interventions><Reference>BUF-17/RAP; EUDRACT NO.: 2007-002082-13; NCT00828230</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study in Healthy Volunteers to Characterize the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="145910"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>GSK-2834425; Relovair; Zephyr</Interventions><Reference>200587; NCT01894386</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>Keloid</ProtocolAcronym><ProtocolTitle>Surgical and Aesthetic Outcome, Quality Of Life, and Cost-Effectiveness of Keloid Treatment</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="116826"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>176</Patients><Biomarkers></Biomarkers><Condition>Scar tissue</Condition><Controls></Controls><EnrollmentCount>176</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>2012-002675-34; Keloid; NL40235.078.12</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluticasone Furoate/GW-642444 Inhalation Powder Long-term Safety Study</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62136"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>503</Patients><Biomarkers>Diastolic blood pressure; Glucose; Heart rate; Potassium; Pulse rate; Systolic blood pressure; Urine cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount>503</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>106839; HZA106839; NCT01018186</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, randomized, double-blind, triple-dummy, parallel group study to compare the safety and efficacy of fluticasone propionate, triamcinolone acetonide, and fluticasone propionate in combination with salmeterol xinafoate, each delivered via a metered-dose inhaler, in subjects with asthma who remain symptomatic despite receiving inhaler corticosteroids</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="115129"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>350</Patients><Biomarkers>FEV1; PEF</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>350</EnrollmentCount><Interventions>fluticasone propionate; fluticasone propionate; fluticasone propionate + salmeterol xinafoate; salmeterol xinafoate; triamcinolone acetonide</Interventions><Reference>FLTA4021</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21563"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00406497; SJE2079/2-03-PC</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intra-articular Injection of Allogeneic Platelet Rich Plasma (PRP) for Adhesive Capsulitis</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="115577"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition>Adhesive capsulitis</Condition><Controls>lidocaine; triamcinolone acetonide</Controls><EnrollmentCount>58</EnrollmentCount><Interventions>Allogenic Platelet Rich Plasma (PRP)</Interventions><Reference>BRM-11-02; NCT01458691</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW-685698X Inhalation Powder 200 microg bid, qd and 400 microg qd in the Morning Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) with Persistent Asthma Symptomatic on Low-Dose ICS Therapy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="117746"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>550</Patients><Biomarkers>Forced expiratory volume in 1 s (FEV1)</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>550</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>2005-001841-40; EudraCT 2005-001841-40; FFA102714</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Efficacy Evaluation of a Fixed Combination of Calcitriol 3 microg/g With Three Concentrations (100, 250, 500 microg/g) of Clobetasol Propionate as Spray Formulation Using the Modified Dumas-Scholtz Psoriasis Mini Plaque Test Under Non-Occlusive Conditions</ProtocolTitle><Sponsor>Galderma SA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="117900"></Trial><Drug id="87535">calcitriol + clobetasol propionate (spray, psoriasis vulgaris), Galderma</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls>Daivobet; Dermoval</Controls><EnrollmentCount>32</EnrollmentCount><Interventions>calcitriol + clobetasol propionate</Interventions><Reference>EudraCT 2006-006487-32; RD.03.SPR. 40041</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III, Randomized, Parallel-Group Study to Compare the Therapeutic Efficacy of SMB Budesonide-Salmeterol DPI Capsule 300/25 microg bid Delivered By The Axahaler Versus Seretide Diskus 500/50 microg (Fluticasonepropionate 500 microg/Salmeterol 50 microg) bid Over 12 Weeks and to Evaluate the Safety of SMB Budesonide-Salmeterol 300/25 microg Over an Additional Period of 12 Weeks in Moderate to Severe Persistent Asthmatic Patients</ProtocolTitle><Sponsor>Laboratoires SMB SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="117985"></Trial><Drug id="78537">budesonide + salmeterol  (inhalation powder, respiratory diseases), Laboratoires SMB</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>Seretide Diskus</Controls><EnrollmentCount>500</EnrollmentCount><Interventions>Axahaler; Busal</Interventions><Reference>BUSAL-III-05-1; EudraCT 2006-001514-33</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI-653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects</ProtocolTitle><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="208883"></Trial><Drug id="56124">BI-653048</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>56</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate</Biomarkers><Condition>Inflammatory disease</Condition><Controls>prednisolone</Controls><EnrollmentCount>56</EnrollmentCount><Interventions>BI-653048</Interventions><Reference>1262.9; NCT02224105</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="70377"></Trial><Drug id="59618">fosdagrocorat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>C-peptide; glucose; insulin</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>prednisone</Controls><EnrollmentCount>18</EnrollmentCount><Interventions>PF-04171327</Interventions><Reference>A9391006; NCT01199900</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of orBec as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)</ProtocolTitle><Sponsor>Soligenix Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="151308"></Trial><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>2</Patients><Biomarkers></Biomarkers><Condition>Graft versus host disease</Condition><Controls></Controls><EnrollmentCount>2</EnrollmentCount><Interventions>orBec</Interventions><Reference>BDP-GVHD-08; NCT01925950</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Budesonide Versus Oral Mesalazine in Active Crohn's Disease (CD)</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="16108"></Trial><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>311</Patients><Biomarkers></Biomarkers><Condition>Crohns disease</Condition><Controls>mesalazine</Controls><EnrollmentCount>311</EnrollmentCount><Interventions>budesonide</Interventions><Reference>2004-001213-34; BUC-52/CDA; NCT00300118</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam</ProtocolTitle><Sponsor>Stiefel</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="193445"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>58</EnrollmentCount><Interventions>clobetasol</Interventions><Reference>NCT00842153; OEF0701</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>RECOPB</ProtocolAcronym><ProtocolTitle>Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid</ProtocolTitle><Sponsor>Rouen University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="221587"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Albumin; C-reactive protein; Creatinine; Extracellular fluid; Lean body mass; Natriuretic peptides B; Phase angle; Sodium; Total body mass; Total body water</Biomarkers><Condition>Bullous pemphigoid</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>Clarelux; Impedance analysis</Interventions><Reference>2014-002804-26; 2014/110/HP; NCT02360202; RECOPB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>ICSADP</ProtocolAcronym><ProtocolTitle>Effectiveness of Inhaled Corticosteroids in Preschool Children With Acute Dyspnea and Wheeze</ProtocolTitle><Sponsor>Isala Klinieken</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="192333"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>93</Patients><Biomarkers></Biomarkers><Condition>Dyspnea</Condition><Controls></Controls><EnrollmentCount>7</EnrollmentCount><Interventions>Qvar</Interventions><Reference>2009-009579-36; ICSADP; NCT00962299; NL26689.075.09</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Lung Health Study II</ProtocolTitle><Sponsor>National Heart Lung and Blood Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="3630"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1116</Patients><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>1116</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>207; NCT00000569</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23384"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Blood pressure; Heart rate; Hydrocortisone; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Asthma</Condition><Controls>Avamys; Relovair</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>vilanterol</Interventions><Reference>HZA102940; NCT00625196</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21748"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls>betamethasone sodium phosphate</Controls><EnrollmentCount>140</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00406887; SJE2079/3-01-PC</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of SJE-2079 for Diabetic Macular Edema</ProtocolTitle><Sponsor>Senju Pharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="243944"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Fovea centralis</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Interventions><Reference>UMIN000011873</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Combination Therapy with Endoscopic Triamcinolone Injection and Fluticasone Swallowing for The Prevention of Esophageal Stricture After Endoscopic Submucosal Dissection</ProtocolTitle><Sponsor>Ishikawa Prefectural Central Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="137612"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Esophageal disease</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>fluticasone; triamcinolone acetonide</Interventions><Reference>JPRN-UMIN000010383</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF-5993 pMDI Combination in Healthy Volunteers</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="221592"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Blood pressure; Heart rate; QT interval</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi; charcoal block; pressurized metered dose inhaler</Interventions><Reference>CCD-05993AB2-01; NCT02359292</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of ciclesonide and beclomethasone on lens opacification in adult subjects with moderate to severe persistent asthma</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22103"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1568</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><EnrollmentCount>1568</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>NCT00254956; SFY6160; XRP1526B/3027</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia</ProtocolTitle><Sponsor>Callender Center for Clinical Research</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="66010"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Alopecia</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>clobetasol propionate</Interventions><Reference>NCT01111981; VDC2009O</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Inhaled Ciclesonide in Adult Patients With Asthma</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22951"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>BY9010/M1-125; NCT00546520</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Ciclesonide (CIC) Administered Twice-Daily in Pediatric Patients With Asthma</ProtocolTitle><Sponsor>Takeda Pharmaceuticals International GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22410"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>528</Patients><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>528</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>EFC6695; EudraCT: 2006-004740-22; NCT00392288; XRP1526</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Inhaled Steroid Reduces Systemic Inflammation in COPD</ProtocolTitle><Sponsor>University of British Columbia</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13589"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>50</Patients><Biomarkers>C-reactive protein (CRP); Interleukin-6 (IL-6); Monocyte chemoattractant protein-1 (MCP-1)</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Allermist</Interventions><Reference>4027; NCT00175565</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="151197"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>599</Patients><Biomarkers>ALP; ALT; AST; Albumin; Basophils; Bilirubin; Blood pressure; Calcium; Chloride; Cholesterol; Cortisol; Creatinine; Diastolic blood pressure; Eosinophils; FEV1; GGT; Heart rate; Hemoglobin; Inorganic phosphorus; LD; Leukocyte count; Lymphocytes; Monocytes; PFE; Platelets; Potassium; Red blood cells; Sodium; Systolic blood pressure; Total neutrophils; Total protein; Uric acid; Urinary specific gravity; White blood cells; glucose</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><EnrollmentCount>599</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>2007-004442-32; FFA109687; NCT00603382</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="201346"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><Patients></Patients><Biomarkers>Albumin; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Bone mineral density; Prothrombin time</Biomarkers><Condition>Primary biliary cholangitis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Entocort</Interventions><Reference>07-003586; BUDESONIDE; NCT00587119</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Ciclesonide on Exercise Induced Bronchoconstriction</ProtocolTitle><Sponsor>Hamilton Health Sciences Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22397"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>26</Patients><Biomarkers>FEV1; eosinophil</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>26</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>BY/M1-121; NCT00525772; OBCIEX</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>ADVICE</ProtocolAcronym><ProtocolTitle>Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 years)</ProtocolTitle><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21993"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>ciclesonide; formoterol fumarate</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>Ultrahaler; ciclesonide + formoterol</Interventions><Reference>2004-004708-19; ADVICE; BY9010/M1-506; NCT00314509</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 years)</ProtocolTitle><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22041"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>468</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume; Peak expiratory flow rate; cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>450</EnrollmentCount><Interventions>Alvesco; spacer AeroChamber Plus; spacer AeroChamberMAX</Interventions><Reference>2005-002163-84; BY9010/M1-145; NCT00163436</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CINGAL Study for Knee Osteoarthritis</ProtocolTitle><Sponsor>Anika Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="144187"></Trial><Drug id="103224">CINGAL</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>368</Patients><Biomarkers>Muscle stiffness</Biomarkers><Condition>Pain</Condition><Controls>Monovisc</Controls><EnrollmentCount>368</EnrollmentCount><Interventions>CINGAL</Interventions><Reference>Cingal 13-01; NCT01891396</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study on Triamcinolone and Bevacizumab Efficacy in Macular Edema Treatment and in Retinic or Chorioretinic Neovessels Treatment</ProtocolTitle><Sponsor>IRCCS Policlinico San Matteo</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="141193"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>bevacizumab; triamcinolone acetonide</Interventions><Reference>08059906; EudraCT 2007-003032-37</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Controlled, Multicenter Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye</ProtocolTitle><Sponsor>EyePoint Pharmaceuticals Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="259049"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>38</EnrollmentCount><Interventions>MK II inserter; fluocinolone acetonide</Interventions><Reference>NCT02748512; PSV-FAI-006</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis</ProtocolTitle><Sponsor>Philippine dermatological society</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="228274"></Trial><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; C-reactive protein; High-density lipoprotein cholesterol; Lipids; Low-density lipoprotein cholesterol; Total cholesterol; Triglycerides</Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>Atorvastatin; betamethasone valerate</Interventions><Reference>NCT02432040; PDS_PGH_2013_002</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>RESPOND</ProtocolAcronym><ProtocolTitle>A Pilot Study on the Effect and Safety of Iluvien in Chronic Diabetic Macular Edema Patients</ProtocolTitle><Sponsor>Association for Innovation and Biomedical Research on Light and Image</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="221579"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>11</Patients><Biomarkers>Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Iluvien</Interventions><Reference>2014-003491-23; 4C-2014-06; NCT02359526; RESPOND</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Platelet Rich Plasma versus Corticosteroid Injections for Treating Greater Trochanteric Pain Syndrome</ProtocolTitle><Sponsor>Carl R Darnall Army Medical Center</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="166920"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>triamcinolone acetonide</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Platelet Rich Plasma</Interventions><Reference>GTPS PRP VS STEROID; NCT02031367</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study Of ME-609 For Treatment Of Herpes Simplex Labialis In Adolescents</ProtocolTitle><Sponsor>Medivir AB</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11579"></Trial><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>134</Patients><Biomarkers></Biomarkers><Condition>Herpes simplex virus infection</Condition><Controls></Controls><EnrollmentCount>254</EnrollmentCount><Interventions>aciclovir + hydrocortisone (dermatological), Medivir</Interventions><Reference>609-07; EudraCT: 2006-002828-42; NCT00375570</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>EOS-2</ProtocolAcronym><ProtocolTitle>Maintenance of Remission With Budesonide Orodispersible Tablets versus Placebo in Eosinophilic Esophagitis</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="234441"></Trial><Drug id="106967">budesonide (orodispersible tablet, eosinophilic esophagitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>204</Patients><Biomarkers></Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls></Controls><EnrollmentCount>204</EnrollmentCount><Interventions>Jorveza</Interventions><Reference>2014-001485-99; BUL-2/EER; EOS-2; NCT02493335</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="58697"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>53</Patients><Biomarkers></Biomarkers><Condition>Acquired immune deficiency syndrome</Condition><Controls></Controls><EnrollmentCount>53</EnrollmentCount><Interventions>Qvar; darunavir; ritonavir</Interventions><Reference>09-CC-0186; 090186; NCT00936793</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Assessing the Efficacy and Safety of Lodotra Compared to Prednisone IR in Subjects Suffering From PMR</ProtocolTitle><Sponsor>Mundipharma Research Limited</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="118246"></Trial><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>62</Patients><Biomarkers>C-reactive protein; Erythrocyte sedimentation rate; Interleukin-6</Biomarkers><Condition>Polymyalgia rheumatica</Condition><Controls>prednisone IR</Controls><EnrollmentCount>62</EnrollmentCount><Interventions>prednisone (oral, delayed release), Horizon/SkyePharma/Merck KGaA</Interventions><Reference>2011-002353-57; LOD3501; NCT01821040</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>MASCOT</ProtocolAcronym><ProtocolTitle>Management of Asthma in School-Age Children on Therapy</ProtocolTitle><Sponsor>The University Hospital Of North Staffordshire NHS Trust</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="84740"></Trial><Drug id="78547">batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>229</EnrollmentCount><Interventions>GSK-961081 + fluticasone propionate (COPD), GlaxoSmithKline; fluticasone propionate; fluticasone propionate; montelukast</Interventions><Reference>HTA 05/503/04; ISRCTN03556343; MASCOT; NCT01526161</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics After Single- and Multiple-Dosing of AZD-5423 in Japanese Healthy Male Subjects</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76864"></Trial><Drug id="64294">AZD-5423</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>96</Patients><Biomarkers>Adrenocorticotropic hormone; Blood pressure; Body temperature; Dehydroepiandrosterone sulfate; Heart rate; Hydrocortisone; Osteocalcin; Urine cortisol</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>96</EnrollmentCount><Interventions>AZD-5423</Interventions><Reference>D2340C00003; NCT01338350</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Intranasal Corticosteroids on Pulmonary Symptoms in Asthmatics With Nasal Congestion</ProtocolTitle><Sponsor>St Olavs Hospital</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="85945"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>14</Patients><Biomarkers>FEV; NO</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>14</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>2009/158; NCT01562093</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Second, Phase III Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Sponsor>Ocular Therapeutix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="178013"></Trial><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>241</Patients><Biomarkers>Anterior chamber; Intraocular pressure</Biomarkers><Condition>Ocular pain</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>NCT02089113; OTX-14-003</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages &gt;/= 12 With Persistent Asthma</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="116989"></Trial><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls>salbutamol MDI, IVAX Corp</Controls><EnrollmentCount>72</EnrollmentCount><Interventions>fluticasone + salmeterol (inhaled/Spiromax, asthma), Teva</Interventions><Reference>ABS-AS-201; NCT01058863</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="180892"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>1620</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><EnrollmentCount>1621</EnrollmentCount><Interventions>Relvar</Interventions><Reference>200820; 2013-004548-44; JapicCTI-142506; NCT02105974</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157082"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1238</Patients><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>619</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline; placebo + fluticasone furoate + vilanterol; umeclidinium; umeclidinium (125 microg) + fluticasone furoate + vilanterol; umeclidinium (62.5 microg) + fluticasone furoate + vilanterol</Interventions><Reference>200109; NCT01957163</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Trilogy</ProtocolAcronym><ProtocolTitle>Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster in COPD</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="149179"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1368</Patients><Biomarkers>Body Mass Index; Diastolic blood pressure; FEV1; Heart rate; PR interval; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Foster</Controls><EnrollmentCount>1368</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>2013-001057-27; CCD-1207-PR-0091; NCT01917331; Trilogy</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>HULK</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="277937"></Trial><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Fovea centralis; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>CLS-1003; triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical; triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Interventions><Reference>CLS1004-101; HULK; NCT02944240; NCT02949024</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Infacort Versus Cortef in Healthy Adult Male and Female Subjects</ProtocolTitle><Sponsor>Diurnal Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="316172"></Trial><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>51</Patients><Biomarkers></Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>Cortef</Controls><EnrollmentCount>51</EnrollmentCount><Interventions>Infacort</Interventions><Reference>INFACORT 007; NCT03311932</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="18517"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>EGP-437</Interventions><Reference>EGP-437-001; NCT00694135</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Bevacizumab Versus Bevacizumab Combined With Triamcinolone for Neovascular AMD</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="5282"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>bevacizumab; bevacizumab; triamcinolone acetonide</Interventions><Reference>8533; NCT00370370</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and safety of Institut Biochimique SA (IBSA) 0.1% Betamethasone Valerate (BMV) Medicated Plaster Versus Reference Marketed Product for the Treatment of Chronic Plaque Psoriasis</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Completed</TrialStatus><Trial id="153953"></Trial><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>281</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls>betamethasone</Controls><EnrollmentCount>231</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Interventions><Reference>04EU/BMT06; EudraCT: 2005-003050-96; ISRCTN68864186</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC-1316</ProtocolTitle><Sponsor>Sun Pharmaceutical Advanced Research Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="168932"></Trial><Drug id="71455">SUN-0597 (nasal, inflammatory disorders), Sun Pharma</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers>Forced expiratory volume in 1 sec (FEV1)</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>64</EnrollmentCount><Interventions>SUN-0597 (nasal, inflammatory disorders), Sun Pharma</Interventions><Reference>NCT02041221; SPARC_LTD_ CLR_13_16</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>ReDOS</ProtocolAcronym><ProtocolTitle>Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Academic and Community Cancer Research United</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="222641"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>123</Patients><Biomarkers>GTPase KRas</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>123</EnrollmentCount><Interventions>clobetasol; regorafenib</Interventions><Reference>NCI-2015-00011; NCT02368886; P30CA015083; RU021407I; ReDOS</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Tristar</ProtocolAcronym><ProtocolTitle>Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="231716"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1479</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Relovair; Spiriva</Controls><EnrollmentCount>1479</EnrollmentCount><Interventions>CHF-5993</Interventions><Reference>2014-001487-35; CCD-05993AA1-07; NCT02467452; Tristar</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>VISION-DMD</ProtocolAcronym><ProtocolTitle>An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Sponsor>ReveraGen BioPharma Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="260111"></Trial><Drug id="70712">vamorolone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>17-alpha-hydroxyprogesterone; Adrenocorticotropic hormone; Body Mass Index; C-terminal telopeptide of collagen type I; Corticosterone; Cortodoxone; Glucose; Hydrocortisone; Insulin; Muscle strength; Osteocalcin; Procollagen Type I N-terminal peptide; Six-minute walk distance; Testosterone</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>vamorolone</Interventions><Reference>1R44NS095423-01; 1U34AR068616-01; 2016-004263-38; NCT02760277; VBP15-003; VISION-DMD</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="70722"></Trial><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>57</Patients><Biomarkers></Biomarkers><Condition>Colitis</Condition><Controls></Controls><EnrollmentCount>57</EnrollmentCount><Interventions>Salofalk Granu-Stix; budesonide</Interventions><Reference>2008-005994-36; BUG-1/LMC; NCT01209208</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema</ProtocolTitle><Sponsor>Wills Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="95811"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>170</Patients><Biomarkers></Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>170</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>NCT00441662; Wills Eye Sub-Tenon Kenalog</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>Synergy</ProtocolAcronym><ProtocolTitle>A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="78033"></Trial><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>294</Patients><Biomarkers>ACR 20; ACR 50; ACR 70; C-reactive protein</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>dipyridamole; prednisolone; prednisone</Controls><EnrollmentCount>294</EnrollmentCount><Interventions>prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Interventions><Reference>NCT01369745; Synergy; Z102-008</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-term, Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Microg in Allergic Rhinitis</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88339"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>529</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>529</EnrollmentCount><Interventions>Qnaze</Interventions><Reference>BDP-AR-303; NCT00988247</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="197089"></Trial><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>338</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="197089"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>338</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="197089"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>338</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the 24 h Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100 microg Fluticasone Furoate [FF]/25 microg Vilanterol [VI]) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50 microg Salmeterol/500 microg Fluticasone Propionate [FP])</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76887"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>528</Patients><Biomarkers>FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Seretide</Controls><EnrollmentCount>528</EnrollmentCount><Interventions>Relvar</Interventions><Reference>113107; NCT01342913</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87162"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>363</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>363</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Reference>793; NCT01591655</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>MAP</ProtocolAcronym><ProtocolTitle>The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="33513"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>6</Patients><Biomarkers>Intraocular pressure (IOP); Visual acuity</Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>Medidur</Interventions><Reference>MAP; NA 00012714; NCT00605423</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>FAVOR</ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="30143"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>fluocinolone acetonide</Interventions><Reference>C-01-08-006; FAVOR; NCT00770770</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW-642444) in Adult and Adolescent Asthmatics</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66853"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>586</Patients><Biomarkers>FEV1; PEF; Urinary cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate; fluticasone propionate</Controls><EnrollmentCount>587</EnrollmentCount><Interventions>fluticasone furoate + vilanterol</Interventions><Reference>106829; EudraCT: 2010-019594-14; HZA106829; JapicCTI-101197; NCT01134042</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TRIPLE10</ProtocolAcronym><ProtocolTitle>A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF-5993 pMDI in Subjects With Renal Impairment</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="168962"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>49</Patients><Biomarkers>Diastolic blood pressure; Heart rate; QRS complex; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Interventions><Reference>2013-002140-91; CCD-05993AA1-10; NCT02040597; TRIPLE10</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>SILENCE</ProtocolAcronym><ProtocolTitle>Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease</ProtocolTitle><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="87549"></Trial><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Cardiovascular inflammation</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos</Interventions><Reference>2011-002686-37; 2011-002686-37 AMC; NCT01601106; NL37190.018.11; NTR2936; SILENCE</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of glycerol, two topical steroids, and a topical immune modulator against skin irritation</ProtocolTitle><Sponsor>Odense University Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="31700"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Contact dermatitis</Condition><Controls>vehicle ointment (paraffin oil/soft white paraffin)</Controls><EnrollmentCount>36</EnrollmentCount><Interventions>Clarelux; Durhalieve; Protopic; glycerol</Interventions><Reference>2008-001678-34; NCT00779792; WA+TR_1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Open-Label, Phase III, Multicenter, Parallel Group Study to Evaluate Efficacy and Safety Study of GK-664-S in Subjects With Moderate-to-Severe Scalp Eczema Dermatitis Except for Seborrheic Dermatitis</ProtocolTitle><Sponsor>Maruho Co Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="366908"></Trial><Drug id="96680">clobetasol propionate shampoo (psoriasis), Galderma/Maruho</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Dermatitis</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>GK-664-S</Interventions><Reference>JapicCTI-184247</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>Salford Lung Study 1</ProtocolAcronym><ProtocolTitle>A Randomized Effectiveness Study Comparing Fluticasone Furoate (FF, GW-685698)/Vilanterol (VI, GW-642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85621"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>2802</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>inhaled corticosteroids (ICS) therapy; long acting bronchodilator therapy; triple maintenance therapy</Controls><EnrollmentCount>2802</EnrollmentCount><Interventions>Relovair</Interventions><Reference>115151; 2011-002452-13; HZC115151; NCT01551758; Salford Lung Study 1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder</ProtocolTitle><Sponsor>Rikshospitalet University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44888"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Musculoskeletal pain</Condition><Controls></Controls><EnrollmentCount>122</EnrollmentCount><Interventions>lidocaine; triamcinolone acetonide</Interventions><Reference>IT-avdelingen; Interne tjenester; NCT00840229; REK; Rikshospitalet HF; S-08546</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide Insert (Iluvien) for Diabetic Macular Edema (FAD) Study</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="271751"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients></Patients><Biomarkers>Intraocular pressure; Macula retinae; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Iluvien</Interventions><Reference>IRB00082826; NCT02902744</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>PlenadrEMA</ProtocolAcronym><ProtocolTitle>Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism</ProtocolTitle><Sponsor>H:S Rigshospitalet, Rigshospitalet, Denmark</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="214973"></Trial><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Blood pressure; Hydrocortisone</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>hydrocortisone</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Plenadren</Interventions><Reference>2014-002039-32; H-1-2014-073; NCT02282150; PLEN-EMA-HYPO; PlenadrEMA; PlenadrEMA/1.1/2014</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Use of Corticosteroids (Budenofalk) as a Chemopreventative Agent in Ulcerative Colitis Associated Neoplasia</ProtocolTitle><Sponsor>University Hospital Birmingham NHS Foundation Trust</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="140176"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Secreted frizzled-related protein 1; sFRP1</Biomarkers><Condition>Ulcerative colitis</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Uceris</Interventions><Reference>EudraCT 2009-015077-12; rrk3681</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of Two Different Doses of Topical GW-870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="74969"></Trial><Drug id="70428">870086 (topical, atopic dermatitis), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>25</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Blood platelets; Calcium; Diastolic blood pressure; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Neutrophils; PR interval; Potassium; QRS complex; QT interval; Skin; Sodium; Systolic blood pressure</Biomarkers><Condition>Atopic dermatitis</Condition><Controls>fluticasone</Controls><EnrollmentCount>25</EnrollmentCount><Interventions>870086 (topical, atopic dermatitis), GlaxoSmithKline</Interventions><Reference>113434; 2010-022280-35; NCT01299610</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of triamcinolone in suprascapular nerve block for adhesive capsulitis</ProtocolTitle><Sponsor>Ajou University Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="343336"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>46</Patients><Biomarkers></Biomarkers><Condition>Adhesive capsulitis</Condition><Controls>bupivacaine, AstraZeneca</Controls><EnrollmentCount>46</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; triamcinolone acetonide (sustained-release, pain), Flexion</Interventions><Reference>AJIRB-MED-CT4-17-414; KCT0002926</Reference></Row><Row><ArmCount>7+</ArmCount><ProtocolAcronym>CAPTAIN</ProtocolAcronym><ProtocolTitle>A Phase III, Parallel-Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate + Umeclidinium Bromide + Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline Research &amp; Development Ltd, GlaxoSmithKline SA/Spain, GlaxoSmithKline plc, Innoviva Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="274454"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2544</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Blood pressure; Calcium; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Forced expiratory volume; Glucose; Heart rate; Hematocrit; Hemoglobin; Immunoglobulin E; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Potassium; Sodium; Systolic blood pressure; Total protein; Urea nitrogen</Biomarkers><Condition>Asthma</Condition><Controls>Albuterol + salbutamol; DISKUS DPI; ELLIPTA DPI; Foxair; Metered-dose inhaler; Relvar Ellipta</Controls><EnrollmentCount>2544</EnrollmentCount><Interventions>Albuterol + salbutamol; DISKUS DPI; ELLIPTA DPI; Foxair; GSK-2834425; Metered-dose inhaler</Interventions><Reference>2016-001304-37; 205715; CAPTAIN; JapicCTI-173792; NCT02924688</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF/Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="97979"></Trial><Drug id="90982">fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline; umeclidinium</Interventions><Reference>116524; NCT01725685</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-center, prospective, randomized, double-blind, intra-patient (left-to-right) placebo-controlled, pilot study to assess the efficacy and safety of a betamethasone valerate 0.1% medicated plaster in the treatment of finger nail psoriasis</ProtocolTitle><Sponsor>Institut Biochimique SA</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="329808"></Trial><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Betesil</Interventions><Reference>14I-BMT01; 2014-000291-25</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of AGN-208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62499"></Trial><Drug id="65121">beclomethasone dipropionate (intravitreal injection), Allergan</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>121</Patients><Biomarkers></Biomarkers><Condition>Macular disease</Condition><Controls></Controls><EnrollmentCount>121</EnrollmentCount><Interventions>AGN-208397</Interventions><Reference>208397-001; NCT01027650</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Efficacy of Coadministration of FOV-1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation</ProtocolTitle><Sponsor>Fovea Pharmaceuticals SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="54107"></Trial><Drug id="56186">ciclosporin + prednisolone (allergic conjunctivitis), CombinatoRx/Fovea</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>155</Patients><Biomarkers></Biomarkers><Condition>Allergic conjunctivitis</Condition><Controls></Controls><EnrollmentCount>155</EnrollmentCount><Interventions>FOV-1101-00; Pred Forte; Pred Mild</Interventions><Reference>08-003-27; NCT00833495</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of macular edema following BRVO with STTA</ProtocolTitle><Sponsor>Aichi Medical University, Kamiiida daiichi General Hospital</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="330917"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>MaQaid</Interventions><Reference>UMIN000031215</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Compare Exposure of TA Following Administration of Either FX-006 or TAcs in Patients With Bilateral Knee OA</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="323314"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition>Osteoarthritis</Condition><Controls>Kenalog-40</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX-006-2017-012; NCT03378076</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long Term Safety Of GW-685698X Via Nasal Biopsy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12096"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls>mometasone (nasal/ dermatological)</Controls><EnrollmentCount>125</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>FFR104503; NCT00224523</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>OTO-104 for the Treatment of Meniere's Disease</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79896"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>154</Patients><Biomarkers></Biomarkers><Condition>Meniere disease</Condition><Controls></Controls><EnrollmentCount>154</EnrollmentCount><Interventions>dexamethasone (sustained release, intratympanic injection, ear disorders), Otonomy</Interventions><Reference>104-201102; NCT01412177</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>STORM</ProtocolAcronym><ProtocolTitle>Lung Deposition of TRIMBOW pMDI in Healthy Volunteers, Asthmatic and COPD Patients</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="365704"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers>FEV / FVC ratio; Forced expiratory flow ; Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>2017-005030-29; CLI-05993AA1-20; NCT03795350; STORM</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>NASANIF</ProtocolAcronym><ProtocolTitle>A Study to Assess Efficacy and Safety of Nasacort Nasal Spray in Comparison With Flixonase Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="316886"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>260</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls>Flixonase</Controls><EnrollmentCount>260</EnrollmentCount><Interventions>Nasacort AQ</Interventions><Reference>NASANIF; NCT03317015; TRICAL07830; U1111-1178-4882</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="308369"></Trial><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Adrenocorticotropic hormone; Bone mineral density</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>budesonide</Interventions><Reference>NCT03245840; SHP621-303</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histological Response and Determine if Reduction in Dysphagia is Achieved</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="246014"></Trial><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>420</Patients><Biomarkers>Eosinophils</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls></Controls><EnrollmentCount>420</EnrollmentCount><Interventions>budesonide</Interventions><Reference>NCT02605837; SHP621-301; SHP621-301 induction study</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="36009"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>15</Patients><Biomarkers>Tryptase</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>16367B (OC 3); NCT00791973</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD-5423 When Administered in Different Ways</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="96548"></Trial><Drug id="64294">AZD-5423</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>blood pressure; heart rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>AZD-5423</Interventions><Reference>D2340C00012; Eudract 2012-002307-17; NCT01635985</Reference></Row><Row><ArmCount>15+</ArmCount><ProtocolAcronym>ICS-Life</ProtocolAcronym><ProtocolTitle>Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>University of Ferrara</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="352724"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1032</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Bretaris Genuair; Duaklir Genuair; Incruse; Laventair; Onbrez Breezhaler; Serevent; Spiolto Respimat; Spiriva Respimat; Striverdi Respimat; Tovanor Breezhaler; Ultibro Breezhaler; formoterol; usual care for comorbidity</Controls><EnrollmentCount>1032</EnrollmentCount><Interventions>Alabaster; Aliflus Diskus; Fobuler; Revinty Ellipta; usual care for comorbidity</Interventions><Reference>AIFA-ICSLIFE-001; ICS-Life; NCT03662711</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of FX-006 on Synovial Inflammation in Patients With osteoarthritis (OA) of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="340019"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Estimated glomerular filtration rate; Synovial membrane</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>FX-006</Interventions><Reference>FX006-2017-014; NCT03529942</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Research Study to Characterize the Pharmacodynamics and Safety of Repeat-dose SP-102</ProtocolTitle><Sponsor>Semnur Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="348693"></Trial><Drug id="106609">dexamethasone sodium phosphate (epidural steroid injectable gel, sciatia), Scilex Holding</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>15</Patients><Biomarkers>Glucose; Hydrocortisone; Leukocyte count</Biomarkers><Condition>Sciatica</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>SP-102</Interventions><Reference>NCT03613662; SP-102-03</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>MANDALA</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT-027) in Adults and Children 4 Years of Age or Older With Asthma</ProtocolTitle><Sponsor>Avillion LLP</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="365206"></Trial><Drug id="109733">budesonide + salbutamol (asthma), Pearl/ Avillion</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3100</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>PT-007</Controls><EnrollmentCount>3100</EnrollmentCount><Interventions>PT-027</Interventions><Reference>2018-003673-10; AV003; MANDALA; NCT03769090</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>MF/F Pediatric Asthma HPA Axis Study</ProtocolAcronym><ProtocolTitle>Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5 to 11 Years Old With Persistent Asthma</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="88259"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers>cortisol</Biomarkers><Condition>Asthma</Condition><Controls>Qvar; montelukast</Controls><EnrollmentCount></EnrollmentCount><Interventions>ZENHALE; albuterol; prednisolone</Interventions><Reference>2009-010108-27; MF/F Pediatric Asthma HPA Axis Study; NCT01615874; P05574; PN158</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Recovery and Survival of EryDex in Non-patient Volunteers</ProtocolTitle><Sponsor>EryDel SPA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="223659"></Trial><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>2,3-Diphosphoglycerate; Adenosine Triphosphate; Body temperature; Diastolic blood pressure; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Lactic Acid; Potassium; Systolic blood pressure</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Interventions><Reference>ERY51CR-01-2014; NCT02380924</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Detect Oral Administration of Budesonide in Women</ProtocolTitle><Sponsor>Parc de Salut Mar</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="340871"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>4</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>4</EnrollmentCount><Interventions>Entocord</Interventions><Reference>2017-004839-37; IMIMFTCL/DACORSIN/3; NCT03537326</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="74849"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>142</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>142</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Reference>664; NCT01298752</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label, Multicenter, Phase Ib/IIa Clinical Trial Designed To Evaluate The Safety And Efficacy Of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution In Patients Having Undergone Cataract Surgery With Implantation Of A Posterior Chamber Intraocular Lens (IOL)</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="242633"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>79</Patients><Biomarkers>Anterior chamber; Intraocular pressure; Visual acuity</Biomarkers><Condition>Cataract</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>EyeGate II drug delivery system; dexamethasone</Interventions><Reference>EGP-437-008; NCT02571556</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>DREAM</ProtocolAcronym><ProtocolTitle>Dual Release Hydrocortisone Versus Conventional Glucocorticoid Replacement Therapy in Hypocortisolism</ProtocolTitle><Sponsor>Universita degli Studi di Roma La Sapienza</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="214912"></Trial><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>89</Patients><Biomarkers>Blood cell count; Bone mineral density; Calcium; Collagen type I trimeric cross-linked peptide; Epicardial adipose tissue; Erythrocyte sedimentation rate; Fibrinogen; Hemoglobin A, glycosylated; High-density lipoprotein cholesterol; Immunoglobulins; Low-density lipoprotein cholesterol; Osteocalcin; Parathyroid hormone; Phosphate; Total cholesterol; Triglycerides; Vitamin D</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>cortisone acetate; hydrocortisone</Controls><EnrollmentCount>89</EnrollmentCount><Interventions>Plenadren</Interventions><Reference>DREAM; HYPOSURRENALISM_1; NCT02277587</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population</ProtocolTitle><Sponsor>University of Florida</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="103767"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>28</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>319-2010; NCT01382771</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rapid effect of Flutiform on pulmonary function compared with Relvar and Symbicort</ProtocolTitle><Sponsor>Tohno Chuo Clinic</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="314707"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>15</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>Flutiform; Relvar Ellipta; Symbicort Turbohaler</Interventions><Reference>UMIN000029379</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis</ProtocolTitle><Sponsor>Ocular Therapeutix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="229470"></Trial><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>73</Patients><Biomarkers>Visual acuity</Biomarkers><Condition>Allergic conjunctivitis</Condition><Controls></Controls><EnrollmentCount>73</EnrollmentCount><Interventions>OTX-DP</Interventions><Reference>NCT02445326; OTX-14-007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Subacromial Injection With Corticosteroid Versus Nonsteroidal Anti-inflammatory Drugs (NSAID) in Shoulder Impingement Syndrome</ProtocolTitle><Sponsor>Madigan Army Medical Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="147302"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers>Shoulder motion</Biomarkers><Condition>Tendon disease</Condition><Controls>Azmacort</Controls><EnrollmentCount></EnrollmentCount><Interventions>ketorolac</Interventions><Reference>IMPINGEMENT; NCT01449448</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Triamcinolone Assisted Anterior Vitrectomy</ProtocolTitle><Sponsor>Cairo University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="116449"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Cataract</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>NCT01051648; TRIAM1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Open-Label, Active-Controlled, Two-Period Crossover Study to Evaluate Relative Efficacy and Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebulizer and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebulizer in Children with Mild-to-Moderate Persistent Asthma</ProtocolTitle><Sponsor>Verus Pharmaceuticals Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="116845"></Trial><Drug id="93782">budesonide (Captisol-enabled inhalation solution/eFlow, asthma), Verus Pharmaceuticals</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>20</Patients><Biomarkers>FEV 25 to 75; FEV1; FVC; blood pressure; cortisol; creatinine; heart rate; nitric oxide; peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>budesonide (Captisol-enabled inhalation solution/eFlow, asthma), Verus Pharmaceuticals</Controls><EnrollmentCount>20</EnrollmentCount><Interventions>budesonide (inhaled formulations), AstraZeneca</Interventions><Reference>EudraCT 2006-003801-21; VPI-102-04</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, repeat-dose, multicenter study to compare the safety and pharmacokinetics of Nasacort in pediatric patients with that of adult patients with perennial allergic rhinitis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="89198"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>XRG 5029C/1000</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="56932"></Trial><Drug id="59618">fosdagrocorat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>78</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>prednisolone</Controls><EnrollmentCount>78</EnrollmentCount><Interventions>PF-04171327</Interventions><Reference>A9391002; NCT00812825</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of GW-685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11789"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>112</Patients><Biomarkers>6-beta hydroxycortisol; Cortisol</Biomarkers><Condition>Allergic rhinitis</Condition><Controls>prednisone</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>FFR20002; NCT00116818</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>IVTA</ProtocolAcronym><ProtocolTitle>Triamcinolone versus Laser for Diabetic Macular Edema</ProtocolTitle><Sponsor>University of Oklahoma</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="180232"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>11</Patients><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>11</EnrollmentCount><Interventions>laser; triamcinolone acetonide</Interventions><Reference>2746; IVTA; IVTA - DME; NCT00229931</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III, unblinded, continued long-term administration study of BTR-15 targeting pediatric asthma patients</ProtocolTitle><Sponsor>Teijin Pharma Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="122481"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>BTR-15</Interventions><Reference>JapicCTI-090806</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23198"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Birth weight; FOXP3; IL-10; TGF-alpha</Biomarkers><Condition>Sleep apnea</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>15868B; 15868B; NCT00603044</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>YSCO</ProtocolAcronym><ProtocolTitle>The Protective Effect of a Nasal Corticosteroid (Avamys) On Exercise Induced Airway Obstruction in Cold Air in Children</ProtocolTitle><Sponsor>Stichting Pediatrisch Onderzoek Enschede</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="118794"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>91</Patients><Biomarkers>FEV1; FeNO</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>91</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>EudraCT: 2009-010563-17; FF1; ISRCTN90761040; NL26953.044.09; YSCO</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Two Combined Therapeutic Methods for Treatment of Lateral Epicondylitis</ProtocolTitle><Sponsor>Islamic Azad University of Tehran-Medical Sciences</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="168727"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Lateral epicondylitis</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Cryotherapy; casting; indomethacin; triamcinolone acetonide</Interventions><Reference>NCT00554476; RCT-246910-06</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray in Chinese Adult and Adolescents with Seasonal Allergies</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="283339"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>365</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>365</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>2015-004889-28; FFR113342</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Injection of Triamcinolone Acetonide in Retinitis</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="122471"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>87</Patients><Biomarkers></Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>87</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>IRCT201104266293N1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, comparative, dose-confirmation study of BTR-15 to target pediatric asthma patients</ProtocolTitle><Sponsor>Teijin Pharma Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="122480"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>beclomethasone dipropionate</Controls><EnrollmentCount></EnrollmentCount><Interventions>BTR-15</Interventions><Reference>JapicCTI-090805</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>DOGWOOD</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="212568"></Trial><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>22</Patients><Biomarkers>Anterior chamber; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>Zuprata</Interventions><Reference>CLS1001-201; DOGWOOD; NCT02255032</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Single-Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics</ProtocolTitle><Sponsor>PTC Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="215409"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Liver disease</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>deflazacort</Interventions><Reference>MP-104-CL-023; NCT02286609</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>POPCICLE</ProtocolAcronym><ProtocolTitle>Efficacy of Ciclesonide Inhaled Once-Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 years) (BY9010/CA-101)</ProtocolTitle><Sponsor>Takeda GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22004"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>240</Patients><Biomarkers>FEV1; Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>BY9010/CA-101; EudraCT: 2007-003736-34; NCT00163293; POPCICLE; U1111-1189-7814</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cystic Fibrosis; a Hereditary Inflammatory Process</ProtocolTitle><Sponsor>Universitair Medisch Centrum Utrecht </Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124286"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>60</Patients><Biomarkers>Body height; CD11a; CD11b; Forced expiratory volume in one second (FEV1); Forced vital capacity (FVC); Intercellular adhesion molecule-1; Interleukin 8; Lean body mass; Lung; MoPhabs A17; MoPhabs A27; Soluble intercellular adhesion molecule 1 (sICAM1); Total body mass; Tumor necrosis factor; sE-Selectin; umour necrotising factor alpha (TNFa)</Biomarkers><Condition>Cystic fibrosis</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Reference>ISRCTN03484127; NTR91</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>HAS-EU-2010</ProtocolAcronym><ProtocolTitle>A Retrospective Trial of Suprachoroidal Drug Therapy for Advanced Exudative Age-Related Macular Degeneration</ProtocolTitle><Sponsor>Iscience Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="127743"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>bevacizumab; triamcinolone acetonide</Interventions><Reference>011/1231; DRKS00000609; HAS-EU-2010</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>IMPACT</ProtocolAcronym><ProtocolTitle>A Study Comparing the Efficacy, Safety and Tolerability of Fixed-Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline BR, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="196961"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>10355</Patients><Biomarkers>Eosinophils; Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>10355</EnrollmentCount><Interventions>Relovair; Trelegy Ellipta; Zephyr</Interventions><Reference>1.137.774; 100603; 116855; 2013-003075-35; 38506514.7.1001.0070; 883.250; ANZstudy; CTT116855; HKUCTR-1885; IMPACT; JapicCTI-142653; NCT02164513; RBR-4sxpff; U1111-1160-5241; UW 14-364</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TOPICAL-1</ProtocolAcronym><ProtocolTitle>Budesonide 9 mg Capsules in Active UC</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="241407"></Trial><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>61</Patients><Biomarkers>Calprotectin</Biomarkers><Condition>Ulcerative colitis</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>budesonide</Interventions><Reference>2014-005635-14; BUX-3/UCA; NCT02550418; TOPICAL-1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21747"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls>Rinderon</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00405496; SJE2079/2-02-PC</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To determine whether ultrasound-guided intraarticular injection with high dose corticosteroid in patients with adhesive capsulitis is better than low dose or placebo in improving pain and function</ProtocolTitle><Sponsor>Ajou University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="128627"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>53</Patients><Biomarkers></Biomarkers><Condition>Adhesive capsulitis</Condition><Controls></Controls><EnrollmentCount>53</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>AJIRB-MED-CT4-10-072; KCT0000103</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22672"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>FFA10013; NCT00419237</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Ciclesonide Versus Fixed Combination of Fluticasone Propionate/Salmeterol Versus Placebo in Patients With Mild Persistent Asthma (12 to 75 years)</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22090"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>657</Patients><Biomarkers>Eosinophils; FEV1; Forced Vital Capacity; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>1432</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Interventions><Reference>BY9010/M1-132; NCT00163358</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of GW-685698X In Patients With Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13132"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>38</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>FFR100652; NCT00363740</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW-642444) in Adult and Adolescent Asthmatics</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="68324"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>609</Patients><Biomarkers>Forced expiratory volume in 1 s (FEV1); Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>612</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>106827; 2010-019590-15; HZA106827; NCT01165138; P/119/2011</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>PAW01</ProtocolAcronym><ProtocolTitle>Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma</ProtocolTitle><Sponsor>University of Dundee</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="42844"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>17</Patients><Biomarkers>E-selectin; ICAM-1; cortisol; creatinine</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>Qvar; fluticasone; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; prednisolone</Interventions><Reference>Eudract no: 2008-001811-40; NCT00829257; PAW01; PAW01</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Ciclesonide MDI 50 mg/Day and 200 mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22281"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>450</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>450</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>LTS6159; NCT00270348; XRP1526B - 343</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Pharmacodynamics of GW-685698 in Pediatric Asthmatic Patients</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76319"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>27</Patients><Biomarkers>Serum cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>102942; HZA102942; NCT01332292</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Seasonal Allergic Rhinitis In Pediatric Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13567"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>554</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>576</EnrollmentCount><Interventions>GW685698X; GW685698X 110 microg; GW685698X 55 microg</Interventions><Reference>FFR100010; NCT00107757</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>SAPPHIRE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With intravitreal Aflibercept in Subjects With Macular Edema Following RVO</ProtocolTitle><Sponsor>Clearside Biomedical Inc, Syneos Health Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="281144"></Trial><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>460</Patients><Biomarkers>Fovea centralis; Retina; Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls>Eylea</Controls><EnrollmentCount>460</EnrollmentCount><Interventions>CLS-1003</Interventions><Reference>2016-004648-12; 2017-CT0411; CLS1003-301; CLS1003-301 Amendment 1; CTRI/2017/11/010451; NCT02980874; PHRR170812-001654; SAPPHIRE</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Non-Randomized, Single-Center, Open-Label, Case Series Study of Intravitreal Triamcinolone Acetate Injections (IVTA) Used as Adjunctive to Verteporfin Photodynamic Therapy (PDT) in the Treatment Predominantly Classic CNV Lesions Associated With Age-Related Macular Degeneration (AMD)</ProtocolTitle><Sponsor>Semmelweis University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="142748"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Wet age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Photodynamic therapy; triamcinolone acetonide; verteporfin</Interventions><Reference>EudraCT 2005-005290-30; TCA-05-01</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants &gt;/= 6 to &lt; 12 Years With Severe Atopic Dermatitis (AD)</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="319940"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>367</Patients><Biomarkers>Body surface area</Biomarkers><Condition>Atopic dermatitis</Condition><Controls>Azmacort; clobetasone butyrate; fluocinolone acetonide</Controls><EnrollmentCount>367</EnrollmentCount><Interventions>Azmacort; clobetasone butyrate; dupilumab; fluocinolone acetonide</Interventions><Reference>2016-004997-16; IND Number-107969; NCT03345914; P/069/2017; P/219/2016; R668-AD-1652</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="166763"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>72</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Reference>BDB-AS-101; NCT02030457</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once-Daily Versus Fluticasone Propionate (FP) Twice-Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)</ProtocolTitle><Sponsor>GlaxoSmithKline Research &amp; Development Ltd, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="257624"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>75</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>Relvar; fluticasone</Interventions><Reference>2017-001516-11; 201832; NCT02730351</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Evaluation of Prophylactic Effect of Intralesional Steroid Injection to Prevent Esophageal Stricture After ESD (Endoscopic Submucosal Dissection) of Superficial Esophageal Cancers</ProtocolTitle><Sponsor>Kobe University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="149189"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>JPRN-UMIN000005649</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 6-Month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate(FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="63573"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1030</Patients><Biomarkers>Cortisol; FEV1</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>1031</EnrollmentCount><Interventions>GW-642444; Relovair; fluticasone furoate</Interventions><Reference>112206; HZC112206; JapicCTI-101096; NCT01053988</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 microg Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 microg Inhalation Powder, and Fluticasone Propionate 250 microg Inhalation Powder in Adults and Adolescents With Persistent Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="216821"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1526</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>Advair; fluticasone</Controls><EnrollmentCount>1526</EnrollmentCount><Interventions>Ellipta</Interventions><Reference>1209850; 201378; 2014-002253-19; 40739015.4.1001.5336; 86/2015; 942328; NCT02301975; RBR-4f9tcc; U1111-1172-1687</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>BASALT</ProtocolAcronym><ProtocolTitle>Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term</ProtocolTitle><Sponsor>National Heart Lung and Blood Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22479"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>342</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>342</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Reference>494; BASALT; NCT00495157; U10 HL074073; U10 HL074204; U10 HL074206; U10 HL074208; U10 HL074212; U10 HL074218; U10 HL074225; U10 HL074227; U10 HL074231</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TANZANITE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="216985"></Trial><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>46</Patients><Biomarkers>Choroid; Fovea centralis; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls>aflibercept</Controls><EnrollmentCount>46</EnrollmentCount><Interventions>CLS-TA; aflibercept</Interventions><Reference>CLS1003-201; NCT02303184; TANZANITE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Functional Respiratory Imaging Study (FRI)</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="311029"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Bronchial wall; Lung; Specific airway resistance; Specific airway volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>CHF-5993</Interventions><Reference>2017-000438-79; CCD-05993AA1-16; NCT03268226</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics After Single- and Multiple-Dosing of AZD-5423 in Japanese Healthy Male Subjects</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76864"></Trial><Drug id="64294">AZD-5423</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>96</Patients><Biomarkers>Adrenocorticotropic hormone; Blood pressure; Body temperature; Dehydroepiandrosterone sulfate; Heart rate; Hydrocortisone; Osteocalcin; Urine cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>96</EnrollmentCount><Interventions>AZD-5423</Interventions><Reference>D2340C00003; NCT01338350</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Inhaled Steroids on Gene Expression in the Lungs-2</ProtocolTitle><Sponsor>Weill Medical College of Cornell University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="42589"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Macrophages</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>beclomethasone dipropionate, CFC-free), Teva</Interventions><Reference>0809009975; NCT00826748</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Effects of FX-006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="260068"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>33</Patients><Biomarkers>Glucose</Biomarkers><Condition>Osteoarthritis</Condition><Controls>triamcinolone acetonide injectable suspension (Kenalog)</Controls><EnrollmentCount>33</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2015-010; NCT02762370</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized, Double-blind, Placebo-controlled Trial</ProtocolTitle><Sponsor>Yonsei University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157615"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>111</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>111</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; bupivacaine, AstraZeneca; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Reference>4-2012-0147; NCT01961752</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 years)</ProtocolTitle><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22089"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>28</Patients><Biomarkers>Blood pressure; Body height; Forced expiratory volume; Heart rate; Total body mass; cortisol</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><EnrollmentCount>28</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>2005-001386-34; BY9010/M1-208; NCT00163371</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Relvar on ACOS</ProtocolTitle><Sponsor>Toyama City Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="196622"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers>Forced expiratory volume; Fractional concentration of exhaled nitric oxide; Nitric oxide; Peak expiratory flow rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>budesonide/formoterol; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Interventions><Reference>UMIN000014191</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Relvar on ACOS</ProtocolTitle><Sponsor>Toyama City Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="196622"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers>Forced expiratory volume; Fractional concentration of exhaled nitric oxide; Nitric oxide; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>budesonide/formoterol; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Interventions><Reference>UMIN000014191</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PEACHTREE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="244835"></Trial><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>160</Patients><Biomarkers>Fovea centralis; Intraocular pressure; Macula retinae; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>160</EnrollmentCount><Interventions>Zuprata</Interventions><Reference>CLS1001-301; CLS1001-301 Version 3.2; CTRI/2016/09/007269; NCT02595398; PEACHTREE</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis</ProtocolTitle><Sponsor>Mantecorp Industria Quimica e Farmaceutica Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="180987"></Trial><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>170</Patients><Biomarkers></Biomarkers><Condition>Contact dermatitis</Condition><Controls></Controls><EnrollmentCount>170</EnrollmentCount><Interventions>Prednisolone acetate cream; betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Interventions><Reference>NCT01011621; PRE/P/08-1</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rosiglitazone Versus Theophylline in Asthmatic Smokers</ProtocolTitle><Sponsor>University of Glasgow</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21855"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>91</Patients><Biomarkers>Bronchial epithelial cells; Eosinophils; Epithelial cells; Exhaled breath pH; Exhaled nitric oxide; FEF; FEV1; FVC; Histone deacetylase; Lymphocytes; Macrophages; Neutrophils</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>79</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva; beclometasone (inhaled, CFC-free), Teva; beclometasone (inhaled, CFC-free), Teva + theophylline; rosiglitazone; theophylline; theophylline</Interventions><Reference>2004-004247-22 EUDRACT; NCT00119496; RES104033</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of T-Pred compared to Pred-Forte</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="31880"></Trial><Drug id="53134">tobramycin + prednisolone acetate (ophthalmic), ISTA</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition>Cataract</Condition><Controls>Pred Forte</Controls><EnrollmentCount>56</EnrollmentCount><Interventions>tobramycin + prednisolone acetate (ophthalmic), ISTA</Interventions><Reference>CL-PKT-0312081-P; NCT00699803</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>WP-0508ST (uveitis) Phase III trial</ProtocolTitle><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="215369"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>WP-0508ST</Interventions><Reference>JapicCTI-142695</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CAPRA-1</ProtocolAcronym><ProtocolTitle>Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="2351"></Trial><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>288</Patients><Biomarkers>ACR 20; Erythrocyte sedimentation rate; Hydrocortisone; Interleukin-6; Joint stiffness; Joint swelling; Painful joint count</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>immediate-release prednisone</Controls><EnrollmentCount>288</EnrollmentCount><Interventions>prednisone</Interventions><Reference>CAPRA-1; EMR 62215-003; NCT00146640</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients</ProtocolTitle><Sponsor>EryDel SPA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75227"></Trial><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>22</Patients><Biomarkers>Blood pressure; Hydrocortisone; T-cell surface glycoprotein CD4</Biomarkers><Condition>Ataxia telangiectasia</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>EryDex</Interventions><Reference>2010-022315-19; IEDAT 01; NCT01255358</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>TOPAZ</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="303712"></Trial><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>460</Patients><Biomarkers>Fovea centralis; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls>Lucentis</Controls><EnrollmentCount>460</EnrollmentCount><Interventions>Avastin; Lucentis; triamcinolone acetonide</Interventions><Reference>2017-002089-37; CLS1003-302; CTRI/2018/05/014044; NCT03203447; TOPAZ</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat</ProtocolTitle><Sponsor>Soonchunhyang University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="56389"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>143</Patients><Biomarkers></Biomarkers><Condition>Throat disease</Condition><Controls>chlorhexidine gluconate</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>triamcinolone acetonide; triamcinolone acetonide + chlorhexidine gluconate</Interventions><Reference>NCT00908817; ST</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="80716"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>238</Patients><Biomarkers>FEV1; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>238</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>114496; FFA114496; NCT01431950</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="197089"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>338</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>338</EnrollmentCount><Interventions>Arnuity; GSK-2834425; Relvar Ellipta; Seretide; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Reference>2014-000883-16; GSK: 200699; NCT02164539</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>AZD5423 COPD study</ProtocolAcronym><ProtocolTitle>Multicenter Study to Assess the Efficacy and Safety of AZD-5423 in COPD Patients on a Background Therapy of Formoterol</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85693"></Trial><Drug id="64294">AZD-5423</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>353</Patients><Biomarkers>Cortisol; FEV1; hsCRP</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>budesonide</Controls><EnrollmentCount>353</EnrollmentCount><Interventions>AZD-5423</Interventions><Reference>2011-005389-39; AZD5423 COPD study; D2340C00011; NCT01555099</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Repeat Injection of Cingal for Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Anika Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="223638"></Trial><Drug id="103224">CINGAL</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>242</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>242</EnrollmentCount><Interventions>CINGAL</Interventions><Reference>Cingal 13-02; NCT02381652</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6 to 11 Years) With Seasonal Allergies</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75462"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>713</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>715</EnrollmentCount><Interventions>Qnaze</Interventions><Reference>BDP-AR-305; NCT01307319</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87162"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>363</Patients><Biomarkers></Biomarkers><Condition>Ocular pain</Condition><Controls></Controls><EnrollmentCount>363</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Reference>793; NCT01591655</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ELIOT</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) Spiromax as Compared to Symbicort Turbohaler as Treatment for Adult Patients With Asthma</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="206087"></Trial><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>budesonide + formoterol fumarate, AstraZeneca</Controls><EnrollmentCount>400</EnrollmentCount><Interventions>fluticasone + salmeterol (inhaled/Spiromax, asthma), Teva</Interventions><Reference>2013-004630-14; BFS-AS-40035; ELIOT; NCT02062463</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert</ProtocolTitle><Sponsor>EyePoint Pharmaceuticals Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="92797"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>129</Patients><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>129</EnrollmentCount><Interventions>Iluvien</Interventions><Reference>2013-001810-14; NCT01694186; PSV-FAI-001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>MACS</ProtocolAcronym><ProtocolTitle>Ciclesonide for the Treatment of Airway Hyperresponsiveness</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="42845"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>64</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>64</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>BY9010/CH-101; MACS; NCT00826969; U1111-1137-3949</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>SILENCE</ProtocolAcronym><ProtocolTitle>Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease</ProtocolTitle><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="87549"></Trial><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Atherosclerosis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos</Interventions><Reference>2011-002686-37; 2011-002686-37 AMC; NCT01601106; NL37190.018.11; NTR2936; SILENCE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW-642444-M Combination in Healthy Subjects and in Subjects With Severe Impairment</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="73501"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>Blood pressure; Heart rate; Heart rate; Serum cortisol; Serum potassium</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>Relovair</Interventions><Reference>113970; NCT01266980</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>Western Sky Medical Research</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="61214"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>2008-4; NCT00997620</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects with Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71819"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>365</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>365</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>113342; NCT01231464</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study Assessing Critical Errors, Training/Teaching Time, And Preference Attributes Of The Ellipta Dry Powder Inhaler, In Comparison To Combinations Of Dry Powder Inhalers Used To Provide Triple Therapy, In Patients With Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="281232"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>160</Patients><Biomarkers></Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>160</EnrollmentCount><Interventions>Diskus; Ellipta; Spiriva HandiHaler; Turbuhaler</Interventions><Reference>206215; NCT02982187</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Efficacy of Fluticasone Furoate/Vilanterol Versus Fluticasone Furoate on Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="321810"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients></Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>ELLIPTA dry powder inhaler; fluticasone furoate; salbutamol</Controls><EnrollmentCount></EnrollmentCount><Interventions>ELLIPTA dry powder inhaler; fluticasone furoate; salbutamol; vilanterol</Interventions><Reference>206962; NCT03363191</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TPESP2011-12</ProtocolAcronym><ProtocolTitle>Evaluation of Efficacy and Hypothalamus-Pituitary-Adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection</ProtocolTitle><Sponsor>Istituti Ortopedici Rizzoli</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="89690"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>44</Patients><Biomarkers>ACTH; Blood cortisol; Urinary cortisol</Biomarkers><Condition>Tendinitis</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>methylprednisolone (Pfizer); triamcinolone acetonide</Interventions><Reference>2012-000866-40; NCT01652495; TPESP2011-12; TPESP2011-12</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="282838"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Hearing loss</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>OTO-104</Interventions><Reference>104-201607; NCT02997189</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of Fluticasone Furoate, Umeclidinium and Vilanterol in Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="92256"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers>Blood glucose; Diastolic blood pressure; Heart rate; Heart rate; Serum potassium; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>fluticasone furoate; umeclidinium; vilanterol</Interventions><Reference>116415; 873; CTT116415; IND IDE Number 114; NCT01691547</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ILA115938</ProtocolAcronym><ProtocolTitle>Evaluate the Safety, Efficacy and Dose Response of GSK-573719 in Combination With Fluticasone Furoate in Subjects With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86335"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>421</Patients><Biomarkers>FEV1; Peak Expiratory Flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline; fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Controls><EnrollmentCount>421</EnrollmentCount><Interventions>fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline</Interventions><Reference>115938; ILA115938; ILA115938; NCT01573624</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microg (mcg), FF/VI 100/25 Microg (mcg), and FF 100 Microg (mcg) in Adults and Adolescents With Persistent Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="91744"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1039</Patients><Biomarkers>FEV1; PEF (peak expiratory flow); Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>1040</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate (100/25 microg); fluticasone furoate + vilanterol trifenatate (200/25 microg); vilanterol trifenatate</Interventions><Reference>116863; 2012-002797-32; HZA116863; NCT01686633</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Delayed-Release Prednisone in PMR</ProtocolTitle><Sponsor>Dinora, Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="255348"></Trial><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>8</Patients><Biomarkers>Interleukin-6</Biomarkers><Condition>Polymyalgia rheumatica</Condition><Controls>prednisone (immediate release)</Controls><EnrollmentCount>8</EnrollmentCount><Interventions>Rayos</Interventions><Reference>HZNP-PRE-IIS02; NCT02702778</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>VALFRID</ProtocolAcronym><ProtocolTitle>Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma</ProtocolTitle><Sponsor>Skåne University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="97190"></Trial><Drug id="81677">valproic acid + prednisone (oral, diffuse large B-cell lymphoma), Valcuria/Respiratorius</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers>B-lymphocyte antigen CD20</Biomarkers><Condition>Diffuse large B-cell lymphoma</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>VAL-001, Valcuria; cyclophosphamide; doxorubicin; prednisone; rituximab; vincristine</Interventions><Reference>NCT01622439; VALFRID; Version1.1</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis</ProtocolTitle><Sponsor>Ocular Therapeutix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="281747"></Trial><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>86</Patients><Biomarkers></Biomarkers><Condition>Allergic conjunctivitis</Condition><Controls>Ora-CAC model</Controls><EnrollmentCount>86</EnrollmentCount><Interventions>OTX-DP; Ora-CAC model</Interventions><Reference>NCT02988882; OTX-15-002</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of macular edema following BRVO with STTA</ProtocolTitle><Sponsor>Aichi Medical University, Kamiiida daiichi General Hospital</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="330917"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>MaQaid</Interventions><Reference>UMIN000031215</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="81600"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>26</Patients><Biomarkers>Blood pressure; Cortisol; Glucose; Heart rate; Peak expiratory flow rate; Potassium</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Controls><EnrollmentCount>26</EnrollmentCount><Interventions>fluticasone furoate + vilanterol (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>112777; NCT01453023</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="301426"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>101</Patients><Biomarkers>Anterior chamber</Biomarkers><Condition>Cataract</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>EyeGate; dexamethasone</Interventions><Reference>EGP-437-009; NCT03180255</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CARSAF</ProtocolAcronym><ProtocolTitle>Phase II Study to Evaluate the Cardiac Safety of two Doses of CHF-5993 Both Combined With CHF-1535 Twice-Daily Versus CHF-1535 Twice-Daily in Patients With Moderate to Severe COPD</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86885"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>191</Patients><Biomarkers>Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Glucose; Heart rate; Heart rate; PR interval; Potassium; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>CHF-1535</Controls><EnrollmentCount>191</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>2011-004759-37; CARSAF; CCD-1107-PR-0067; NCT01584505</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>REACT</ProtocolAcronym><ProtocolTitle>Evaluation of Iluvien for the treatment of DME</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="330740"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Iluvien</Interventions><Reference>2016-001680-37; REACT; REACT</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TYBEE</ProtocolAcronym><ProtocolTitle>Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="295885"></Trial><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>71</Patients><Biomarkers>Intraocular pressure; Macula retinae; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls>Eylea</Controls><EnrollmentCount>71</EnrollmentCount><Interventions>Eylea; triamcinolone acetonide</Interventions><Reference>CLS1004-201; NCT03126786; TYBEE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese versus Caucasians</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="371937"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>32</Patients><Biomarkers>Creatinine; Diastolic blood pressure; Glucose; Heart rate; Hydrocortisone; Potassium; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>CHF-5993</Interventions><Reference>CLI-05993AB4-01; NCT03859414</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>Iluvit</ProtocolAcronym><ProtocolTitle>Investigation of the influence of the corticosteroid agent Iluvien on inflammation and growth factors in the eye of patients suffering from diabetic-related retina damage with swelling of the center of the retina</ProtocolTitle><Sponsor>Johann Wolfgang Goethe-Universitat Frankfurt am Main</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="337288"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>12</Patients><Biomarkers>C-C motif chemokine 2; C-X-C motif chemokine 10; Intercellular adhesion molecule-1; Interleukin-1 beta; Interleukin-6; Interleukin-8; Pigment epithelium-derived factor; Placenta growth factor; Platelet-derived growth factor; Vascular endothelial growth factors</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Iluvien</Interventions><Reference>2016-004488-38; 347/17; DRKS00014915; ILV-001; Iluvit</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PRF in Management of Chronic Multiple Oral Ulcers</ProtocolTitle><Sponsor>Beni-Suef University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373754"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Stevens Johnson syndrome</Condition><Controls>Dermovate; orabase</Controls><EnrollmentCount>20</EnrollmentCount><Interventions>orabase; platelet rich fibrin gel</Interventions><Reference>00UAD; NCT03878771</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>DENALI</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT-027) Used Four Times Daily in Adults and Children 4 Years of Age or Older With Asthma</ProtocolTitle><Sponsor>Avillion LLP</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="370792"></Trial><Drug id="109733">budesonide + salbutamol (asthma), Pearl/ Avillion</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>600</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>PT-008; PT007</Controls><EnrollmentCount>600</EnrollmentCount><Interventions>PT-027</Interventions><Reference>2018-003674-27; AV004; DENALI; NCT03847896</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TOPICAL-2</ProtocolAcronym><ProtocolTitle>Novel budesonide capsules versus budesonide tables in patients with ulcerative colitis refractory to standard treatment with mesalazine</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="379131"></Trial><Drug id="59671">budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>777</Patients><Biomarkers></Biomarkers><Condition>Ulcerative colitis</Condition><Controls>Budesonide MMX</Controls><EnrollmentCount>777</EnrollmentCount><Interventions>budesonide (gastroresistant capsule, Crohn's disease/ulcerative colitis), Dr Falk Pharma/Salix</Interventions><Reference>2017-004576-57; BUX-4/UCA; TOPICAL-2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Flovent Diskus versus Qvar versus Pulmicort Flexhaler on Short Term Growth</ProtocolTitle><Sponsor>West Penn Allegheny Health System Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="84529"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>Flovent Diskus; Pulmicort Flexhaler; Qvar</Interventions><Reference>NCT01520688; RC#5255</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus</ProtocolTitle><Sponsor>Orion Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="104633"></Trial><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Charcoal; Seretide Diskus; Seretide Diskus; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion; fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Interventions><Reference>3106007; EudraCT 2012-00378-41; NCT01766843</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Short-Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11760"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>91</Patients><Biomarkers>Ear pressure</Biomarkers><Condition>Otitis media</Condition><Controls></Controls><EnrollmentCount>91</EnrollmentCount><Interventions>Azmacort</Interventions><Reference>103-04; IST4008; NCT00279916; XRG5029C/4008</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ANDA1</ProtocolAcronym><ProtocolTitle>Beta Blocker Therapy in Mild to Moderate Asthmatics</ProtocolTitle><Sponsor>University of Dundee</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="173490"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Blood pressure; Cortisol; Creatinine; Forced expiratory volume in 1 second (FEV1); Forced expriatory flow; Forced vital capacity (FVC); Heart rate; Histamine provocative; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>Qvar; propranolol</Interventions><Reference>2011-002512-89; 2011RC16; ANDA1; NCT01544634</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study in Healthy Volunteers to Characterize the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="145910"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>GSK-2834425; Relovair; Zephyr</Interventions><Reference>200587; NCT01894386</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy Study of Synbitide HFA MDI in Asthma Patients</ProtocolTitle><Sponsor>Intech Biopharm Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="196587"></Trial><Drug id="91606">budesonide + procaterol hydrochloride (MDI formulation, asthma), Intech Biopharm</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>Ventolin</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Synbitide HFA MDI</Interventions><Reference>INTB012; INTB012; NCT02162784</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, open-label study to assess the safety and efficacy of Nasacort in patients with seasonal and perennial allergic rhinitis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="89194"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>651</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>651</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>XRG5029C/4005</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 500 microg of GW-799943X Administered qd in the Morning, 500 microg of GW-799943X Administered qd in the Evening, and 1000 microg GW-799943X Administered qd in the Morning Compared With Placebo and Fluticasone Propionate 250 microg bid, All Delivered by Rotadisk/Diskhaler for 28 Days in Subjects With Persistent Bronchial Asthma Symptomatic on Low-Dose ICS</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="117524"></Trial><Drug id="47921">799943</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>650</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><EnrollmentCount>650</EnrollmentCount><Interventions>GW-799943X</Interventions><Reference>EudraCT 2004-005058-30; ODS100207</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee</ProtocolTitle><Sponsor>Thammasat University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="139011"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>adrenaline; lidocaine; triamcinolone acetonide</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>adrenaline; hylan G-F 20; lidocaine</Interventions><Reference>NCT01874574; ORTHOTU-01</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of topical CRx-191 in normal healthy volunteers</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23649"></Trial><Drug id="56234">mometasone + nortriptyline (topical cream, psoriasis), CombinatoRx</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls>Karison® Creme; mometasone furoate; nortriptyline HCl</Controls><EnrollmentCount>20</EnrollmentCount><Interventions>CRx-191</Interventions><Reference>CRx-191-002; EudraCT Number: 2006-005903-33; NCT00544687</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Glaucoma Drainage Device With and Without Adjunctive Intra-Bleb Injection of Triamcinolone Acetonide: A Randomized Controlled Trial</ProtocolTitle><Sponsor>Hong Kong Eye Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="125878"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>20</Patients><Biomarkers>IOP</Biomarkers><Condition>Glaucoma</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Glaucoma drainage device; triamcinolone acetonide</Interventions><Reference>CUHK_CCT00049; ChiCTR-TRC-09000744</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>DOGWOOD</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="212568"></Trial><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>22</Patients><Biomarkers>Anterior chamber; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>Zuprata</Interventions><Reference>CLS1001-201; DOGWOOD; NCT02255032</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase IV, Double-blind, Double-dummy, Randomized, Placebo-controlled, Parallel-group, Comparison of Fluticasone Propionate Aqueous Nasal Spray and Triamcinolone Acetonide Aqueous Nasal Spray in Subjects With Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157120"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>475</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>450</EnrollmentCount><Interventions>fluticasone propionate; triamcinolone acetonide</Interventions><Reference>FLTA4008</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phaco-Trabeculectomy With Intra-Bleb Injection of Triamcinolone Acetonide Versus Phaco-Trabeculectomy With Mitomycin C in Patients With Co-Existing Cataract and Glaucoma – a Randomized, Controlled Trial</ProtocolTitle><Sponsor>Hong Kong Eye Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124137"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Glaucoma</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>mitomycin; triamcinolone acetonide</Interventions><Reference>CUHK_CCT00045; ChiCTR-TRC-09000644</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phaco-Trabeculectomy With Intra-Bleb Injection of Triamcinolone Acetonide Versus Phaco-Trabeculectomy With Mitomycin C in Patients With Co-Existing Cataract and Glaucoma – a Randomized, Controlled Trial</ProtocolTitle><Sponsor>Hong Kong Eye Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124137"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Cataract</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>mitomycin; triamcinolone acetonide</Interventions><Reference>CUHK_CCT00045; ChiCTR-TRC-09000644</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms (NSRS)</ProtocolTitle><Sponsor>Research in Real-Life Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="216230"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>360</Patients><Biomarkers>Eosinophils; FEV / FVC ratio; Forced Vital Capacity; Forced expiratory volume; Nitric oxide; Peak expiratory flow rate</Biomarkers><Condition>Respiratory disease</Condition><Controls></Controls><EnrollmentCount>360</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Reference>NCT02294279; OR01013</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>It is a Study of Two Modes of Treatment; Which Are Called Laser Photocoagulation Alone And With Drug Triamcinolone, in The Patients Which Are Suffering From Eye Disease Caused by Diabetes Mellitus</ProtocolTitle><Sponsor>Government Medical College, Bhavnagar, Sir Takhtsinhji General Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="127814"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>CTRI/2012/08/002878</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW-870086-X In Healthy Volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22368"></Trial><Drug id="54598">870086 (inhaled, asthma), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Cortisol; Fasting glucose; Osteocalcin</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>870086 (inhaled, asthma), GlaxoSmithKline</Interventions><Reference>NCT00549497; SIG110405</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allergic Rhinitis Changes the Sinus Microbiome</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="130194"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>Qnaze</Interventions><Reference>IRB 12-1812; NCT01852513</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 years)</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22010"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>30</Patients><Biomarkers>FEV1; Forced Vital Capacity; cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>ciclesonide; fluticasone propionate</Interventions><Reference>BY9010/M1-129; NCT00163332</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PINTe</ProtocolAcronym><ProtocolTitle>Optimizating corticosteroid injection for lateral epicondylalgia with the addition of physiotherapy: A randomized control trial with placebo comparison</ProtocolTitle><Sponsor>Griffith University, National Health and Medical Research Council, University of Queensland</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="128680"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>165</Patients><Biomarkers>Muscle strength</Biomarkers><Condition>Lateral epicondylitis</Condition><Controls></Controls><EnrollmentCount>132</EnrollmentCount><Interventions>lidocaine (endometriosis), Isifer; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Reference>2007001703; ACTRN12609000051246; ANZCTR82438; PINTe</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate in the Treatment of Uveitis</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21754"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls>Pred Forte</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00501579; ST-601A-001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of ciclesonide and beclomethasone on lens opacification in adult subjects with moderate to severe persistent asthma</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22103"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1568</Patients><Biomarkers></Biomarkers><Condition>Respiratory disorder</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><EnrollmentCount>1568</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>NCT00254956; SFY6160; XRP1526B/3027</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>MONA</ProtocolAcronym><ProtocolTitle>A New Modified-Release Tablet Formulation of Prednisone (Lodotra) in Patients With Nocturnal Asthma</ProtocolTitle><Sponsor>Horizon Pharma GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22273"></Trial><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>5</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Lodotra</Interventions><Reference>EudraCT-Number: 2007-007316-29; MONA; NCT00686335; NP01-201</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Proof of Concept Study Comparing FX-006 to Kenalog-40 in Patients With Post-Traumatic Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="231796"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers>Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>Kenalog-40</Controls><EnrollmentCount>6</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2014-007; NCT02468583</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Is a Single Dose Intramuscular (IM) Triamcinolone Acetonide Injection More Effective in Treating Symptomatic Flare in Established Rheumatoid Arthritis Than Equivalent Dose Of Oral Prednisolone?</ProtocolTitle><Sponsor>Trafford Healthcare NHS Trust</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="133394"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>prednisolone</Controls><EnrollmentCount>58</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>EudraCT 2007-006729-28</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>WP-0508ST phase II/III trial</ProtocolTitle><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="139399"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>WP-0508ST</Interventions><Reference>JapicCTI-132139</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Of GW-685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics</ProtocolTitle><Sponsor>GlaxoSmithKline Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13948"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>FFR100012; NCT00116883</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dot matrix laser + Betamethason Copound Injection / Triamcinolone Acetonide + NB-UVB versus dipropionate betamethasone cream + NB-UVB for the treatment of the acral type (including the subcarinal parts) of vitiligo: the efficacy and safety of the multicenter, open, randomized, controlled clinical trial</ProtocolTitle><Sponsor>Science and Technology Education Department of the Ministry of Health, The First Hospital Of China Medical University</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="102612"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>289</Patients><Biomarkers></Biomarkers><Condition>Vitiligo</Condition><Controls></Controls><EnrollmentCount>1000</EnrollmentCount><Interventions>Lattice laser; Narrow Band Ultra Violet B (NB-UVB) phototherapy; betamethasone; betamethasone; triamcinolone acetonide</Interventions><Reference>ChiCTR-TRC-12002593</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomised Controlled Trial of Intravitreal Triamcinolone in Patients With Diabetic Macular Edema Refractory to Laser Treatment</ProtocolTitle><Sponsor>The Queen's Medical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="141188"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>EudraCT 2005-000397-45; OY060301</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of SPARC-1310 in Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>Sun Pharmaceutical Advanced Research Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="154380"></Trial><Drug id="71455">SUN-0597 (nasal, inflammatory disorders), Sun Pharma</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>222</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>222</EnrollmentCount><Interventions>SUN-0597</Interventions><Reference>CLR_13_10; NCT01940146; SPARC LTD CLR_13_10</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>SCORE</ProtocolAcronym><ProtocolTitle>Steroid Injections versus Standard Treatment For Macular Edema Due To Retinal Blood Vessel Blockage</ProtocolTitle><Sponsor>National Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="95382"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1260</Patients><Biomarkers></Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>1260</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>05-EI-0101; 050101; NCT00106132; SCORE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Non-Randomized, Open-Label, Single-Center, Phase IV Study of the Effect and Safety of Iluvien in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="232076"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>16</Patients><Biomarkers>Fovea centralis; Intraocular pressure; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>Iluvien</Interventions><Reference>M-01-13-002; NCT02472366</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation of Different Concentrations of ZK-245186 in Atopic Dermatitis</ProtocolTitle><Sponsor>Bayer AG, Intendis GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59066"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers></Biomarkers><Condition>Atopic dermatitis</Condition><Controls></Controls><EnrollmentCount>64</EnrollmentCount><Interventions>ZK-245186</Interventions><Reference>1402942; 14501; NCT00944632</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of CHF-1535 200/6 microg in Not Adequately Controlled Asthmatic Patients</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86498"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>542</Patients><Biomarkers>Diastolic blood pressure; FEV1; Heart rate; Peak expiratory flow rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>beclometasone (inhaled, CFC-free), Teva</Controls><EnrollmentCount>542</EnrollmentCount><Interventions>beclometasone dipropionate + formoterol (inhaled, Modulite), Chiesi</Interventions><Reference>2010-020602-14; CCD-1005-PR-0040; NCT01577082</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>TELOS</ProtocolAcronym><ProtocolTitle>Study to Assess Efficacy and Safety of PT-009 Compared to PT-005, PT-008 and Symbicort Turbuhaler on Lung Function Over 24 Weeks in Subjects With Moderate to Very Severe COPD</ProtocolTitle><Sponsor>AstraZeneca AB, Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="260435"></Trial><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2389</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort; budesonide; formoterol</Controls><EnrollmentCount>3316</EnrollmentCount><Interventions>PT-009</Interventions><Reference>2016-000154-34; D7820C00001; NCT02766608; PT009002; TELOS</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Of Adults And Adolescents With Vasomotor Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="198181"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>352</Patients><Biomarkers></Biomarkers><Condition>Rhinitis</Condition><Controls></Controls><EnrollmentCount>352</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>2004-004743-22; FFR30006; NCT00117325</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Maintenance Study of Entocort for Children With Crohn's Disease</ProtocolTitle><Sponsor>Perrigo Co plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="81640"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>55</EnrollmentCount><Interventions>Entocort</Interventions><Reference>2011-003742-40; D9422C00002; NCT01453946</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4 to 11 Years Old With Persistent Asthma</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="168945"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>628</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate; forced expiratory volume 1 s; peak expiratory flow</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>628</EnrollmentCount><Interventions>Qvar; albuterol/salbutamol</Interventions><Reference>2013-004632-30; BDB-AS-302; NCT02040766</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>MEND</ProtocolAcronym><ProtocolTitle>Macular Edema Nepafenac Versus Difluprednate Uveitis Trial</ProtocolTitle><Sponsor>University of California San Francisco</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="154306"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>108</Patients><Biomarkers>Fovea centralis; Intraocular pressure; Macula retinae; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>108</EnrollmentCount><Interventions>Durezol; Durezol; Nevanac; prednisolone acetate (Pred Forte)</Interventions><Reference>18-24978; CMEND; MEND; MEND; NCT01939691</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide/formoterol maintenance reliever therapy versus fluticasone furoate /vilanterol fixed-dose treatment of asthma on airway inflammation with adult asthma</ProtocolTitle><Sponsor>Hiroshima Clinic</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="226148"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers>Airway resistance; Forced expiratory volume; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>budesonide + formoterol fumarate, AstraZeneca; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline; procaterol</Interventions><Reference>UMIN000017042</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="74436"></Trial><Drug id="56108">mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>251</Patients><Biomarkers></Biomarkers><Condition>Allergic conjunctivitis</Condition><Controls></Controls><EnrollmentCount>251</EnrollmentCount><Interventions>mapracorat (ophthalmic, ocular inflammation), Bausch &amp; Lomb</Interventions><Reference>685; NCT01289431</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TANZANITE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="216985"></Trial><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>46</Patients><Biomarkers>Choroid; Fovea centralis; Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Retinal venous occlusion</Condition><Controls>aflibercept</Controls><EnrollmentCount>46</EnrollmentCount><Interventions>CLS-TA; aflibercept</Interventions><Reference>CLS1003-201; NCT02303184; TANZANITE</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 years)</ProtocolTitle><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22006"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>503</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume; Hydrocortisone; Peak expiratory flow rate; peak expiratory flow</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>500</EnrollmentCount><Interventions>ciclesonide; fluticasone</Interventions><Reference>2004-001681-40; BY9010/IT-101; BY9010/IT-101 incl. amendment 1; NCT00163319</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study investigating intravenously administrated Oncocort in patients with metastatic prostate cancer</ProtocolTitle><Sponsor>Enceladus Pharmaceuticals</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="291118"></Trial><Drug id="77410">dexamethasone (liposome formulation, castration resistant prostate carcinoma/multiple myeloma), Enceladus</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Alkaline phosphatase; Blood pressure; Body temperature; Estradiol; Follicle-stimulating hormone; Glucose; Heart rate; Hydrocortisone; Luteinizing Hormone; Lymphocytes; PR interval; Prostate-specific antigen; QRS complex; QT interval; Sex hormone-binding globulin; Testosterone</Biomarkers><Condition>Metastatic prostate cancer</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>Oncocort</Interventions><Reference>2016-003121-42; CHDR1635</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery</ProtocolTitle><Sponsor>University of Sao Paulo</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="165535"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>2995/2007; NCT00801450</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62140"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>737</Patients><Biomarkers></Biomarkers><Condition>Acute sinusitis</Condition><Controls></Controls><EnrollmentCount>741</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate (bid); fluticasone furoate (qd)</Interventions><Reference>113203; NCT01018030</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Sponsor>Ocular Therapeutix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258056"></Trial><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>438</Patients><Biomarkers>Anterior chamber; Intraocular pressure; Leukocyte count</Biomarkers><Condition>Ocular pain</Condition><Controls></Controls><EnrollmentCount>438</EnrollmentCount><Interventions>OTX-DP</Interventions><Reference>NCT02736175; OTX-15-003</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Ranging Study of the Salmeterol Component of Fluticasone/Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="105408"></Trial><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers>FEV1</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><EnrollmentCount>72</EnrollmentCount><Interventions>fluticasone + salmeterol (inhaled/Spiromax, asthma), Teva</Interventions><Reference>FSS-AS-201; NCT01772368</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="109683"></Trial><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>8</Patients><Biomarkers>Fovea centralis; IOP; Retina; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>11</EnrollmentCount><Interventions>Zuprata</Interventions><Reference>CLS1001-101; NCT01789320</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>VIDA</ProtocolAcronym><ProtocolTitle>Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma</ProtocolTitle><Sponsor>Milton S. Hershey Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="188785"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>408</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>408</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; vitamin D3</Interventions><Reference>1U10HL098115; ASTHMANET 001; NCT01248065; VIDA</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis</ProtocolTitle><Sponsor>Bausch Health Companies Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="239785"></Trial><Drug id="109395">halobetasol propionate (0.01% topical lotion, plaque psoriasis), Ortho Dermatologics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>217</Patients><Biomarkers>Body surface area</Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>217</EnrollmentCount><Interventions>Bryhali</Interventions><Reference>NCT02514577; V01-122A-301</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22312"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>698</Patients><Biomarkers>FEV1; Urinary cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>648</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>2006-005228-18; FFA106783; NCT00398645</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Symbicort on the Ventilatory Kinematics</ProtocolTitle><Sponsor>Columbia University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="95866"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>9</Patients><Biomarkers>Blood pressure; Heart rate; O2 saturation; Oxygen saturation</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Entocort EC</Controls><EnrollmentCount>9</EnrollmentCount><Interventions>Symbicort</Interventions><Reference>AAAI1932; NCT01712854</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Inhaled Fluticasone Furoate on Short-term Growth in Pediatric Subjects With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="235316"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition>Growth disorder</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>ELLIPTA; fluticasone furoate; salbutamol</Interventions><Reference>107112; NCT02502734</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Psoriasis Plaque Test Trial With LEO-90100 Compared to Betesil in Patients With Psoriasis Vulgaris</ProtocolTitle><Sponsor>LEO Pharma A/S</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="236834"></Trial><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>35</Patients><Biomarkers>Skin</Biomarkers><Condition>Psoriasis</Condition><Controls>Betesil</Controls><EnrollmentCount>35</EnrollmentCount><Interventions>LEO-90100</Interventions><Reference>2015-001798-41; LP0053-1227; NCT02518048</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>WP-0508ST (RVO) Phase III trial</ProtocolTitle><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="215368"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Retinal venous occlusion</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>WP-0508ST</Interventions><Reference>JapicCTI-142694</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>WP-0508ST (uveitis) Phase III trial</ProtocolTitle><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="215369"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>WP-0508ST</Interventions><Reference>JapicCTI-142695</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Topical Dexamethasone Aqueous Solution for Macular Edema</ProtocolTitle><Sponsor>Shimane University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="152050"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>90</Patients><Biomarkers>Blood sugar; Intraocular pressure (IOP); Macular thickness; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>dexamethasone + cyclodextrin; triamcinolone acetonide</Interventions><Reference>JPRN-UMIN000001790</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>BETA-RELIEVED</ProtocolAcronym><ProtocolTitle>Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62581"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>228</Patients><Biomarkers>C-reactive protein (CRP); Serum amyloid A (SAA); Serum urate</Biomarkers><Condition>Gout</Condition><Controls>triamcinolone acetonide</Controls><EnrollmentCount>230</EnrollmentCount><Interventions>canakinumab</Interventions><Reference>2009-015018-23; 2009-017503-29; 2010-019559-23; ACZ885H2356; BETA-RELIEVED; CACZ885H2356; CACZ885H2356E1; CACZ885H2356E2; NCT01029652; NCT01071213; NCT01160016</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An RCT in Treatment of Adhesive Capsulitis Arthrographic Joint Distention With Local Anesthetic Alone</ProtocolTitle><Sponsor>Queen's University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="163100"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>108</Patients><Biomarkers></Biomarkers><Condition>Adhesive capsulitis</Condition><Controls></Controls><EnrollmentCount>108</EnrollmentCount><Interventions>lidocaine; lidocaine; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Reference>NCT02001740; SURG-246-12</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of GW-685698X an Inhaled Corticosteroid Once-Daily and Twice-Daily for the Treatment of Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="30011"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>190</Patients><Biomarkers>Diastolic blood pressure; Forced expiratory volume; Heart rate; Hydrocortisone; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>190</EnrollmentCount><Interventions>Arnuity; fluticasone</Interventions><Reference>112202; NCT00766090</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="236335"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>850</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>ProAir</Controls><EnrollmentCount>713</EnrollmentCount><Interventions>Breath-Actuated Inhaler (BAI); Metered Dose Inhaler (MDI); ProAir; Qvar</Interventions><Reference>2015-002510-80; BDB-AS-30039; NCT02513160</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Short-Term Efficacy and Safety of Two Different Treatment Regimens of Betamethasone Valerate 2.25 Mg Medicated Plaster in Patients With Chronic Tendinopathies of the Upper and Lower Limbs</ProtocolTitle><Sponsor>Institut Biochimique SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="151394"></Trial><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>108</Patients><Biomarkers></Biomarkers><Condition>Tendon disease</Condition><Controls></Controls><EnrollmentCount>108</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Interventions><Reference>12I-BMT08; EUCTR2012-005030-11-IT; EudraCT 2012-005030-11</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79213"></Trial><Drug id="59618">fosdagrocorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>323</Patients><Biomarkers>Adrenocorticotropic Hormone; C-terminal telopeptide of collagen type I; CRP; Collagen type I trimeric cross-linked peptide; Eosinophils; Glucose; Hemoglobin A, glycosylated; Hydrocortisone; Lymphocytes; N-terminal type I collagen telopeptide/Creatinine ratio; Neutrophils; Osteocalcin; P1NP; Parathyroid hormone; UNTx/Ucr; adiponectin</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>prednisone</Controls><EnrollmentCount>323</EnrollmentCount><Interventions>fosdagrocorat</Interventions><Reference>2010-023782-22; A9391010; CTRI/2012/07/002810; NCT01393639; NMRR-11-813-9929</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Perennial Allergic Rhinitis Study In Pediatric Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11727"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>558</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>558</EnrollmentCount><Interventions>GW-685698</Interventions><Reference>2004-004745-18; FFR30008; NCT00108914</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of T-PRED(TM) Compared to Pred Forte(R) II</ProtocolTitle><Sponsor>Bausch &amp; Lomb Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="47631"></Trial><Drug id="53134">tobramycin + prednisolone acetate (ophthalmic), ISTA</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>135</Patients><Biomarkers></Biomarkers><Condition>Cataract</Condition><Controls></Controls><EnrollmentCount>135</EnrollmentCount><Interventions>Pred Forte; T-Pred</Interventions><Reference>CL-PKT-0415083-P; NCT00854061</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) versus Vehicle Foam in the Treatment of Chronic Hand Dermatitis</ProtocolTitle><Sponsor>Stiefel</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75815"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Dermatitis</Condition><Controls></Controls><EnrollmentCount>125</EnrollmentCount><Interventions>clobetasol propionate foam, Connetics</Interventions><Reference>115054; NCT01323673</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym>WISDOM</ProtocolAcronym><ProtocolTitle>Pragmatic randomized controlled trial for stepping down of asthma controller treatment in patients controlled</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="275290"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>231</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>beclometasone dipropionate + formoterol fumarate (inhaled, Modulite), Chiesi; budesonide + formoterol fumarate, AstraZeneca; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><EnrollmentCount>231</EnrollmentCount><Interventions>budesonide (inhaled formulations), AstraZeneca; ciclesonide (metered dose inhaler), Nycomed; fluticasone propionate</Interventions><Reference>2016-0838; KCT0002103; WISDOM</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>DC 06/02</ProtocolAcronym><ProtocolTitle>Once-Daily Oral Modified-Release Hydrocortisone in Patients With Adrenal Insufficiency</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="57668"></Trial><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>64</Patients><Biomarkers>Glycated hemoglobin; Hydrocortisone</Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls>hydrocortisone</Controls><EnrollmentCount>64</EnrollmentCount><Interventions>dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Interventions><Reference>104-07; DC 06/02; EudraCT: 2006-0007084-89; NCT00915343</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</ProtocolTitle><Sponsor>Ocular Therapeutix Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90260"></Trial><Drug id="80269">dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>OTX-DP</Interventions><Reference>NCT01666210; OTX-12-002</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sunovion Growth Study Pediatric Subjects With Mild Asthma and Allergic Rhinitis</ProtocolTitle><Sponsor>West Penn Allegheny Health System Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86234"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>Alvesco; Beconase; Omnaris; Qvar</Interventions><Reference>NCT01550471; RC#5401</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157921"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Reference>200284; NCT01962467</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Sponsor>Salix Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="61738"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>281</Patients><Biomarkers></Biomarkers><Condition>Rectosigmoiditis</Condition><Controls></Controls><EnrollmentCount>281</EnrollmentCount><Interventions>Rectabul</Interventions><Reference>BUCF3002; NCT01008423</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Sponsor>Salix Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="61738"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>281</Patients><Biomarkers></Biomarkers><Condition>Ulcerative proctitis</Condition><Controls></Controls><EnrollmentCount>281</EnrollmentCount><Interventions>Rectabul</Interventions><Reference>BUCF3002; NCT01008423</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II study of AJG-511 in patients with active ulcerative colitis</ProtocolTitle><Sponsor>EA Pharma Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157022"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Ulcerative colitis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Rectabul</Interventions><Reference>JapicCTI-132294</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Midazolam Drug Interaction Study With PF-04171327</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60720"></Trial><Drug id="59618">fosdagrocorat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>PF-04171327; midazolam</Interventions><Reference>A9391007; NCT00987038</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>InfStu</ProtocolAcronym><ProtocolTitle>The Value of Short-term Pain Relief for the Prediction of Long-term Outcome After Cervical or Lumbar Nerve Root Infiltration</ProtocolTitle><Sponsor>Kantonsspital St Gallen</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="155140"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>250</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>250</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; mephamesone; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Reference>EKSG 13/061; InfStu; NCT01945554</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11077"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>350</Patients><Biomarkers></Biomarkers><Condition>Rhinitis</Condition><Controls></Controls><EnrollmentCount>350</EnrollmentCount><Interventions>GW-685698X</Interventions><Reference>2004-004744-43; FFR30007; NCT00118703</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)</ProtocolTitle><Sponsor>Enceladus Pharmaceuticals, Galapagos NV</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="63043"></Trial><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>15</Patients><Biomarkers></Biomarkers><Condition>Multiple sclerosis</Condition><Controls>Solu-Medrol</Controls><EnrollmentCount>15</EnrollmentCount><Interventions>Nanocort</Interventions><Reference>2009-013884-21; GLPG0303-CL-204; NCT01039103</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>20089/Combo</ProtocolAcronym><ProtocolTitle>IBI-20089 + Lucentis Combined Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)</ProtocolTitle><Sponsor>University of Illinois</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="68844"></Trial><Drug id="60951">triamcinolone acetonide (controlled release/intravitreal injection/Verisome, diabetic macular edema), EyePoint</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Choroidal neovascularization</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>IBI-20089; Lucentis</Interventions><Reference>20089/Combo; 2009-1067; NCT01175395</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>CONTRAST</ProtocolAcronym><ProtocolTitle>Effect of High-Dose Ciclesonide on Asthma Control</ProtocolTitle><Sponsor>Takeda Development Centre Europe Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="81694"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>520</Patients><Biomarkers>Blood pressure; Body Mass Index; Body temperature; Diastolic blood pressure; Forced expiratory volume; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>520</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>2011-000683-99; CL-9709-301-RD; CONTRAST; NCT01455194; U1111-1133-6333</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-Invasive Measures of Distal Lung Disease in Asthmatics</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22364"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>34</EnrollmentCount><Interventions>Advair; Qvar; Serevent Diskus</Interventions><Reference>IXR-403-4-196; NCT00250341</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>SHIP</ProtocolAcronym><ProtocolTitle>Study to Compare Exposure of TA Following Administration of FX-006 or TAcs in Patients With OA of the Shoulder or Hip</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="323551"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Kenalog</Controls><EnrollmentCount>55</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2017-013; NCT03382262; SHIP</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>SPIRA</ProtocolAcronym><ProtocolTitle>Small Particle Steroids in Refractory Asthma</ProtocolTitle><Sponsor>University of Nottingham</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="192547"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Eosinophils; Forced Vital Capacity; Forced expiratory volume; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>09115; 2010-018249-78; 9890; MREC N: 10/H0408/19; NCT01171365; SPIRA</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-Round) Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22920"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>550</Patients><Biomarkers>Intraocular pressure; Lens; Optic cup; Optic disc</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>550</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>2015-004891-31; FFR110537; NCT00682643</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="32426"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>17</Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>17</EnrollmentCount><Interventions>Medidur FA</Interventions><Reference>C-01-08-004; NCT00695318</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Compare the Impact of Fulticasone Furoate/Vilanterol versus Tiotropium on Arterial Stiffness in COPD</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79358"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>260</Patients><Biomarkers>Arterial stiffness; Blood pressure; Pulse rate; Pulse wave velocity</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Spiriva HandiHaler</Controls><EnrollmentCount>260</EnrollmentCount><Interventions>Relovair</Interventions><Reference>115247; 2010-024435-16; NCT01395888</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>H2255</ProtocolAcronym><ProtocolTitle>Targeted Dose Finding of Canakinumab (ACZ-885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="37260"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>200</Patients><Biomarkers>C-reactive protein (CRP); Serum amyloid A protein (SAA)</Biomarkers><Condition>Gout</Condition><Controls>triamcinolone acetonide</Controls><EnrollmentCount>200</EnrollmentCount><Interventions>canakinumab</Interventions><Reference>CACZ885H2255; EudraCT 2008-004666-61; H2255; H2255; NCT00798369</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Corrected QT (QTc) Study With Flucticasone Furoate and GW-642444</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="70692"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>85</Patients><Biomarkers>Blood pressure; Forced expiratory volume; Heart rate; PR interval; QRS complex; QT interval; R-R interval</Biomarkers><Condition>Asthma</Condition><Controls>moxifloxacin</Controls><EnrollmentCount>85</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>102936; NCT01209026</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Four-way Crossover, Single- and Repeat-Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90428"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>115441; NCT01669070</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy and Safety of FX-006 in Patients With Hip Osteoarthritis</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="365500"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2018-015; NCT03793010</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GSK-961081 Alone and With Fluticasone Furoate (FF), Phase I (PhI), Single-Dose Regimen (SD), Repeat-Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="251911"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Globulins; Glucose; Hematocrit; Hemoglobin; Ketones; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Nitrite; PR interval; Phosphate; Potassium; QRS complex; QT interval; Respiratory frequency; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea; Uric acid; Urinary specific gravity; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>batefenterol succinate; batefenterol succinate + fluticasone furoate; fluticasone furoate; fluticasone furoate + vilanterol trifenatate; fluticasone furoate + vilanterol trifenatate</Interventions><Reference>201958; NCT02666287</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GSK-961081 Alone and With Fluticasone Furoate (FF), Phase I (PhI), Single-Dose Regimen (SD), Repeat-Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="251911"></Trial><Drug id="78547">batefenterol succinate + fluticasone furoate (COPD), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Globulins; Glucose; Hematocrit; Hemoglobin; Ketones; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Nitrite; PR interval; Phosphate; Potassium; QRS complex; QT interval; Respiratory frequency; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Urea; Uric acid; Urinary specific gravity; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>batefenterol succinate; batefenterol succinate + fluticasone furoate; fluticasone furoate; fluticasone furoate + vilanterol trifenatate; fluticasone furoate + vilanterol trifenatate</Interventions><Reference>201958; NCT02666287</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Optimizing Steroid Replacement in Patients With Adrenal Insufficiency</ProtocolTitle><Sponsor>Adelaide and Meath Hospital, Tallaght Regional Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312737"></Trial><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Addisons disease</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Plenadren</Interventions><Reference>2016/09/05; NCT03282487</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>ANDA3</ProtocolAcronym><ProtocolTitle>Targeted Small Airways Therapy in Persistent Asthma</ProtocolTitle><Sponsor>Tayside Medical Science Center, University of Dundee</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="145796"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>26</Patients><Biomarkers>Cortisol; Creatinine; Eosinophil; Eosinophil cationic protein; Eosinophilic cationic protein; Mannitol PD15; Nitric Oxide; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>26</EnrollmentCount><Interventions>Qvar</Interventions><Reference>13/ES/0064; 2012-003923-39; 2012RC16; ANDA3; NCT01894048</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>480 Biomedical Sinus Drug Depot</ProtocolTitle><Sponsor>Lyra Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280158"></Trial><Drug id="103922">mometasone furoate (sustained release transmucosal formulation, chronic sinusitis), Lyra Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Rhinitis</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>mometasone</Interventions><Reference>480MFSDD2016-001; NCT02942186; NCT02967731</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>NACHO</ProtocolAcronym><ProtocolTitle>Nasal Allergen Challenge-Reproducibility of Biomarkers and Effect of Topical Steroid Treatment</ProtocolTitle><Sponsor>Hamilton Health Sciences Corp</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329091"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Eosinophils; Peak nasal inspiratory flow</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Nasacort AQ</Interventions><Reference>DC002544/HIREB3820; NACHO; NCT03431961</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese versus Caucasians</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="371937"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>32</Patients><Biomarkers>Creatinine; Diastolic blood pressure; Glucose; Heart rate; Hydrocortisone; Potassium; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>CHF-5993</Interventions><Reference>CLI-05993AB4-01; NCT03859414</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects</ProtocolTitle><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="323386"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>438</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>438</EnrollmentCount><Interventions>Relvar; salbutamol</Interventions><Reference>2017-002266-45; 207040; NCT03380429</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>STARS</ProtocolAcronym><ProtocolTitle>Step-up and Step-down Therapeutic Strategies in Childhood Arthritis</ProtocolTitle><Sponsor>The Gaslini Institute</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="358840"></Trial><Drug id="103224">CINGAL</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>260</Patients><Biomarkers></Biomarkers><Condition>Juvenile rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>260</EnrollmentCount><Interventions>CINGAL; etanercept; methotrexate; methylprednisolone acetate</Interventions><Reference>2018-001931-27; NCT03728478; STARS</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone Furoate</ProtocolTitle><Sponsor>Bispebjerg Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="359853"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>26</Patients><Biomarkers>Maximal oxygen uptake</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>26</EnrollmentCount><Interventions>Relvar Ellipta</Interventions><Reference>NCT03739294; WADAVIL2018</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>CLEAR</ProtocolAcronym><ProtocolTitle>Corticosteroid Lumbar Epidural Analgesia for Radiculopathy</ProtocolTitle><Sponsor>Semnur Pharmaceuticals Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="322493"></Trial><Drug id="106609">dexamethasone sodium phosphate (epidural steroid injectable gel, sciatia), Scilex Holding</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Sciatica</Condition><Controls></Controls><EnrollmentCount>400</EnrollmentCount><Interventions>SP-102</Interventions><Reference>CLEAR; NCT03372161; SP-102-02</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>OLE-IEDAT</ProtocolAcronym><ProtocolTitle>Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study</ProtocolTitle><Sponsor>CliniRx Tangent Research India Pvt Ltd, EryDel SPA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="344005"></Trial><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Bone mineral density; C-reactive protein; Heart rate; Hemoglobin A, glycosylated; PR interval; Q-wave; QRS complex; QT interval; R-wave; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-wave</Biomarkers><Condition>Ataxia telangiectasia</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>EryDex</Interventions><Reference>2018-000338-36; CTRI/2019/02/017732; IEDAT-03-2018; NCT03563053; OLE-IEDAT; US IND 115929</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Vasoconstriction Study With LEO-90100</ProtocolTitle><Sponsor>LEO Pharma A/S</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="155226"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>35</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>LEO-90100; betamethasone dipropionate; calcipotriol + betamethasone dipropionate, LEO; clobetasol propionate foam, Connetics; fluocinolone acetonide (Synalar)</Interventions><Reference>LP0053-69; NCT01946386</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85132"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Qnaze; beclometasone (inhaled, CFC-free), Teva</Interventions><Reference>BDP-AR-101; NCT01537692</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Placebo-controlled, Cross-over Study Comparing the Clinical Pharmacokinetics, Pharmacodynamics and Tolerability of Triamcinolone Acetonide Versus Budesonide in Healthy Volunteers</ProtocolTitle><Sponsor>Aventis Pharmaceuticals Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="106503"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>budesonide (inhaled formulations), AstraZeneca; triamcinolone acetonide</Interventions><Reference>CMS-3104</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>AZD-5423 Single Ascending Dose Study</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59980"></Trial><Drug id="64294">AZD-5423</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>72</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>AZD-5423</Interventions><Reference>D2340C00001; NCT00963183</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Open-Label, Two-Way, Cross-over Study to Assess the Absolute Bioavailability of GW-685698X Administered Intranasally in Healthy Male and Female Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="153600"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>FFR10010</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability and Pharmacokinetics of BI-653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers</ProtocolTitle><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="208311"></Trial><Drug id="56124">BI-653048</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>80</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>glucocorticoid mimetics (inflammation), Boehringer Ingelheim</Interventions><Reference>1262.1; NCT02217644</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>Crodex</ProtocolAcronym><ProtocolTitle>Intra-Erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-Dependent Crohn's Disease</ProtocolTitle><Sponsor>EryDel SPA</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="75025"></Trial><Drug id="70257">dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>51</Patients><Biomarkers>C-reactive protein; Erythrocyte</Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>51</EnrollmentCount><Interventions>EryDex</Interventions><Reference>2008-007329-38; Crodex; Crodex01; NCT01277289</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="68093"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>343</Patients><Biomarkers>FEV1; Hydrocortisone; PEF</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><EnrollmentCount>350</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>112059; 2010-020144-34; FFA112059; NCT01159912</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis</ProtocolTitle><Sponsor>EyePoint Pharmaceuticals Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="258836"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>153</Patients><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>153</EnrollmentCount><Interventions>Iluvien</Interventions><Reference>CTRI/2014/12/005337; NCT02746991; PSV-FAI-005</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled, multicenter study was conducted to evaluate the efficacy and safety of powder for inhalation of fluticasone furoate and powder for inhalation of fluticasone propionate in the treatment of asthma in adults and adolescents who are receiving treatment with inhaled corticosteroids</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="169280"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>fluticasone furoate; fluticasone propionate</Interventions><Reference>FFA115285</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>SMART</ProtocolAcronym><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, crossover, single-center study to assess the efficacy and efficacy of Nasacort in patients with perennial allergic rhinitis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="88927"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>34</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>SMART; XRG5029C/4004</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of clinical efficacy between FFC and VFC</ProtocolTitle><Sponsor>Kyorin Pharmaceutical Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="326992"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Flutiform; Relvar</Interventions><Reference>UMIN000031039</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Olux-E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis</ProtocolTitle><Sponsor>Derm Research, PLLC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="101105"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>63</Patients><Biomarkers>Body surface area</Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>63</EnrollmentCount><Interventions>Sorilux; Sorilux; clobetasol propionate foam, Connetics</Interventions><Reference>NCT01745133; OLX0112</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 12-week, randomized, open-label, parallel-group study to evaluate the safety and efficacy of ciclesonide versus fluticasone propionate in patients with moderate persistent asthma</ProtocolTitle><Sponsor>Takeda GmbH</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="76915"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>474</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>637</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed; fluticasone</Interventions><Reference>BY9010/M1-133</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS Aqueous Nasal Spray 110 microg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="73628"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>56</Patients><Biomarkers>Alanine Aminotransferase; Albumin; Alkaline Phosphatase; Aspartate Aminotransferase; Creatinine; Glucose; Hematocrit; Hemoglobin; Platelets; Potassium; Red blood cells; Sodium; Total Bilirubin; Total Protein; Urea Nitrogen; White blood cells</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Avamys</Interventions><Reference>112185; AVY-REG00108VN; NCT01270958</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, randomized, multicenter, double-blind, placebo-controlled, balanced incomplete block, multiple-dose, three-period crossover study to determine  the effect of 3 days repeat dosing of GW-685698X and fluticasone propionate (1000 microg) on exhaled nitric oxide in patients with mild to moderate asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="87541"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>GW-685698X; fluticasone propionate</Interventions><Reference>FFA10028</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of MK-0140 in Diabetic Patients With Macular Edema</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="16677"></Trial><Drug id="55108">triamcinolone acetonide (intravitreal implant, I-vation, diabetic macular edema), SurModics</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>2</Patients><Biomarkers>Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>2</EnrollmentCount><Interventions>triamcinolone acetonide (intravitreal implant, I-vation, diabetic macular edema), SurModics</Interventions><Reference>0140-001; 2008_521; MK0140-001; NCT00692614</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis</ProtocolTitle><Sponsor>Salix Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77185"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>114</Patients><Biomarkers></Biomarkers><Condition>Proctitis</Condition><Controls></Controls><EnrollmentCount>114</EnrollmentCount><Interventions>Rectabul</Interventions><Reference>BFPS3073; NCT01349673</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>YSCO</ProtocolAcronym><ProtocolTitle>The Protective Effect of a Nasal Corticosteroid (Avamys) On Exercise Induced Airway Obstruction in Cold Air in Children</ProtocolTitle><Sponsor>Stichting Pediatrisch Onderzoek Enschede</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="118794"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>91</Patients><Biomarkers>FEV1; FeNO</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>91</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>EudraCT: 2009-010563-17; FF1; ISRCTN90761040; NL26953.044.09; YSCO</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical study about ophthalmic local administrations of triamcinolone acetonide for macular edema and/or retinal periphlebitis</ProtocolTitle><Sponsor>Yamagata University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="121608"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers>Retinal thickness</Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>JPRN-UMIN000005778</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Ideal Management of Crohn's Disease: Top-Down Versus Step-Up Strategies - A Prospective, Controlled Trial in the Benelux</ProtocolTitle><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="120593"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>130</Patients><Biomarkers></Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>130</EnrollmentCount><Interventions>Budenofalk; Entocort; Flagyl; Medrol; azathioprine; folic acid; infliximab; methotrexate; prednisolone</Interventions><Reference>ISRCTN61510219; NTR379</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Efficacy and Safety of Betesil Medicated Plaster Versus Daivobet/Dovobet Ointment in the Treatment of Chronic Plaque Psoriasis</ProtocolTitle><Sponsor>Institut Biochimique SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="120685"></Trial><Drug id="78444">betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>betamethasone valerate (transdermal patch, skin diseases), Institut Biochimique; calcipotriol + betamethasone dipropionate, LEO</Interventions><Reference>09EU_BMT12; EudraCT: 2009-016969-28; ISRCTN34974208</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study In Adults And Adolescents With Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12091"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>304</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>304</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>FFR30003; NCT00115622</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Macular Laser Photocoagulation With or Without Intravitreal Injection of Bevacizumab (Avastin) or Triamcinolone Acetonide for Diffuse Diabetic Macular Edema</ProtocolTitle><Sponsor>Ahvaz Jundishapur University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="125066"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>105</Patients><Biomarkers>Central macular thickness; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>105</EnrollmentCount><Interventions>bevacizumab; grid laser photocoagulation; triamcinolone acetonide</Interventions><Reference>IRCT201205029617N1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study In Adolescent and Adult Subjects 12 Years of Age and Older With Seasonal Allergic Rhinitis To Assess Onset of Action</ProtocolTitle><Sponsor>GlaxoSmithKline Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12406"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>380</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>380</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>FFR101816; NCT00118729</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study FFR116365, an Open-label Study of GW-685698X in Pediatric Subjects With Perennial Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88495"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>61</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>61</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>116365; FFR116365; JapicCTI-121890; NCT01622231</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>UVEXATE</ProtocolAcronym><ProtocolTitle>Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="169537"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>7</Patients><Biomarkers></Biomarkers><Condition>Sarcoidosis</Condition><Controls></Controls><EnrollmentCount>7</EnrollmentCount><Interventions>methotrexate; methylprednisolone; prednisone; prednisone; triamcinolone acetonide</Interventions><Reference>NCT00918554; P070140; UVEXATE</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis (MS) Patients</ProtocolTitle><Sponsor>2-BBB Medicines BV</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="170415"></Trial><Drug id="64904">methylprednisolone (PEGylated liposomal, neuroinflammation), EnhanX Biopharm</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>42</Patients><Biomarkers>Adrenocorticotropic Hormone; Fasting blood glucose; Hypothalamic-pituitary-adrenal (HPA) axis hormone; Lymphocyte; Osteocalcin</Biomarkers><Condition>Multiple sclerosis</Condition><Controls>methylprednisolone</Controls><EnrollmentCount>47</EnrollmentCount><Interventions>2B3-201</Interventions><Reference>2013-004077-28; 2B3-201-CR-001; NCT02048358</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Effectiveness of Corticosteroid Preparation in Sympathetic Ganglion Block on Lymphedema</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="127593"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>66</Patients><Biomarkers>Arm circumference</Biomarkers><Condition>Anesthesia</Condition><Controls></Controls><EnrollmentCount>66</EnrollmentCount><Interventions>bupivacaine, AstraZeneca; triamcinolone acetonide</Interventions><Reference>2010-0206; KCT0000300</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema</ProtocolTitle><Sponsor>SurModics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="57663"></Trial><Drug id="55108">triamcinolone acetonide (intravitreal implant, I-vation, diabetic macular edema), SurModics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>31</Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>31</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>NCT00915837; SRDX- 001; STRIDE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled, multicenter, parallel group comparative study of fluticasone furoate inhalation powder and fluticasone furoate / GW642444 formulations that target persistent asthma adolescent patients</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="131588"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Relovair</Interventions><Reference>108 627; JapicCTI-101294</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis</ProtocolTitle><Sponsor>Medivir AB</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23303"></Trial><Drug id="17335">aciclovir + hydrocortisone (dermatological), Medivir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>380</Patients><Biomarkers></Biomarkers><Condition>Herpes simplex virus infection</Condition><Controls></Controls><EnrollmentCount>417</EnrollmentCount><Interventions>ME-609</Interventions><Reference>98-609-013; NCT00736437</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus</ProtocolTitle><Sponsor>Orion Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="196211"></Trial><Drug id="81111">fluticasone propionate + salmeterol xinafoate (Easyhaler, asthma/COPD), Orion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>129</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>Carbomix granules; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline; fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline</Controls><EnrollmentCount>129</EnrollmentCount><Interventions>Carbomix granules; fluticasone propionate + salmeterol xinafoate; fluticasone propionate + salmeterol xinafoate</Interventions><Reference>3106009; NCT02162485</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="4334"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>129</Patients><Biomarkers></Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>bevacizumab; bevacizumab; triamcinolone acetonide</Interventions><Reference>8411; NCT00370669</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>VISION-DMD</ProtocolAcronym><ProtocolTitle>A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Sponsor>ReveraGen BioPharma Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="260105"></Trial><Drug id="70712">vamorolone</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>48</Patients><Biomarkers>17-alpha-hydroxyprogesterone; Adrenocorticotropic hormone; Blood pressure; Body Mass Index; Body temperature; Bone formation rate; C-terminal telopeptide of collagen type I; Corticosterone; Cortodoxone; Dystrophin; Glucose; Heart rate; Hemoglobin A, glycosylated; High-density lipoprotein cholesterol; Hydrocortisone; Insulin; Low-density lipoprotein cholesterol; Muscle strength; Osteocalcin; Procollagen Type I N-terminal peptide; Respiratory frequency; Six-minute walk distance; Testosterone; Total body mass; Total cholesterol; Triglycerides</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls>deflazacort; glucocorticoid therapy; prednisone</Controls><EnrollmentCount>48</EnrollmentCount><Interventions>vamorolone</Interventions><Reference>1R44NS095423-01; 1U34AR068616-01; 2016-004263-38; NCT02760264; VBP15-002; VBP15-003; VISION-DMD</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="199220"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Diarrhea</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>Entocort EC</Interventions><Reference>1132-03; IRUSBUEN0002; NCT00217022; UL1RR024150</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 years)</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22011"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>ciclesonide (metered dose inhaler), Nycomed</Interventions><Reference>BY9010/M1-131; NCT00163345</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Thermosmart</ProtocolAcronym><ProtocolTitle>Effect of Heated Humidity With Thermosmart Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure</ProtocolTitle><Sponsor>Clayton Sleep Insititute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="175536"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Obstructive sleep apnea</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>Thermosmart; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Reference>F &amp; P 07-004; NCT00665977; Thermosmart</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Traditional Paper Symptom Diary Versus the VOCEL Mobile Diary</ProtocolTitle><Sponsor>Allergy and Asthma Medical Group and Research Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22407"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>ciclesonide</Interventions><Reference>CICLE-L-01335; NCT00367263</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Proof of Concept Study Comparing FX-006 to Kenalog-40 in Patients With Post-Traumatic Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="231796"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers>Knee stiffness</Biomarkers><Condition>Pain</Condition><Controls>Kenalog-40</Controls><EnrollmentCount>6</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2014-007; NCT02468583</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13328"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>106</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>106</EnrollmentCount><Interventions>Qvar; ciclesonide</Interventions><Reference>BY9010/M1-408; NCT00659048</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Extension Study for Patients Entered Into Study Infacort 003</ProtocolTitle><Sponsor>Diurnal Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="257842"></Trial><Drug id="79146">hydrocortisone (oral granules, adrenal insufficiency), Diurnal/Emerge Health/Medison Pharma</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>24</Patients><Biomarkers>17-alpha-hydroxyprogesterone; Androgens; Androstenedione; Testosterone</Biomarkers><Condition>Congenital adrenal hyperplasia</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>Infacort</Interventions><Reference>2015-000458-40; INFACORT 004; NCT02733367</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD): Study 2</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="183041"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1238</Patients><Biomarkers>Diastolic blood pressure; Forced expiratory volume; Heart rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>620</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline; fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline; placebo + fluticasone furoate + vilanterol; umeclidinium; umeclidinium (125 microg) + fluticasone furoate + vilanterol; umeclidinium (62.5 microg) + fluticasone furoate + vilanterol</Interventions><Reference>077; 200110; 2013-002239-44; 479; 855; IND IDE 104; NCT02119286</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Single-Center, Open-Label, Randomized, Two-Way Cross Over Study to Determine the Effects on the Short-Term Lower Leg Growth Rate Between Qvar 100 microg BD Delivered via a Metered Dose Inhaler (MDI) (TEVA UK Ltd) With a Reference Beclometasone Formulation via a Reference MDI in Children With Mild to Moderate Asthma</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="151641"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>52</Patients><Biomarkers>cortisol</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>beclometasone; beclometasone (inhaled, CFC-free), Teva</Interventions><Reference>EudraCT 2007-007455-14; QV-001/2007-Pae</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label, Multicenter, Phase Ib/IIa Clinical Trial Designed To Evaluate The Safety And Efficacy Of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution In Patients With Macular Edema</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="233505"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>25</Patients><Biomarkers>Fundus of eye; Intraocular pressure; Macula retinae</Biomarkers><Condition>Macular edema</Condition><Controls>dexamethasone (sustained release ophthalmic), Allergan/Sanwa</Controls><EnrollmentCount>25</EnrollmentCount><Interventions>dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate</Interventions><Reference>EGP-437-007; NCT02485249</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13825"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>299</Patients><Biomarkers>Body height; Cortisol/Creatinine ratio; Hydrocortisone</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>299</EnrollmentCount><Interventions>loratadine; triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Interventions><Reference>2014-004645-27; NCT00449072; XRG5029C_3503</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Compare Captisol-Enabled Budesonide Nasal Solution and Rhinocort Aqua in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis</ProtocolTitle><Sponsor>Ligand Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59051"></Trial><Drug id="62431">budesonide + azelastine (intranasal Captisol-enabled, allergic rhinitis), Sedor Pharmaceuticals</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>65</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>65</EnrollmentCount><Interventions>CDX-313; Pulmicort</Interventions><Reference>CDX947CT001; NCT00938613; P2DS06001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>COMET-1</ProtocolAcronym><ProtocolTitle>CRx-102 Osteoarthritis Multicenter Evaluation Trial</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="22235"></Trial><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>279</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>prednisolone</Controls><EnrollmentCount>279</EnrollmentCount><Interventions>CRx-102</Interventions><Reference>COMET-1; CRx-102-006; NCT00521989</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>ADVICE</ProtocolAcronym><ProtocolTitle>Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 years)</ProtocolTitle><Sponsor>AstraZeneca plc, Takeda GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21993"></Trial><Drug id="48419">ciclesonide + formoterol (inhaled, asthma), Altana/sanofi-aventis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>ciclesonide; formoterol fumarate</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>Ultrahaler; ciclesonide + formoterol</Interventions><Reference>2004-004708-19; ADVICE; BY9010/M1-506; NCT00314509</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>SAPPHIRE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of Triamcinolone Acetonide With intravitreal Aflibercept in Subjects With Macular Edema Following RVO</ProtocolTitle><Sponsor>Clearside Biomedical Inc, Syneos Health Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="281144"></Trial><Drug id="92483">suprachoroidal triamcinolone acetonide + intravitreal aflibercept (diabetic macular edema), Clearside Biomedical</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>460</Patients><Biomarkers>Fovea centralis; Retina; Visual acuity</Biomarkers><Condition>Macular edema</Condition><Controls>Eylea</Controls><EnrollmentCount>460</EnrollmentCount><Interventions>CLS-1003</Interventions><Reference>2016-004648-12; 2017-CT0411; CLS1003-301; CLS1003-301 Amendment 1; CTRI/2017/11/010451; NCT02980874; PHRR170812-001654; SAPPHIRE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100 microg for 52 Weeks in Adult and Adolescent Subjects With Perennial Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="140891"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>736</Patients><Biomarkers>Blood pressure; Cortisol; Heart rate; Pulse rate</Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>736</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK</Interventions><Reference>EudraCT 2004-000091-14; FFR102123</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>FAME</ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75048"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>120</Patients><Biomarkers>Intraocular pressure; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Iluvien</Interventions><Reference>C-01-11-008; FAME; NCT01304706</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma</ProtocolTitle><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="308779"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>870</Patients><Biomarkers>Forced expiratory volume; Glucose; PR interval; Peak expiratory flow rate; QRS complex; QT interval</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate</Controls><EnrollmentCount>870</EnrollmentCount><Interventions>ELLIPTA dry powder inhaler; Ellipta</Interventions><Reference>107116; 2016-004086-87; CTR20181312; HZA107116; JapicCTI-183937; NCT03248128</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>K-IMPROvE</ProtocolAcronym><ProtocolTitle>Efficacy of Lodotra (Prednisone) in Reduction of Morning Stiffness Duration</ProtocolTitle><Sponsor>Mundipharma Korea Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="175309"></Trial><Drug id="54733">prednisone (oral, delayed release), Vectura/Mundipharma/Merck KGaA</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>147</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>147</EnrollmentCount><Interventions>prednisone (oral, delayed release), Horizon/Mundipharma</Interventions><Reference>K-IMPROvE; LOD13-KR-401; NCT02072200</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery</ProtocolTitle><Sponsor>Icon Bioscience Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="63370"></Trial><Drug id="65274">dexamethasone intraocular injection (controlled/sustained release/Verisome), EyePoint</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Ocular inflammation</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>IBI-10090</Interventions><Reference>C09-01; NCT01048593</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD</ProtocolTitle><Sponsor>Enteron Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="26921"></Trial><Drug id="49161">beclomethasone dipropionate (oral, radiation enteritis), Soligenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>129</Patients><Biomarkers></Biomarkers><Condition>Graft versus host disease</Condition><Controls></Controls><EnrollmentCount>130</EnrollmentCount><Interventions>orBec; orBec; prednisone</Interventions><Reference>ENT 00-02; NCT00233896</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children</ProtocolTitle><Sponsor>Rambam Health Care Campus</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="61615"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Reference>NCT01006655; qvar-adenosineCTIL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>FAME</ProtocolAcronym><ProtocolTitle>Fluocinolone Acetonide Implant Compared to Sham Injection in Patients with Diabetic Macular Edema</ProtocolTitle><Sponsor>Alimera Sciences Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="4321"></Trial><Drug id="52822">fluocinolone acetonide (intraocular implant), Alimera/pSivida</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>956</Patients><Biomarkers>Intraocular pressure; Retina; Visual acuity</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>956</EnrollmentCount><Interventions>Iluvien; standard of care laser photocoagulation</Interventions><Reference>C-01-05-001; FAME; NCT00344968</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA</ProtocolTitle><Sponsor>Zalicus Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25682"></Trial><Drug id="50159">prednisolone + dipyridamole (osteoarthritis, inflammation), Zalicus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>59</Patients><Biomarkers>C-reactive protein</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>DMARD therapy</Controls><EnrollmentCount>59</EnrollmentCount><Interventions>CRx-102; DMARD therapy</Interventions><Reference>CRx-102-002; NCT00747214</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CORE II</ProtocolAcronym><ProtocolTitle>Randomized, placebo-controlled trial of budesonide-MMX 6 and 9 mg in patients with ulcerative colitis</ProtocolTitle><Sponsor>Salix Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="18729"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>511</Patients><Biomarkers></Biomarkers><Condition>Ulcerative colitis</Condition><Controls>Entocort EC</Controls><EnrollmentCount>514</EnrollmentCount><Interventions>Budesonide-MMX</Interventions><Reference>CB-01-02/02; CORE II; NCT00679380</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FST-201 in the Treatment of Acute Otitis Externa</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59715"></Trial><Drug id="64095">dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Otitis externa</Condition><Controls>Ciprodex</Controls><EnrollmentCount>70</EnrollmentCount><Interventions>FST-201</Interventions><Reference>FST201-AOE-AS; NCT00961675</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>Sandoz Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="176014"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>962</Patients><Biomarkers></Biomarkers><Condition>Seasonal allergic rhinitis</Condition><Controls>fluticasone furoate (nasal, allergic rhinitis), GSK</Controls><EnrollmentCount>962</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>71047201; LEK PROJECT NUMBER: 2010-02; NCT01279057</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA Presentation</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="208426"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Blood pressure; Body temperature; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>200939; NCT02218723</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo</ProtocolTitle><Sponsor>ORA Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="64469"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Patanase; Veramyst</Interventions><Reference>10-270-0006; NCT01076439</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Characterize the Local Duration of Exposure From FX-006 in Patients With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Flexion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="163029"></Trial><Drug id="72124">triamcinolone acetonide (sustained-release, pain), Flexion</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Kenalog-40</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Zilretta</Interventions><Reference>FX006-2013-005; NCT02003365</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FST-201 In The Treatment of Acute Otitis Externa</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="59121"></Trial><Drug id="64095">dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>5</Patients><Biomarkers></Biomarkers><Condition>Ear disease</Condition><Controls>Ciprodex</Controls><EnrollmentCount>5</EnrollmentCount><Interventions>FST-201</Interventions><Reference>FST201-AOE-02; NCT00945802</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TRIMARAN</ProtocolAcronym><ProtocolTitle>Triple in Asthma With Uncontrolled Patient on Medium Strength of ICS + LABA</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="252805"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1153</Patients><Biomarkers>Forced expiratory flow ; Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>CHF-1535</Controls><EnrollmentCount>1153</EnrollmentCount><Interventions>CHF-5993</Interventions><Reference>2015-000716-18; CCD-05993AB1-03; NCT02676076; TRIMARAN</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="80962"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Bronchospasm</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount></EnrollmentCount><Interventions>Relovair</Interventions><Reference>106847; NCT01435902</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of D-9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="18570"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>Entocort</Interventions><Reference>D9421C00002; JapicCTI-080566; NCT00573469</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Efficacy and Safety of Budesonide (PT-008) in Adult Subjects With Mild to Moderate Persistent Asthmaa</ProtocolTitle><Sponsor>Pearl Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="180805"></Trial><Drug id="90863">budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>150</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory flow ; Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>budesonide (aerosol inhalant/MDI, asthma), Pearl Therapeutics</Interventions><Reference>NCT02105012; PT008001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-Round) Allergic Rhinitis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13885"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>315</Patients><Biomarkers>Peak nasal inspiratory flow; Peak nasal inspiratory flow</Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>315</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>2007-006562-15; FFU111439; NCT00609674</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 microg Once-Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="115209"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Forced expiratory volume (FEV1); Peak expiratory flow (PEF)</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Interventions><Reference>117156; NCT01808339</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="229982"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>423</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>Advair; Symbicort</Controls><EnrollmentCount>423</EnrollmentCount><Interventions>Relovair</Interventions><Reference>116492; NCT02446418</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PEACHTREE</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="244835"></Trial><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>160</Patients><Biomarkers>Fovea centralis; Intraocular pressure; Macula retinae; Visual acuity</Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>160</EnrollmentCount><Interventions>Zuprata</Interventions><Reference>CLS1001-301; CLS1001-301 Version 3.2; CTRI/2016/09/007269; NCT02595398; PEACHTREE</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis</ProtocolTitle><Sponsor>Mantecorp Industria Quimica e Farmaceutica Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="180987"></Trial><Drug id="53978">betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>170</Patients><Biomarkers></Biomarkers><Condition>Atopic dermatitis</Condition><Controls></Controls><EnrollmentCount>170</EnrollmentCount><Interventions>Prednisolone acetate cream; betamethasone valerate (topical emollient foam, psoriasis/dermatitis), Foamix</Interventions><Reference>NCT01011621; PRE/P/08-1</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, randomized, parallel, control study to assess the safety and efficacy of intracameral triamcinolone acetonide in combination with phacoemulsification and trabeculectomy in glaucoma patients</ProtocolTitle><Sponsor>Beijing Shijitan Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="96132"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Intraocular Pressure</Biomarkers><Condition>Glaucoma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>dexamethasone; phacoemulsification; trabeculectomy; triamcinolone acetonide</Interventions><Reference>ChiCTR-TRC-12002313</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A One Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom</ProtocolTitle><Sponsor>Otonomy Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="213744"></Trial><Drug id="65289">dexamethasone (sustained release/intratympanic injection, ear disorders), Otonomy</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>128</Patients><Biomarkers></Biomarkers><Condition>Meniere disease</Condition><Controls></Controls><EnrollmentCount>128</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>104-201403; 2014-001337-86; NCT02265393</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>Beta-RELIEVED-II</ProtocolAcronym><ProtocolTitle>Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a One Year Open-label Extension Study</ProtocolTitle><Sponsor>Novartis AG, Novartis Pharma Services AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="202551"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>226</Patients><Biomarkers>C-reactive protein; Serum amyloid A protein</Biomarkers><Condition>Gout</Condition><Controls></Controls><EnrollmentCount>226</EnrollmentCount><Interventions>canakinumab; triamcinolone acetonide</Interventions><Reference>2009-017802-35; 2010-018913-32; 2010-020060-38; Beta-RELIEVED-II; CACZ885H2357; CACZ885H2357E1; CACZ885H2357E2; H2357; NCT01080131; NCT01137344; NCT01194921</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Pediatric Subjects Aged 5 to &lt; 12 Years</ProtocolTitle><Sponsor>Mundipharma Research Limited</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="173450"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Forced expiratory volume; Forced expiratory volume or FEV1; Hydrocortisone; Peak expiratory flow rate; Peak expiratory flow rate (PEFR)</Biomarkers><Condition>Asthma</Condition><Controls>Aerobec Autohaler; Flixotide</Controls><EnrollmentCount>48</EnrollmentCount><Interventions>FlutiForm</Interventions><Reference>2013-004719-32; FLT2504; NCT02063139</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>WP-0508ST (RVO) Phase III trial</ProtocolTitle><Sponsor>Wakamoto Pharmaceutical Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="215368"></Trial><Drug id="81991">triamcinolone acetonide (intravitreal injection, diabetic macular edema), Wakamoto/ Hanmi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Macular edema</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>WP-0508ST</Interventions><Reference>JapicCTI-142694</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>TREXA</ProtocolAcronym><ProtocolTitle>Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma</ProtocolTitle><Sponsor>National Heart Lung and Blood Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22487"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>288</Patients><Biomarkers>Methacholine</Biomarkers><Condition>Asthma</Condition><Controls>salbutamol</Controls><EnrollmentCount>288</EnrollmentCount><Interventions>Combined beclomethasone dipropionate group; Daily beclomethasone dipropionate group; Qvar</Interventions><Reference>445; 5U10HL064287; 5U10HL064288; 5U10HL064295; 5U10HL064305; 5U10HL064307; 5U10HL064313; NCT00394329; TREXA</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="58785"></Trial><Drug id="59618">fosdagrocorat</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>86</Patients><Biomarkers>CRP; Total body mass</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>prednisone</Controls><EnrollmentCount>86</EnrollmentCount><Interventions>PF-04171327</Interventions><Reference>2009-013223-37; A9391005; NCT00938587</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy</ProtocolTitle><Sponsor>PTC Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="211918"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Duchenne dystrophy</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>deflazacort</Interventions><Reference>MP-104-CL-005; NCT02251600</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, randomized, double-blind, single-dose, crossover pilot study to assess the safety and efficacy of Nasacort and Nasonex in patients with allergic rhinitis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="89192"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>mometasone (nasal); triamcinolone acetonide</Interventions><Reference>XRG5029C_4006</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="250160"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Macular disease</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>EyeGate II drug delivery system; dexamethasone</Interventions><Reference>EGP-437-010; NCT02644694</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate Annual Rate of Exacerbations and Safety of Three Dosage Strengths of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62127"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1635</Patients><Biomarkers>Eosinophils; Forced expiratory volume in 1 s</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>vilanterol</Controls><EnrollmentCount>1635</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>102970; 2009-013064-40; HZC102970; NCT01017952</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sunovion Growth Study Pediatric Subjects With Mild Asthma and Allergic Rhinitis</ProtocolTitle><Sponsor>West Penn Allegheny Health System Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86234"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>Alvesco; Beconase; Omnaris; Qvar</Interventions><Reference>NCT01550471; RC#5401</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sunovion Growth Study Pediatric Subjects With Mild Asthma and Allergic Rhinitis</ProtocolTitle><Sponsor>West Penn Allegheny Health System Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86234"></Trial><Drug id="12803">ciclesonide (metered dose inhaler), Teijin/Covis/AstraZeneca</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>Alvesco; Beconase; Omnaris; Qvar</Interventions><Reference>NCT01550471; RC#5401</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="157921"></Trial><Drug id="42259">fluticasone furoate (nasal, allergic rhinitis), GSK</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Perennial allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>fluticasone furoate (nasal, allergic rhinitis), GSK; fluticasone furoate + levocabastine; levocabastine hydrochloride</Interventions><Reference>200284; NCT01962467</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery</ProtocolTitle><Sponsor>Sirion Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21689"></Trial><Drug id="55599">difluprednate (ophthalmic emulsion, ocular inflammation/pain ), Alcon</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>difluprednate</Interventions><Reference>NCT00616070; ST-601-003</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>EOS-1</ProtocolAcronym><ProtocolTitle>Budesonide Orodispersible Tablet versus Placebo in Active Eosinophilic Esophagitis</ProtocolTitle><Sponsor>Dr Falk Pharma GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="228513"></Trial><Drug id="106967">budesonide (orodispersible tablet, eosinophilic esophagitis), Dr Falk Pharma/Salix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>88</Patients><Biomarkers>Hydrocortisone</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls></Controls><EnrollmentCount>88</EnrollmentCount><Interventions>Jorveza</Interventions><Reference>2014-001484-12; BUL-1/EEA; EOS-1; EOS-1; NCT02434029</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Effect of Repeat Doses of GW-870086-X in Mild to Moderate Asthmatics</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59095"></Trial><Drug id="54598">870086 (inhaled, asthma), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>37</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>870086 (inhaled, asthma), GlaxoSmithKline</Interventions><Reference>112851; NCT00945932</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>20089/Combo</ProtocolAcronym><ProtocolTitle>IBI-20089 + Lucentis Combined Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)</ProtocolTitle><Sponsor>University of Illinois</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="68844"></Trial><Drug id="60951">triamcinolone acetonide (controlled release/intravitreal injection/Verisome, diabetic macular edema), EyePoint</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Intraocular pressure</Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>IBI-20089; Lucentis</Interventions><Reference>20089/Combo; 2009-1067; NCT01175395</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TRIPLE10</ProtocolAcronym><ProtocolTitle>A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF-5993 pMDI in Subjects With Renal Impairment</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="168962"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>49</Patients><Biomarkers>Diastolic blood pressure; Heart rate; QRS complex; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Interventions><Reference>2013-002140-91; CCD-05993AA1-10; NCT02040597; TRIPLE10</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to see if it is safe to give a new asthma controller drug and a new asthma reliever drug together (called fluticasone furoate/vilanterol) to 5 to 11 year old children with asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="211035"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>26</Patients><Biomarkers>Diastolic blood pressure; Glucose; Heart rate; Hydrocortisone; Potassium; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Controls><EnrollmentCount>26</EnrollmentCount><Interventions>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Interventions><Reference>2012-000754-55; HZA112777</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Inhaled TPI-1020 versus inhaled budesonide in smokers with mild reversible asthma</ProtocolTitle><Sponsor>Pharmaxis Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22059"></Trial><Drug id="29656">TPI-1020</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls>budesonide</Controls><EnrollmentCount>27</EnrollmentCount><Interventions>TPI-1020</Interventions><Reference>NCT00327808; TPI 1020-202</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>BEAM</ProtocolAcronym><ProtocolTitle>An 8-week, Dose Ranging Study of CHF-718 pMDI in Asthmatic Subjects</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="295866"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>619</Patients><Biomarkers>Creatinine; Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Hydrocortisone; PR interval; Peak expiratory flow rate; QRS complex; QT interval; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls>Qvar</Controls><EnrollmentCount>619</EnrollmentCount><Interventions>CHF-781</Interventions><Reference>BEAM; CCD-05993AA3-01; NCT03084718</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Evaluate Efficacy and Safety of GK-664-S in Subjects With Moderate-to-Severe Scalp Seborrheic Dermatitis</ProtocolTitle><Sponsor>Maruho Co Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="366907"></Trial><Drug id="96680">clobetasol propionate shampoo (psoriasis), Galderma/Maruho</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Seborrheic dermatitis</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>GK-664-S</Interventions><Reference>JapicCTI-184246</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>GO Nanocort</ProtocolAcronym><ProtocolTitle>A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of grave's orbitopathy with reduced systemic steroid exposure</ProtocolTitle><Sponsor>Oogziekenhuis Rotterdam</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="307691"></Trial><Drug id="59891">prednisolone (injectable liposome formulation, rheumatoid arthritis/ulcerative colitis), Enceladus</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Blood pressure; Body Mass Index; Body height; Diastolic blood pressure; Eyelid; Glucose; Heart rate; Hemoglobin A, glycosylated; Insulin; Intraocular pressure; Respiratory frequency; Systolic blood pressure; Total body mass; Visual acuity; Waist to Hip Ratio</Biomarkers><Condition>Thyroid associated ophthalmopathy</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Nanocort</Interventions><Reference>GO Nanocort; NL61298.078.17 OZR-2016-34; NTR6579</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of SPARC-1203 in Allergic Rhinitis</ProtocolTitle><Sponsor>Sun Pharmaceutical Advanced Research Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88219"></Trial><Drug id="71455">SUN-0597 (nasal, inflammatory disorders), Sun Pharma</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>159</Patients><Biomarkers></Biomarkers><Condition>Allergic rhinitis</Condition><Controls></Controls><EnrollmentCount>159</EnrollmentCount><Interventions>SPARC-1203</Interventions><Reference>2012-001613-16; CLR_12_03; NCT01614691; SPARC_Ltd._CLR_12_03</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III, Randomized, Double-blind, Placebo-controlled and Active-comparator Study to Evaluate the Safety and Efficacy of Deflazacort and Prednisone in Male Patients With Duchenne Muscular Dystrophy (DMD)</ProtocolTitle><Sponsor>Marathon Pharmaceuticals LLC</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="262577"></Trial><Drug id="86985">deflazacort (oral tablet/suspension, Duchenne muscular dystrophy), PCT Therapeutics</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>196</Patients><Biomarkers>Aspartate aminotransferase; Body Mass Index; Creatine kinase; Forced Vital Capacity; Lactate dehydrogenase; Muscle strength; Total body mass</Biomarkers><Condition>Duchenne dystrophy</Condition><Controls>prednisone</Controls><EnrollmentCount>196</EnrollmentCount><Interventions>Emflaza; prednisone</Interventions><Reference>MP-104-NM-001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder</ProtocolTitle><Sponsor>Rikshospitalet University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44888"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Myalgia</Condition><Controls></Controls><EnrollmentCount>122</EnrollmentCount><Interventions>lidocaine; triamcinolone acetonide</Interventions><Reference>IT-avdelingen; Interne tjenester; NCT00840229; REK; Rikshospitalet HF; S-08546</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>SUMMIT</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75513"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>16568</Patients><Biomarkers>Body Mass Index; Forced expiratory volume in 1 s (FEV1); Pulse wave velocity; Troponin I, cardiac muscle</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>16568</EnrollmentCount><Interventions>Relovair; fluticasone furoate; vilanterol</Interventions><Reference>113782; 2010-021638-72; CCRN 593 (COPD); CTRI/2012/04/002563; HZC113782; HZC113782 14824; IND IDE 077855; NCT01313676; NMRR-13-59-14824; PHRR131025-000134; SUMMIT; UKCRN 10474</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>SUMMIT</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75513"></Trial><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>16568</Patients><Biomarkers>Body Mass Index; Forced expiratory volume in 1 s (FEV1); Pulse wave velocity; Troponin I, cardiac muscle</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>16568</EnrollmentCount><Interventions>Relovair; fluticasone furoate; vilanterol</Interventions><Reference>113782; 2010-021638-72; CCRN 593 (COPD); CTRI/2012/04/002563; HZC113782; HZC113782 14824; IND IDE 077855; NCT01313676; NMRR-13-59-14824; PHRR131025-000134; SUMMIT; UKCRN 10474</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension</ProtocolTitle><Sponsor>Shire plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="89242"></Trial><Drug id="60523">budesonide (oral, eosinophilic esophagitis), Shire</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>119</Patients><Biomarkers>Body height; Eosinophils; Total body mass</Biomarkers><Condition>Eosinophilic esophagitis</Condition><Controls></Controls><EnrollmentCount>93</EnrollmentCount><Interventions>budesonide</Interventions><Reference>MPI-101-06; NCT01642212</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparison Between Clobetasol Propionate 0.05% (Clobex) Spray and Clobetasol Propionate 0.05% (Olux) Foam</ProtocolTitle><Sponsor>Galderma Laboratories LP</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="171257"></Trial><Drug id="18168">clobetasol propionate foam, Connetics</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>78</Patients><Biomarkers></Biomarkers><Condition>Psoriasis</Condition><Controls>Olux</Controls><EnrollmentCount>78</EnrollmentCount><Interventions>Clobex</Interventions><Reference>NCT00436540; US10013</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Long-term Safety Study of Fluticasone Furoate (FF)/GW-642444 and FF in Japanese Subjects With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="72445"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>243</Patients><Biomarkers></Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>243</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + GW-642444</Interventions><Reference>113989; JapicCTI-101343; NCT01244984</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="80895"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>351</Patients><Biomarkers>FEV1; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone propionate</Controls><EnrollmentCount>351</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>115285; NCT01436110</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Dose-ranging Study of Fluticasone Furoate (FF)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85984"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>593</Patients><Biomarkers>FEV1; Hydrocortisone; PEF</Biomarkers><Condition>Asthma</Condition><Controls>fluticasone</Controls><EnrollmentCount>597</EnrollmentCount><Interventions>fluticasone furoate</Interventions><Reference>106855; 2011-003338-15; HZA106855; JapicCTI-121885; NCT01563029</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF/Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="97979"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>fluticasone furoate; fluticasone furoate + umeclidinium (asthma, DPI), GlaxoSmithKline; umeclidinium</Interventions><Reference>116524; NCT01725685</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIa, AMP Challenge, Dose-Escalation Study to Assess the Dose-Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects</ProtocolTitle><Sponsor>Glaxo Group Research Ltd, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="282142"></Trial><Drug id="57097">fluticasone furoate (inhaled, respiratory disorders), GlaxoSmithKline</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>56</Patients><Biomarkers>Body temperature; Diastolic blood pressure; Forced Vital Capacity; Forced expiratory volume; Forced expiratory volume; Heart rate; Hydrocortisone; Peak expiratory flow rate; Respiratory frequency; Systolic blood pressure</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>56</EnrollmentCount><Interventions>budesonide; fluticasone; fluticasone furoate</Interventions><Reference>2016-003002-14; 203162; NCT02991859</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-up</ProtocolTitle><Sponsor>Anika Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="324751"></Trial><Drug id="103224">CINGAL</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>526</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Monovisc; triamcinolone hexacetonide</Controls><EnrollmentCount>526</EnrollmentCount><Interventions>CINGAL</Interventions><Reference>2017-003205-18; CINGAL 17-02; NCT03390036</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of AGN-208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62499"></Trial><Drug id="65121">beclomethasone dipropionate (intravitreal injection), Allergan</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>121</Patients><Biomarkers></Biomarkers><Condition>Retinal venous occlusion</Condition><Controls></Controls><EnrollmentCount>121</EnrollmentCount><Interventions>AGN-208397</Interventions><Reference>208397-001; NCT01027650</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Optimizing Steroid Replacement in Patients With Adrenal Insufficiency</ProtocolTitle><Sponsor>Adelaide and Meath Hospital, Tallaght Regional Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312737"></Trial><Drug id="58174">dual-release hydrocortisone (oral, adrenal insufficiency), ViroPharma</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Adrenal gland hypofunction</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Plenadren</Interventions><Reference>2016/09/05; NCT03282487</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery</ProtocolTitle><Sponsor>Eyegate Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="301426"></Trial><Drug id="54573">dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>101</Patients><Biomarkers>Anterior chamber</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>EyeGate; dexamethasone</Interventions><Reference>EGP-437-009; NCT03180255</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>AZALEA</ProtocolAcronym><ProtocolTitle>Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis</ProtocolTitle><Sponsor>Clearside Biomedical Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="292964"></Trial><Drug id="75376">triamcinolone acetonide (suprachoroidal, macular edema/uveitis), Clearside Biomedical</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>38</EnrollmentCount><Interventions>Zuprata</Interventions><Reference>AZALEA; CLS1001-302; NCT03097315</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TRIVERSYTI</ProtocolAcronym><ProtocolTitle>Active-Controlled Trial of CHF-5993 Pressurized Metered-dose Inhaler (pMDI) Versus Symbicort Turbuhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Chiesi Farmaceutici SpA</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="303203"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>990</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Symbicort Turbuhaler</Controls><EnrollmentCount>990</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>CCD-5993AA1-14; CHINA; NCT03197818; SOUTH KOREA; TAIWAN; TRIVERSYTI</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Inhaled Extra-Fine Hydrofluoalkane-Beclomethasone (Qvar) in Premature Infants With Bronchopulmonary Dysplasia (BPD)</ProtocolTitle><Sponsor>B'nai Zion Medical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="78295"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Lung malformation</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>beclometasone (inhaled, CFC-free), Teva</Interventions><Reference>0110-10; NCT01373008</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 microg and QVAR 40 microg, Inhalation Aerosol</ProtocolTitle><Sponsor>Amneal Ireland Limited</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="343764"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1204</Patients><Biomarkers>Forced expiratory volume</Biomarkers><Condition>Asthma</Condition><Controls>Qvar</Controls><EnrollmentCount>1204</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Reference>AI-BDP-001; NCT03562949</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients</ProtocolTitle><Sponsor>University of Kansas Medical Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="282139"></Trial><Drug id="55981">budesonide (oral capsule/enema, Crohn's disease/microsopic colitis/ulcerative colitis), AstraZeneca/ Tillotts Pharma/ Perrigo</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>9</Patients><Biomarkers></Biomarkers><Condition>Diarrhea</Condition><Controls></Controls><EnrollmentCount>9</EnrollmentCount><Interventions>Entocort</Interventions><Reference>IIT-BUDESONIDE-MPA; NCT02991768; STUDY00140436</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TRIFLOW</ProtocolAcronym><ProtocolTitle>A Study Comparing the Effects of Trimbow to Fostair in COPD</ProtocolTitle><Sponsor>Medicines Evaluation Unit</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="370288"></Trial><Drug id="73605">beclomethasone dipropionate + formoterol fumarate + CHF-5992 (inhaled, COPD), Chiesi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Airway resistance; Forced Vital Capacity; Forced expiratory flow ; Forced expiratory volume; Inspiratory capacity; Lung; Specific airway conductance </Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls>Fostair</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>Trimbow</Interventions><Reference>2018-003113-17; MEU 17/361; NCT03842904; TRIFLOW</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy</ProtocolTitle><Sponsor>ReveraGen BioPharma Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="372311"></Trial><Drug id="70712">vamorolone</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Duchenne dystrophy</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>vamorolone</Interventions><Reference>NCT03863119; VBP15-EAP</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>RhiCNANI</ProtocolAcronym><ProtocolTitle>Efficacy and safety study of Nasacort in chronic non-allergic and non-infectious rhinitis in adults</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="13146"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition>Rhinitis</Condition><Controls></Controls><EnrollmentCount>77</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>EudraCT #: 2006-000059-16; NCT00344942; RhiCNANI; TRICA_L_00872</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Trial to Study The Effects of Beclomethasone Dipropionate Metered Dose Inhaler in Patients With Asthma</ProtocolTitle><Sponsor>AXIS Clinicals Limited, Aurobindo Pharma Research Center II</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="371803"></Trial><Drug id="44414">beclomethasone dipropionate, (CFC-free), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1550</Patients><Biomarkers>Forced expiratory volume; Nitric oxide</Biomarkers><Condition>Asthma</Condition><Controls>Qvar</Controls><EnrollmentCount>1550</EnrollmentCount><Interventions>beclomethasone dipropionate</Interventions><Reference>CR176-17; CTRI/2019/02/017719</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD-5423 When Administered in Different Ways</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="96548"></Trial><Drug id="64294">AZD-5423</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>blood pressure; heart rate</Biomarkers><Condition>Chronic obstructive pulmonary disease</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>AZD-5423</Interventions><Reference>D2340C00012; Eudract 2012-002307-17; NCT01635985</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>SALIENT</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of SX-600 Administered by Lumbosacral Transforaminal Epidural Injection for Radicular Pain</ProtocolTitle><Sponsor>SpineThera, SpineThera Australia PTY LTD</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="380882"></Trial><Drug id="113006">reformulated dexamethasone acetate (epidural/sustained release, low back pain), SpineThera</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>180</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>SX-600</Interventions><Reference>CLIN-0012-STA19-01; NCT03952377; SALIENT</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>CLEAR</ProtocolAcronym><ProtocolTitle>Corticosteroid Lumbar Epidural Analgesia for Radiculopathy</ProtocolTitle><Sponsor>Semnur Pharmaceuticals Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="322493"></Trial><Drug id="106609">dexamethasone sodium phosphate (epidural steroid injectable gel, sciatia), Scilex Holding</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>400</EnrollmentCount><Interventions>SP-102</Interventions><Reference>CLEAR; NCT03372161; SP-102-02</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="281056"></Trial><Drug id="95991">salmeterol xinafoate + fluticasone propionate (inhaled/Spiromax, asthma), Teva</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>841</Patients><Biomarkers>Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Asthma</Condition><Controls></Controls><EnrollmentCount>841</EnrollmentCount><Interventions>Aerivio Spiromax; fluticasone propionate RespiClick</Interventions><Reference>2016-003835-39; FSS-AS-30003; NCT02980133</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85132"></Trial><Drug id="76229">beclomethasone dipropionate  (waterless nasal spray, allergic rhinitis), Teva</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Qnaze; beclometasone (inhaled, CFC-free), Teva</Interventions><Reference>BDP-AR-101; NCT01537692</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema</ProtocolTitle><Sponsor>National Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="166130"></Trial><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Blood pressure; Eye pressure; HbA1C</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>triamcinolone acetonide</Interventions><Reference>05-EI-0251; 050251; NCT00231023</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-Inferiority of Gatifloxacin/Prednisolone Association Versus Isolated Administration in Prevention of Ocular Infection/Inflammation</ProtocolTitle><Sponsor>Federal University of Sao Paulo</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="89902"></Trial><Drug id="79969">gatifloxacin + prednisolone acetate (ophthalmic, bacterial infection/inflammation), Allergan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>101</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>gatifloxacin (ophthalmic), Allergan; prednisolone acetate</Controls><EnrollmentCount>101</EnrollmentCount><Interventions>gatifloxacin + prednisolone acetate (ophthalmic, bacterial infection/inflammation), Allergan</Interventions><Reference>AG9890X-001; NCT01218737</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Budesonide Rectal Aerosol Foam and Uceris Rectal Aerosol Foam</ProtocolTitle><Sponsor>Perrigo Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="263269"></Trial><Drug id="59670">budesonide (rectal foam, ulcerative colitis), Dr Falk Pharma/Salix/Ajinomoto/EA Pharma/Kissei/Meda</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Rectabul</Controls><EnrollmentCount></EnrollmentCount><Interventions>budesonide</Interventions><Reference>NCT02800824; PRG-NY-16-007</Reference></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>